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Rhythms characterise the physiology of all living things, and rhythmic patterns can be 
observed in almost all aspects of daily human life. Disruption of rhythms is linked to poor 
health and may be caused by disease, or desynchrony between activity, behaviour, and 
internal time cues. Since rhythms are individual and dynamic, single time point assessment 
provides limited information and is potentially misleading. On the other hand, capturing 
dynamic information is traditionally difficult and invasive. In this thesis I investigated how 
these difficulties could be overcome using a novel, prototype portable microdialysis sampling 
device, U-RHYTHM. 
I have shown that U-RHYTHM is a safe, reliable method and well-tolerated by participants. In 
a series of small proof-of-principle studies using healthy volunteers, the U-RHYTHM device 
and abdominal subcutaneous microdialysis, diurnal and ultradian rhythms of 8 adrenal 
steroids were shown and validated against plasma, 7 of which have never previously been 
described in tissue. Next, using a targeted metabolomics approach, multiple tissue 
metabolites were found, showing daily- and food-driven rhythms. Finally, in ambulatory 
studies, the novel detection of tissue melatonin rhythms simultaneously with cortisol and 
cortisone was achieved and presented alongside rhythmic data from other non-invasive 
wearable devices. Across all studies, limitations on the technique related to the recovery of 
some lipophilic, hydrophobic compounds. 
These studies show that U-RHYTHM can be used to investigate daily trends, ultradian details, 
and interactions between rhythmic processes. Data from U-RHYTHM studies could lead to 
new methods for diagnosis of endocrine and metabolic conditions, and to the increased 
understanding how lifestyle-related rhythm disruption leads to poor health outcomes. The 
unintrusive nature of the technique provides the flexibility to investigate in both free living 
and controlled conditions. Further work is needed to validate findings in a larger population.  
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In 2017, the Nobel Prize in Physiology or Medicine was jointly awarded for the discovery of 
the molecular mechanisms that control the circadian clock. In announcing the prize, the 
Nobel Committee described how the work explains “how plants, animals and humans adapt 
their biological rhythm so that it is synchronised with the Earth’s revolutions”1. In other 
words, rhythmicity is so fundamental to the biological processes of living things that it has 
become encoded in our genetic makeup.  
In this dissertation I will describe the development of a novel sampling technology, U-
RHYTHM microdialysis, that allows ambulatory and blood-free study of biological rhythms at 
a tissue level, and in combination with highly sensitive measurement techniques, repeated 
measurement of multiple metabolite rhythms in the same individual over time. The concept 
of measuring the dynamics of metabolism over time is here given the name 
metabolodynamics. As demonstration of the potential uses of the device, I will present three 
proof-of-concept studies that each outline different applications of the U-RHYTHM 
technology.  
1.1 Clocks in the brain and the periphery 
The mechanisms by which internal biological time is maintained and depends on a network of 
intracellular clocks, coordinated by a central pacemaker in the suprachiasmatic nucleus of the 
hypothalamus (SCN). The SCN consists of tiny bilateral nuclei of a few thousand cells each – 
the cells are tightly coupled, and output oscillates with a circadian free running period – that 
is, very close to 24 hours2. Outputs from the SCN project to other brain structures, including 
locally within the hypothalamus, and also synchronise peripheral clocks to the light/dark cycle 
via autonomic (parasympathetic and sympathetic) and hormonal signals (especially cortisol 
and melatonin)3–5. In rats, lesions of the SCN abolish normal physiological rhythms of 




Time-of-day information is conveyed to the SCN via the direct synaptic connections of 
specialised photosensitive retinal ganglion cells within the retinohypothalamic tract2. 
Traditionally it was assumed that the SCN was the only tissue capable of generating self-
sustaining oscillations, and therefore the sole source of daily timing information in mammals. 
In this model, the vast majority of peripheral tissues acted as subservient ‘slaves’ to the 
master clock8. Following the discovery that exposing cultured fibroblasts to serum shock 
induced circadian gene expression9, and the subsequent demonstration that individual 
fibroblasts could function as independent circadian oscillators10, it has been proven that 
molecular clocks are present in almost all cells and tissues of the body11. The SCN functions 
to coordinate and synchronise these rhythms8, rather than simply operating in a master-slave 
relationship. 
1.1.1 Molecular basis of biological clocks 
The intrinsic cell clock machinery present both in neurons of the SCN and in peripheral 
tissues consists of transcriptional-translational feedback loops that oscillate with a period of 
approximately 24 hours. The principal loop is made up of two transcription activators: brain 
and muscle ARNTL-like protein 1 (BMAL1) and circadian locomotor output cycles kaput 
(CLOCK). The BMAL1/CLOCK dimer complex activates numerous so-called ‘clock-controlled 
genes’ as well as inducing transcription of Period (PER) and Cryptochrome (CRY). Increasing 
levels of PER and CRY proteins act via negative feedback to inhibit CLOCK and BMAL 
transcription, PER and CRY are degraded and the cycle begins once more12. In addition to 
these core components, feedback is also regulated by a number of post-translational 
mechanisms including phosphorylation and glycosylation of clock proteins13. Studies in 
rodents have demonstrated that malfunction of clock genes lead to alterations of circadian 
period14, while deactivating mutations of Per2/Cry1 result in the complete dysregulation of 




gene expression in mice15. In humans, an hereditary delayed sleep phase disorder has been 
associated with a gain-of-function mutation in the Cry1 gene16. 
1.2 Definitions of biological rhythms 
Biological rhythms are natural oscillations that occur in living systems. They can be described 
in terms of their length, and by the circumstances in which they occur. For example, humans 
and many other animals have a diurnal behaviour rhythm, meaning that there is generally 
more activity during daylight hours, and rest or sleep at night. By contrast, nocturnal species, 
such as rodents, are active at night and rest during the day. Biological rhythms that occur 
over periods longer than a day are called infradian, such as the human menstrual cycle, while 
rhythms that occur with short periods of minutes to hours are termed ultradian.  
Rhythmicity is evident and important in almost all aspects of human daily life: externally 
visible in behaviour such as the patterns of feeding17, rest and activity18, alterations in 
alertness and cognition19, and in the type of language used in social media posts20; and 
internally through examples such as the secretion of hormones21–24, changes in body 
temperature25, insulin sensitivity26 and glucose tolerance27, and the rhythmic production of 
metabolites28–30.  
1.2.1 Circadian rhythms 
Circadian rhythms are endogenous, self-sustained processes that oscillate with a period that 
approximates one day. In carefully controlled conditions, the endogenous period of the 
human circadian rhythm has been accurately measured at 24.18 hours31. Circadian rhythms 
are entrained or synchronised to external cues (zeitgebers, from the German ‘time giver’) and 
in humans and other mammals the most potent of these are light, and the timing of food17. 
The important point is that circadian rhythms are intrinsic – they continue to oscillate even in 




Common circadian rhythms in mammals include the sleep-wake cycle32, feeding33, body 
temperature34, and the secretion of hormones, most notably melatonin35 – which signals the 
onset of the biological night - and the rhythmic secretion of glucocorticoids, which begin to 
rise in anticipation of waking36. 
1.2.2 Ultradian rhythms 
Ultradian rhythms are very frequently superimposed upon rhythms of longer periods. In 
endocrinology, pulsatile ultradian secretion is a characteristic feature of many hormones 
including growth hormone37, insulin38, and the reproductive axis39,40. Ultradian rhythms also 
characterise the structure of sleep41, and are present in measurements of both core42 and 
peripheral temperature43. Of particular interest is the ultradian rhythm of glucocorticoids, 
which is coordinated by pulsatile release of pituitary adrenocorticotropic releasing hormone 
(ACTH)44–47, which will be described further.  
1.3 Rhythmicity in the hypothalamic-pituitary-adrenal axis 
As alluded to, pituitary hormones, including ACTH, are not released continuously – rather, 
they are secreted in pulses that vary in amplitude and/or frequency within a diurnal or 
circadian period48,49. The hypothalamic-pituitary-adrenal (HPA) axis is responsible for the 
synthesis and secretion of essential hormones that regulate growth, metabolism, and the 
response to stress. Glucocorticoids also act as potent synchronisers of peripheral clocks50,51 – 
the synthetic glucocorticoid dexamethasone alters the phase of clock gene expression in 
multiple tissues including liver, kidney and heart muscle4 but not in the suprachiasmatic 
nucleus, since glucocorticoid receptors are not expressed there52. 
Basal secretion of the adrenal steroid hormone cortisol in humans (and corticosterone in 
rodents) is circadian with peak secretion just prior to waking, anticipating the start of a new 
day53. The rhythm is coordinated by inputs from the SCN, where axons project directly into 




regulate corticotrophin-releasing hormone (CRH) release from neurons in the PVN, and thus 
ACTH release from the anterior pituitary54. Additionally, it appears that peripheral sensitivity 
to ACTH, and thus secretion of cortisol, is regulated by an autonomous clock in the adrenal 
cortex. Using mouse adrenal tissue slices, Oster et al (2006) were able to demonstrate that 
the adrenal response to ACTH varies depending on the phase of the circadian cycle15. In a 
wild-type animal model, ACTH stimulation at the clock time of zenith corticosterone release 
resulted in significantly higher secretion than the same stimulus given at the nadir of the 
corticosterone rhythm15. However, in mice with mutated clock genes and a non-functioning 
circadian clock, this variation was abolished – the ACTH response at both time points was 
similar to the ‘corticosterone nadir’ time point in wild-type animals15. Additionally, the authors 
demonstrated that the peripheral adrenal clock could be entrained to light, suggesting that 
neuronal pathways connect the SCN and the adrenal gland, likely via the autonomic nervous 
system15,55. 
1.3.1 Origins of glucocorticoid ultradian pulsatility 
High resolution blood sampling in both animals45 and humans47,49 demonstrates that the 
frequency of glucocorticoid pulses is 60-90 minutes54,56. The origin of this ultradian rhythm 
was previously assumed to be hypothalamic. However, while lesions to the SCN produce the 
expected abolishment of circadian glucocorticoid secretion, pulsatile secretion persists57. This 
suggests that the ultradian rhythm of glucocorticoids does not necessarily require the SCN, 
and that the rhythm could be intrinsic to the properties of the HPA axis itself58. Mathematical 
modelling predicts that ultradian oscillations in ACTH and cortisol secretion are a 
consequence of the dynamic interaction between positive feed-forward from hypothalamic 
CRH drive and pituitary ACTH secretion, and negative feed-back generated by adrenal cortex 
secretion of cortisol58. Under conditions of constant CRH infusion, ultradian oscillations in 
both ACTH and corticosterone do persist59 validating the model hypothesis, and supporting 




ultradian rhythm. Further, rapid negative feedback by glucocorticoid inhibition on the 
anterior pituitary must also be a crucial factor regulating the dynamic rhythm59. 
1.3.2 Significance of glucocorticoid ultradian pulsatility  
The physiological impact of ultradian glucocorticoid secretion has been investigated in animal 
experiments. These include the demonstration that expression of genes and gene transcripts 
in the liver60,61 and brain62,63 are differentially influenced by the altering patterns of exposure 
to corticosterone. In contrast to rats exposed to constant levels of glucocorticoid, ultradian 
pulses induce cyclical glucocorticoid receptor-mediated gene transcription, or ‘gene 
pulsing’60. In humans, the evidence is more limited. It is proposed that that pattern of 
exposure to cortisol is likely to have significant biological consequences, evidence for which 
is hinted at in the finding of differences in HPA axis pulsatility in adults with depression64, 
sleep apnoea65, and following major cardiac surgery66,67. Specific evidence of the potential 
importance of glucocorticoid pulsatility for normal cognitive function has emerged from 
recent experiments in healthy adults. In a protocol in which endogenous cortisol production 
was suppressed by metyrapone, only participants who received pulsatile replacement therapy 
were able to perform well in cognitively demanding tasks, compared with those participants 
who received standard oral or continuous infusion replacement regimens68. 
1.4 Metabolism and the circadian clock 
Metabolism is intrinsically linked with the circadian timing system, with nearly all metabolic 
processes showing time of day variation33,69. Many metabolic rhythms are under circadian 
control, including energy expenditure70, lipid, amino acid and carbohydrate metabolism69, and 
a recent study in mouse liver found that more 50% of metabolites were circadian71. Daily 
rhythms constitute the outcome of relationships between signals from the SCN, broadcasting 
daily time information, and peripheral tissue clocks, which are also influenced by external 
cues, most significantly by the timing of food17,72. Evidence from rodent studies has shown 




rhythms in mice whose feeding schedule is shifted from night to day73,74. In humans, a 5-hour 
delay in meal timing was associated with phase shifts in glucose rhythms and the expression 
of clock genes in peripheral adipose, without affecting the timing of melatonin or cortisol75.  
1.5 Factors that result in rhythm disturbance 
1.5.1 Loss of rhythm synchrony 
The importance of clock coordinated rhythms in the maintenance of metabolic health is most 
starkly evident in clock-absent animal models - disabling mutations in core clock genes results 
in loss of not only behavioural rhythmicity but also development of abnormal metabolic 
phenotypes that include obesity, impaired glucose metabolism, lipid disorders and reduced 
life span33,76. In the wildtype condition, factors that normally function to synchronise and 
entrain daily rhythms, such as hormones, light, and food timing, can become instead 
‘desynchronisers’ – that is, exert harmful phase shifting effects - when presented at the 
wrong time of day, or without coordination. Examples of desynchronisers in humans include 
mistiming of sleep and meals, exposure to bright light during normal periods of sleep and rest, 
and the pathological changes in rhythmicity that occur in endocrine conditions. 
1.5.2 Sleep and shift work 
There is an increasing body of associative evidence from human studies that links 
misalignment of rhythms with metabolic dysfunction. Epidemiological evidence links late 
chronotype (evening preference) with increased risk of multiple comorbidities and all-cause 
mortality77. Short sleep duration has been associated with increased risk of diabetes and 
obesity77,78, and sleep fragmentation with impaired glucose tolerance79. Following 7 days of 
partial sleep deprivation, transcriptome analysis of plasma obtained from 26 adult volunteers 
found that over 700 genes were either up- or down-regulated including a significant 




and CLOCK gene transcripts, and an upregulation of genes associated with immune and 
stress responses80. 
Shift workers are a particular vulnerable group. A meta-analysis of 26 studies involving over 
300 000 participants found that shift work was associated with a significant increased risk of 
overweight and obesity81, and a review of 38 meta-analyses and 24 systematic reviews 
additionally found links with shift work and increased risk of type 2 diabetes, coronary artery 
disease, stroke, and cancer82. A systematic review of 33 observational studies found that shift 
workers overall consumed a less healthy diet, were less regular with meal timing, and were 
more likely to consume food at night83.  
1.5.3 Timing of food 
Late meal timing has been associated with impaired glucose tolerance in a cohort of 32 
healthy women84, and with increased body fat and body mass index in a cohort of 110 free-
living healthy young men and women85, although a separate study of 97 normal weight 
volunteers found that the time between melatonin onset and sleep was not associated with 
increased weight or body fat86 when conducted in laboratory conditions. Morning-to-evening 
and sleep-versus-waking differences in insulin and glucose responses to meals have been 
identified in both males and females, potentially modulated by the circadian phase of cortisol 
and other counterregulatory hormones87,88. In a rigorously controlled forced-desynchrony 
experiment in which 10 healthy adults ate and slept 12 hours out of normal phase, the 
resulting circadian misalignment resulted in significant increases in glucose, blood pressure, 
and poorer quality sleep89.  
1.5.4 Timing of light exposure 
Light is the most potent synchroniser of the circadian clock, and its effect is modulated by the 
time of day. Acting through the SCN, light information is conveyed to the pineal gland which 




controlled, dimly lit conditions, melatonin begins to rise in the evening, prior to habitual bed 
time, and remains elevated during the night, before falling to very low levels during the day35. 
Profiles of melatonin vary between individuals, across gender, age and chronotype91–95 but 
are generally stable within an individual, meaning that measurement of melatonin is 
considered a robust and reliable marker of circadian phase94. Bright light exposure in the 
morning leads to a phase advance (earlier melatonin onset) whereas light exposure in the 
evening delays or suppresses melatonin secretion96–99.  
With the rise of modern society has come the ubiquitous presence of artificial light in our 
homes and workplaces, and an increasing level of concern about the potential negative 
effects of mistimed bright light on the circadian rhythm. Delaying the melatonin onset 
potentially shortens the period of melatonin, and the onset and duration of sleep100. While 
there is unequivocal evidence that artificial light in modern life does influence melatonin100–
103, there is yet no strong mechanistic link between this disruption and any specific pathology. 
Associative evidence has linked alterations in glucose tolerance with melatonin secretion. In a 
case-control study of nurses, those with the lowest excretion of urinary melatonin 
metabolites were significantly more lively to have developed type 2 diabetes than those with 
highest levels104. In a study of 21 healthy female volunteers, 5mg of exogenous melatonin 
resulted in impaired glucose tolerance at both morning and evening time points, when 
glucose was measured acutely after dose administration105. Melatonin receptor 
polymorphisms have been linked with increased risk of impaired glucose tolerance and type 2 
diabetes in gene-wide association and prospective studies106–108, but in an analysis of data 
from more than 189,000 participants in the UK Biobank, presence of the mutation was not 
associated with increased risk of diabetes in shift workers109. Untangling the complex 
relationships between evening bright light-induced melatonin suppression with associated 
behaviours such as late meals, natural interindividual variation in chronotype and light 




1.5.5 Endocrine disease 
Pathological rhythmicity driven by tumour secretion of hormones is the hallmark of many 
endocrine diseases. High frequency blood sampling in patients with pituitary adenomas 
reveals pulsatility of growth hormone, prolactin and cortisol secretion rather than simply 
tonic hypersecretion110. Disorganised, irregular pulsatile secretion can be identified in profiles 
of patients with both Cushing’s disease111 and pulsatility with diurnal rhythms was observed 
in a cohort of 12 patients with adrenal Cushing’s syndrome112. Diurnal rhythms and ultradian 
pulsatility also characterise the rhythms of aldosterone secretion in health and in primary 
aldosteronism, but with higher basal release and secretion irregularity in the disease 
condition113. 
1.6 Limitations of single time point assessments 
Given that hormonal and metabolic processes are dynamic, occasional assessment of single 
analytes at restricted time points will provide at best incomplete, and at worst potentially 
misleading information. Likewise, in studies that investigate daily changes in the metabolome, 
sampling points are typically limited to a handful over the day29,114, limiting the ability to 
investigate any ultradian rhythmicity, or to examine in detail responses to acute changes that 
occur following food intake or other intervention. Again, similar to the secretion of 
glucocorticoid hormones, interindividual variation in metabolite secretion patterns can be 
large115, making normal ranges broad and potentially less meaningful.  
Finally, single time point measurements fail to capture the significant and important 
metabolic and hormonal changes that occur during sleep. The major fluxes of both melatonin 
and cortisol occur during this time, and the sleep period is typically the only part of the day in 




1.7 The need for a dynamic sampling approach 
To make substantial progress in understanding the significance of dynamic changes in human 
endocrinology and metabolism, including changes that occur during undisturbed sleep, 
information needs to gathered at high resolution, and with a minimum of inconvenience or 
disruption. Microdialysis is an attractive solution in that it can sample at similar temporal 
resolution to inpatient blood sampling protocols, but without the need for blood, and with 
considerably less restriction on the participant. Microdialysis has traditionally been used as a 
tool for limited time course investigations of both endogenous and exogenous compounds in 
a variety of tissues, including subcutaneous fluid116. A major breakthrough came with the 
development of a prototype portable collection device by the Lightman group117, allowing 
frequent (20 minute) automated sampling by microdialysis over an entire 24-hour period, 
during which the participant is able to continue normal activities118,119.  
Work using the prototype device has so far demonstrated that circadian profiles of free 
cortisol are not only detectable in subcutaneous fluid117, but remain robust over time, and 
correlate with total plasma concentrations118. However, the technique has much broader 
potential. Previous studies have shown that a variety of other small molecules can be 
recovered using microdialysis in a wide range of tissues116. In the subcutaneous fluid this 
includes amino acids120, biogenic amines121 glucose and lactate 122, cytokines123, IGF-1124 and 
endocannabinoids125. With the emergence of mass-spectrometry as an analytical method126, 
the possibility to measure multiple analytes, not just cortisol, can now also be considered. 
Together, this suggests that the metabolome of subcutaneous fluid is suitable for 24-hour 
metabolodynamic assessment using portable microdialysis sampling.  
1.8 History and applications of clinical microdialysis 
The concept of microdialysis first emerged in the 1950s when the term was used to describe 




al. (1966) used the term microdialysis to describe measurement of tissue-specific amino acid 
concentrations in dogs, using dextran-filled sacs implanted in brain and subcutaneous 
tissue128. While novel, the methods used in these early papers were restricted to single time 
point or limited resolution samples, thereby providing only a static view of physiology. 
Modern microdialysis emerged in the 1970s when Ungerstedt and Pycock (1974) published a 
technique that used continuously perfused implantable hollow fibres to directly measure 
dopamine activity in the brains of freely moving rats129, demonstrating for the first time 
microdialysis as a method for in vivo monitoring of dynamics.  
Over the decades since, microdialysis has been used extensively in both animal and human 
studies. Most human microdialysis has focused on applications in neuroscience, principally 
the pathogenesis of brain trauma and recovery130 through the intracranial monitoring of 
lactate, glucose and other small molecules131. However, the technique has now also been 
used in a variety of other clinical settings116 including for continuous monitoring of glucose in 
both adults and neonates122,132,133, short term dynamic measurements of metabolite and 
inflammatory markers in muscle124,134–136, adipose125,137,138 and skin123,139–141, investigation of 
tumour interstitial fluid142, intrathoracic monitoring of cardiac enzymes following cardioplegic 
arrest143, and therapeutic drug monitoring144–146. Acute changes in tissue free cortisol have 
been investigated in the setting of severe sepsis147, and burns148. As mentioned, a novel 
application of microdialysis for measurement of 24-hour cortisol dynamics in humans was 
first described by Bhake et al. (2013)117, and since used to measure cortisol changes in 
relation to pregnancy body weight and gestational age149, and currently in trials monitoring 




1.8.1 Review of the microdialysis technique 
 
Figure 1-1 Schematic illustration of a linear microdialysis probe. Perfusate is pumped through the inlet part of the tubing, 
before passing across a semipermeable membrane. At the membrane, substances in the space around the probe diffuse 
into the perfusate and can reach near equilibrium concentrations at slow perfusion rates. The resulting fluid containing 
diffused substances, the dialysate, is then collected from the outlet tube for analysis. (Image from Kho et al. (2017)). 
Clinical microdialysis involves the placement of a semipermeable membrane (probe) into the 
tissue of interest, and then perfusion of the probe at a slow flow rate, producing a 
microdialysate containing dialysed substances of interest (Figure 1-1). While it is possible to 
perform microdialysis in blood138,151 the clear advantage of the technique is the ability to 
sample adjacent to, or directly within a tissue of interest. Due to the relatively small size of 
the pores in most commercially available probe membranes (typically 6 – 100 kDa cut-off), 
the membrane acts as a filter that effectively prevents larger molecules, such as proteins, 
from diffusing into the microdialysate. Therefore, when using a low-molecular weight cut-off 
membrane the contents of the dialysate typically contain only the ‘free’ or non-protein bound 
fraction of the hormone or metabolite being measured.  
The choice of microdialysis probe type is determined by the tissue and type of molecule of 
interest. Linear catheters (Figure 1-1) are suitable for peripheral soft tissue due to their 
strength and flexibility116. Although there is a need for both an entry and exit puncture site, 
placement of a linear probe is minimally invasive, often does not require anaesthetic, and 




for intravenous, intramuscular and central nervous system studies, being introduced with a 
guide cannula116. 
1.8.1.1.1 Relative versus absolute recovery 
Microdialysis works through the principle action of membrane diffusion, the rate of which is 
determined by levels of analyte in the interstitial fluid compared with the perfusate. Since 
there is a continuous flow of perfusate across the membrane, complete equilibrium between 
both compartments is never fully achieved116. Therefore, the amount of substance in the 
microdialysate is expressed in terms of its relative recovery, which is defined as the 
concentration of the analyte collected in the dialysate divided by the concentration in the 
fluid surrounding the probe152. High relative recovery therefore reflects a concentration that 
is close to the true value in the sample. 
Relative recovery can be expressed by the equation: 
𝑅𝑅 =  𝐸𝑑 =  
𝐶𝑑
𝐶𝑏
 × 100 
where RR is relative recovery (or Ed extraction efficiency), Cd is concentration in the dialysate 
and Cb the concentration in the sample (tissue, or water bath during in vitro experiments). 
When conducting in vitro experiments, the relationship between perfusate flow and relative 
recovery is inversely related, such that relative recovery falls as perfusion rate increases. On 
the other hand, absolute recovery (also known as mass recovery) is defined as the amount of 
analyte extracted in the dialysate as a function of time116. Therefore absolute recovery 
increases with increasing flow rate, up until the point that the diffusion rate of the analyte 
across the membrane becomes the limiting step152. In vivo, the relative recovery of a 
substance should remain constant throughout the experiment, provided that perfusion 
conditions do not change, while absolute recovery will alter depending on how much of the 




1.8.1.1.2 Factors that influence recovery 
Recovery is influenced by several factors (Table 1-1). To optimise recovery in vivo, 
experiments to determine ideal recovery conditions are often first performed in vitro. In such 
experiments, the microdialysis probe is submerged in a bath solution (‘water bath’) containing 
varying concentrations of the analyte of interest. By comparing the concentration in the 
recovered sample with the concentration in the water bath, the relative recovery can be 
calculated under different flow rates, types of perfusate154, or probe conditions155.  
Flow rate of the perfusate 
Composition of the perfusate 
Membrane length and molecular weight cut-off  
Temperature of the probe 
Structure of the sample matrix (tissue) 
Table 1-1 Factors influencing recovery in microdialysis experiments (Plock & Kloft, 2005). 
As hinted at, the flow rate of the perfusion fluid is a major determinant of recovery, and in 
general, lower flow rates result in higher relative recovery and closer matching to ‘true’ tissue 
values. Therefore, flow rate may be crucial when the analyte of interest is only present in 
very low concentrations116. In practice, flow rates in most microdialysis experiments range 
from 0.3-5.0µL/min116. Recovery rates for glucose, urea and glycerol equal 100% at very 
slow perfusion rates156 but the obvious consequence of slow flow is small sample volumes 
per unit time. Increasing perfusion speed in order to obtain larger samples comes at the cost 
of potentially reducing relative recovery, and paradoxically, the risk of perfusate loss into 
surrounding tissue caused by pressure increases within the tubing (ultrafiltration)116.  
The chemical composition of the perfusate should be as similar as possible to the essential 
physiological makeup of the sampled extracellular space (interstitial fluid). Typically this is an 




recovery of certain types of analyte, or to reduce ultrafiltration125,157,158. The addition of a 
colloid to the perfusate, for example can reduce loss of perfusate across the membrane that 
occurs at very low flow rates156. 
Increasing the length of the membrane increases the area available for diffusion, and thus the 
relative recovery – a 30mm membrane has a significantly larger area than a 10mm probe – 
but again, the trade-off of increasing membrane length is the greater likelihood of 
ultrafiltration116. The physical composition of the membrane material, the pore size159 and the 
type of molecule160 determine the maximum size of molecules that can reliably traverse the 
membrane surface and enter the microdialysate.  
Since diffusion rate is directly influenced by temperature it is asserted that microdialysis 
should occur at ‘constant’ temperatures, preferably body temperature116. However, since the 
mammalian body temperature has a circadian rhythm25 this may prove challenging. 
Nevertheless, when sampling in vivo the choice of sampling site is important since it may be 
subject to large changes in environmental conditions during the experiment.  
While probe ‘calibration’ in a water bath provides an estimate of relative recovery, the 
relationship between the true extracellular (interstitial) concentration and what is measured 
in the dialysate is much more complex. The local composition of the extracellular matrix, 
metabolism, ability of the analyte to passively or actively transport across membranes, and 
local blood supply may all influence in vivo recovery of a substance152. 
1.8.2 Structure of the interstitial space 
The interstitium describes the space containing supporting and connective tissues localised 
outside of the parenchyma, blood, and lymphatic vessels. The interstitial space consists of 
two principle components, interstitial fluid (IF) and the extracellular matrix (ECM)161. The 
interstitial fluid makes up around 20% of body weight and serves several important functions. 




capillaries, and immune regulation by delivery of antigens and cytokines to local lymphatic 
nodes161. The exact composition of interstitial fluid varies depending on the organ, its 
functional cycle, permeability of surrounding capillaries, and the influence of underlying 
pathology or inflammatory processes161.For example, placement of a microdialysis probe 
within the interstitial space itself may cause trauma and a local inflammatory response162,163.  
The extracellular matrix (ECM) consists of a framework of collagen fibres, 
glycosaminoglycans, salt solution, and proteins that have either been produced locally164 or 
originated from the plasma. The composition of the matrix regulates local tissue fluid balance, 
the ability of molecules to diffuse by steric and charge exclusion, and the interstitial fluid 
pressure161. Therefore, sampling from interstitial spaces requires the investigator to 
appreciate that measurements may be strongly influenced by conditions within the interstitial 
space and surrounding tissues.  
When using samples obtained from the interstitium to estimate concentrations of the same 
analyte in blood, it is extremely important to recognise that the analyte content of interstitial 
fluid is not simply an instantaneous reflection of the systemic circulation. The degree to 
which molecules may or may not be able to freely diffuse from capillaries and navigate the 
interstitial space can result in a time lag between blood and interstitium, altering equilibration 
conditions, and consequently the degree to which dynamic changes in plasma are reflected in 
the interstitial fluid. This is not a unique situation to sampling with a microdialysis probe. Time 
delay between blood and the interstitial changes in glucose concentrations is a well-
recognised phenomenon, and affects the accuracy of subcutaneous electrochemical 
continuous glucose monitors (CGM) to estimate plasma glucose concentrations165. The lag, 
and the consequent effect on glucose fluxes, means that the measurements in the 






Humans have evolved to live in a dynamic environment, and rhythmicity has become an 
intrinsic and ubiquitous feature of human physiology. Rhythms of different periods 
coordinate and synchronise to create systems of dynamic equilibrium that can uniquely adapt 
to the circumstances of the individual. 
Essentially all hormonal and metabolic processes are rhythmic and are coordinated by an 
intricate system of cellular clocks and feedback/feedforward loops that coordinate 
physiological processes so that function is optimised for the appropriate time of the day. 
Misalignment, or loss of rhythm synchrony, is associated with pathological outcomes, 
although to date, most of the evidence in humans is associative and there is a substantial lack 
of knowledge about the mechanisms by which asynchrony causes disease. 
Traditional methods for high frequency measurement of dynamics are burdensome and 
invasive, while single time point, single measurement sampling regimens fail to capture the 
dynamics and interactions of hormones and metabolism, and the significant interindividual 
variation that exists. The technique of microdialysis combined with a portable sample 
collection device presents as an attractive solution for the dynamic measurement of small 
molecule hormones and metabolites. 
1.10 Aims, hypotheses, and objectives 
The purpose of this thesis is to describe the development of a novel microdialysis sample 
collection system – U-RHYTHM - for measurement of dynamical changes in hormones and 
metabolites - metabolodynamics. The technique is less invasive than standard diagnostic 
procedures and has the potential to provide an increased understanding of human endocrine 





1. To describe the use, improvement, and acceptability of a prototype method for 
ambulatory dynamic sampling of hormones and metabolites. 
2. To identify limitations of the current technique and areas for future development. 
3. To provide an initial validation of microdialysis measurements of multiple adrenal 
steroids and metabolites against traditional measurements in blood. 
1.10.2 Objectives 
1. Develop and optimise a novel microdialysate sampling device and analysis system for 
in vivo ambulatory hormone and metabolomic profiling in humans. 
2. Apply the methodology in laboratory validation settings, and in ambulatory free-living 
conditions.  
1.10.3 Hypothesis 
In addition to cortisol, multiple other adrenal steroids, metabolites, and the hormone 
melatonin will be detectable in the subcutaneous fluid, temporally correlate with blood, 




2 General Methods 
2.1 Introduction 
This chapter describes the general equipment, methods, and laboratory-based assays used in 
the in vitro and in vivo studies that form this thesis. Study-specific protocols using the 
equipment and assays are described in the relevant chapters. 
2.2 Microdialysis procedure 
Equipment certified for human clinical microdialysis was purchased from M Dialysis AB 
(Stockholm, Sweden) including the portable microdialysis pump, pump syringe, and sampling 
catheter.  
2.2.1 Portable microdialysis pump 
The model 107 microdialysis pump (Figure 2-1) is a small portable device that weighs 70g, 
including the 6V battery. The infusion rate is selected by the user - in all experiments this was 
pre-set to 1 µL/minute. Pumps are manufacturer calibrated to a flow rate tolerance of +/-5% 
at 0.3µL/minute. Pumps were returned to the manufacturer for servicing and calibration 
checks at 24-month intervals.  
 
Figure 2-1 107 microdialysis pump. 
2.2.2 Microdialysis catheter 
The 66 linear microdialysis catheter (Figure 2-2) is a sterile, single use device licenced for use 




using a 21g needle with 50mm length. The catheter is available with either 10 or 30mm 
length and 0.5mm diameter polyarylethersulphone membrane, and with either a 20kDa or 
100kDa molecular weight cut-off. In all clinical studies described, the 20kDa, 30mm probe 
was used. The probe inlet and outlet tubing consist of 0.38mm diameter polyurethane 
measuring 400mm and 100mm in length, respectively. The dead volume of the outlet tubing 
is 1.8µL.  
 
Figure 2-2 A 66 linear microdialysis catheter and introducer needle. .  The membrane can be seen in the bottom right. 
During experiments, probes were perfused using a 2.5mL sterile, single use syringe (model 
106) filled with 2.0-2.5mL of sterile, isotonic ‘Perfusion fluid T1’ (see Table 2-1 for 
composition). 
NaCl 147mmol/L 
KCl 4 mmol/L 
CaCl2 2.3mmol/L 
Total chloride content 155.6mmol/L 
Osmolality 290mOsm/kg 
pH ~6 
Table 2-1 Contents of Perfusion Fluid T1 used in clinical microdialysis experiments. Source: mDialysis data sheet, M 
Dialysis AB Hammarby Fabriksväg 43, SE-120 30 Stockholm, Sweden. NaCl = sodium chloride, KCl = potassium chloride, 




2.2.3 Commencement of sampling procedure 
Fitting of the syringe and closing the 107-pump lid initiates a 5-minute flush sequence (flow 
rate 15 µL/minute, total volume of flush 75 µL). The flush liquid is discarded prior to the 
commencement of sample collection. 
As the manufactured probe outlet length is only 100mm, it is necessary to extend this length 
to connect the portable microdialysis sample collector (U-RHYTHM). This is achieved by 
attaching 20-25cm of fluorinated ethylene propylene (FEP) tubing (dead volume 1.2µL/10cm, 
Microbiotech/SE, Stockholm, Sweden) using specialised tubing adaptors (Microbiotech/SE) 
pre-soaked in 100% ethanol. 
2.2.4 Microdialysis sample collection using U-RHYTHM 
For ambulatory microdialysis experiments, microdialysate samples were collected and stored 
in a prototype fraction collector. The concept, basic design and general mechanism of action 
of the ‘sampler’ has been described previously117 (see also Figure 2-3). However, during the 
period of this project substantial improvements were made to both the form and function of 
the device. The development of the prototype is described in detail in Chapter 3, including 





Figure 2-3 Block diagram illustrating how microdialysis samples are collected and stored using the U-RHYTHM sampler. 
The infusion pump (top left) delivers a continuous flow of perfusion fluid through the microdialysis probe, which is 
connected to the U-RHYTHM sampler using a tubing adapter. Inward flow of fluid triggers the pressure sensor (right) and 
activation of the servo pumps (centre), which act to maintain a consistent low-pressure system and steady flow of fluid 
through the device. At set time intervals, a second pump (bubble pump, lower left) pushes a volume of air into the tubing, 
separating the sample fluid column with air bubbles. The separated samples are stored in a coil of plastic tubing (typically 
5.0m in length) until the end of the sampling session. Image from Bhake et al. (2013). 
2.2.5 Sample timing 
Since microdialysis fluid was generated continuously during sampling, the midpoint of each 
sample was taken as the sample time (e.g., microdialysis fluid collected between 09:01-09:20 
would be labelled 09:10, between 09:21-09:40 labelled 09:30 and so on).  
2.3 In vitro relative recovery and volume recovery experiments 
2.3.1 Perfusion equipment 
Plastic 2.5mL or 5.0mL luer lock syringes (Terumo UK, Bagshot, Surrey, UK) were prefilled 
with the selected perfusate and fitted to an 8-gang programmable syringe pump (Harvard 




216mL/min). The pump was programmed to replicate the flow parameters of the portable 
microdialysis infusion pump (see previous section) when delivering at 1µL/min – specifically: 
1. Flush sequence - infuse at 15µl/min for 5 minutes. 
2. Deliver 0.5µL over 1 second. 
3. Pause 29 seconds. 
4. Repeat from Step 2. 
2.3.2 Relative- and volume-recovery experiments 
Solutions containing analytes for recovery were prepared in 0.9% physiological saline and 
dispensed into 50mL Falcon tubes (Fisher Scientific, Loughbrough, UK). The tubes were then 
placed in a water bath heated to 37ºC with constant agitation (20 rpm). Following connection 
to the infusion pump, microdialysis probes were submerged in the recovery solution and 
allowed to equilibrate for 20 minutes before any sample was obtained for analysis. Samples 
were recovered into 300µl polypropylene microvials (Microbiotech/se). The recovered 
volume per unit time was calculated by subtracting the weight of the sample collection vial 
before and after sample collection. To calculate relative recovery, the measured 
concentration in the recovered sample was divided by the concentration in the water bath. 
2.4 Description of the ULTRADIAN study 
The “Dynamic Hormone Diagnostics in Endocrine Disease (ULTRADIAN)” study 
(NCT02934399) was a multi-centre observational study sponsored by Haukeland University 
Hospital, Norway with collaborating partners at the Karolinska Institute, Sweden, University 
of Bristol, United Kingdom, and Evangelismos Hospital, Athens, Greece. 
The purpose of the study was to use novel ambulatory microdialysis technology to 
investigate daily profiles of hormones in the subcutaneous tissue of healthy people and 





Males and females aged 18-68 were eligible for the study. General exclusion criteria included 
pregnancy or lactation, alcohol intake >26 units/week, and use of interfering medication.  
For the healthy volunteer cohort, specific exclusion criteria were BMI <16.0 or >29.9, active 
medical conditions, regular medication, prior or current endocrine disease, use of 
glucocorticoids within 3 months, and current illicit substance use. For the comparative blood 
sampling studies, tobacco smokers and women taking estrogen containing oral contraception 
were excluded (see Section 4.3 for more details). 
For the investigation of participants with endocrine disease, patients with biochemically 
confirmed Cushing’s syndrome (pituitary or adrenal origin) and primary aldosteronism were 
included before and after surgical intervention. Patients with a biochemical confirmation of 
autoimmune primary adrenal insufficiency (presence of adrenal autoantibodies) taking 
standard oral glucocorticoid replacement were also included. 
2.5 Blood sampling using the Human Automated Blood Sampling system 
For 24-hour comparison studies between microdialysis and plasma, an automated system 
was used to draw samples of peripheral venous blood (Human Automated Blood Sampling 
(HABS))47. Briefly, the HABs system consists of a peristaltic pump, fraction collector, and 
standard medical infusion pump, attached to an interface unit controlled by a personal 
computer. Collection of blood samples is achieved by entering a timed and repeated 
sequence of events into the computer software (flush the line, draw blood, move the fraction 
collector head etc.). To obtain samples, participants were cannulated using an 18g peripheral 
venous catheter placed in an antecubital vein, to which the blood sample collection and flush 
line were attached. The HABs device was placed in an adjacent room, to avoid disturbing the 




collection tubing were flushed with physiological saline (0.9%) containing 1000 IU/litre 
heparin sodium, to prevent line occlusion caused by the formation of blood clots. 
2.6 Collection of plasma and saliva samples 
2.6.1 Plasma samples 
Aliquots of whole blood were immediately centrifuged at 4°C for 5 minutes at 2000rpm. The 
separated plasma was then pipetted into 2.0mL storage tubes (Sarstedt AG & Co. KG, 
Nümbrecht, Germany). Plasma for metabolomics was snap frozen to -80°C on dry ice 
immediately after centrifugation. Other sample types were frozen at -20°C until the end of 
the experiment and then stored at -80°C until analysis. 
2.6.2 Saliva samples 
Participants were provided with a cotton swab saliva collection system (Sarstedt Salivette® 
Cortisol) for collection of samples. Saliva was obtained by either placing the swab into the 
mouth and chewing for approximately 1-2 minutes until the swab was soaked with saliva. 
Participants were instructed not to consume food, any liquid other than water, or brush teeth 
within 30 minutes of collecting saliva samples. Participants were asked to store the sample at 
room temperature, and all samples were returned with 24 hours of collection. Extraction of 
saliva from the swab was achieved by centrifugation at 1000g for 2 minutes as per 
manufacturer’s instructions. 
2.6.3 Measurement of plasma ACTH and analysis of adrenal metabolome by 
ULTRADIAN multiplex adrenal steroid panel  
Multiplex analysis of adrenal steroids in microdialysate and plasma was performed at 
Haukeland University Hospital, Bergen, Norway. All samples were analysed by liquid 
chromatography-mass spectrometry using an assay developed and expanded from a 
previously published method166,167 and further optimised for measurement of free steroids in 




developed specifically for the ULTRADIAN study (NCT02934399) and have not yet been 
published in a peer-reviewed journal.  
Microdialysis samples were decanted from the sample spool into 300µL polypropylene vials 
(Microbiotech/se), capped with rubber lids and placed in 96 well plates (Fisher Scientific Ltd). 
Multiplex steroid measurement in the microdialysis samples was achieved using a fully 
automated robotic system and 10µL of sample fluid. Appendices I and J provide details of the 
measuring range, precision, and accuracy for each steroid in the panel.  
Measurement of plasma adrenocorticotropic hormone (ACTH) in 200µL aliquots of plasma 
was achieved using the Siemens IMMULITE 2000 immunoassay system (Siemens Healthcare 
GmbH, Erlangen, Germany).  
2.6.4 Quantification of metabolites in plasma and microdialysate 
Concentrations of metabolites in plasma and microdialysate were determined using the 
AbsoluteIDQ p180 targeted metabolomics kit (Biocrates Life Sciences AG, Innsbruck, Austria) 
with a Waters Xevo TQ‐S mass spectrometer coupled to an Acquity ultra performance liquid 
chromatography (UPLC) system (Waters Corporation, Milford, MA) The method of analysis is 
described in detail in Isherwood et al. (2017)168. Briefly, the kit measures concentrations of up 
to 184 compounds including amino acids, biogenic amines, glycerophospholipids, and 
sphingolipids (see Appendix L for list and Chapter 3 for further description). The order of 
samples was randomised with three levels of quality control (QC). Data were normalised 
between batches using the Biocrates METIDQ software (QC2 correction). Metabolites were 
excluded where >25% concentrations were below the limit of detection (<LOD), below the 
lower limit of quantification (≪LLOQ), or above the limit of quantification (>LOQ), or blank 




2.6.5 Simultaneous measurement of glucocorticoids and melatonin 
Simultaneous measurement of total and/or free cortisol, cortisone and melatonin was 
performed in samples of plasma, saliva and microdialysate at a collaborator laboratory at 
University Medical Center Groningen (UCMG). Microdialysis samples were prepared in Bristol 
by first decanting the whole volume into 0.2mL polypropylene tubes. Tubes were centrifuged 
at 1000g for 60 seconds and 10µL of each spun sample pipetted into 700µL capacity 96-well 
sample plates (Waters UK Ltd., Elstree, UK). Aliquots of saliva and venous plasma (250µL) 
were pipetted into 2.0mL Eppendorf tubes. All samples were then frozen at -80ºC prior to 
transfer. At UCMG, the analysis method involved online solid phase extraction before 
quantification by liquid chromatography-mass spectrometry (LC-MS/MS). The method has 
previously been validated in plasma and saliva169 and was further optimised for very low 
volume samples in microdialysate. The lower limit of quantification for cortisol and cortisone 
was 0.2nmol/L in microdialysate and 0.1nmol/L in saliva, and for melatonin the lower limit of 
quantification was 10pmol/L in microdialysate and 4pmol/L in saliva.  
2.6.6 Peripheral skin temperature measurement and validation 
Core body temperature (CBT) is a circadian phase marker that closely corresponds with 
melatonin phase and sleep propensity170. However, since CBT measurement is invasive, 
alternative methods including measurement at peripheral skin sites can provide useful and 
valid estimates of the daily rhythm171–174. Since there is no ‘gold standard’ of peripheral skin 
measurement, it was important to report the method and conditions of measurement as 
accurately as possible to allow valid comparison with other studies175.  
2.6.6.1 Ambulatory studies of hormones and wearable devices 
In the studies described in Chapter 6, peripheral skin temperature was measured from the 
dorsum of a finger using a consumer-grade sleep tracking ring containing an uncalibrated 
negative temperature coefficient thermistor (resolution 0.07ºC, Oura ring, Oura Health Ltd., 




downloaded as tables in comma separate value (CSV) files from the Oura Cloud Dashboard 
(cloud.ouraring.com/dashboard). The advantage of the Oura ring over other methods for 
peripheral skin temperature measurement171 include the ease of wear, waterproof design, 
and ability to data transfer wirelessly using a Bluetooth connection and mobile phone 
software. 
Validation of the Oura temperature data was performed at the University of Bristol in 4 
healthy volunteers (n=1 female, mean age 37) against a commercially available temperature 
data logger (iButton, Maxim Integrated, model DS1922L-F5#, San Jose, CA, USA), commonly 
used in sleep/wake research176. The iButton has a mean accuracy of -0.09°C and precision of 
0.05°C177. Data from the iButton were transferred using an adapter (DS1402D, DS9490R, 
Maxim) to a computer running OneWireViewer 4.1.0 (Maxim). 
Experiments were conducted on skin of the non-dominant arm overnight (length of 
comparison ranging between 15.3-25.5 hours). Participants were fitted with an appropriately 
sized Oura ring worn on one of the middle 3 fingers of the hand. iButtons were configured at 
11-bit resolution (0.0625ºC) allowing up to 4096 sequential temperature recordings at 1-
minute temporal epoch. One iButton was fitted to the volar aspect of a finger adjacent to the 
Oura ring, between the metacarpophalangeal and proximal interphalangeal joints with a 
waterproof dressing. A second iButton was placed over the radial artery and held in place 
with an elasticated cotton band as previously described174. Measurements using the Oura 
ring were very highlighted correlated with those of the finger iButton (mean Pearson r = 0.98, 
p<0.001). The full results of the validation studies are presented in Appendix N. 
2.6.7 Dynamic time series analysis tool 
A toolkit for analysis of the time series data was developed by the author with assistance 




The toolkit was implemented in the NumPy (ver. 1.19.1), SciPy (ver. 1.5.0), and Matplotlib 
(ver. 3.2.2) numeric libraries for Python (ver. 3.7.6), available at http://www.scipy.org and 
https://www.python.org.  
The script performed the following functions: 
1. Read time series and specify pairs of time series elements to compare (E1, E2). 
2. Interpolate data where plasma and microdialysate samples are offset by 10 minutes. 
3. For missing data points, do not interpolate more than 3 consecutive points. 
4. Calculate the ratio of E1:E2 at each time point. 
5. Calculate the area under the curve for each element using Simpson’s rule. 
6. Calculate the Spearman correlation coefficient of E1 compared with E2. 
7. Calculate and plot the first order differentials with Spearman correlation. 
8. Standardise each element by Z-score (𝑍 =  
𝑥− ?̅?
𝜎
) and plot the data. 
9. Plot the Z-scored rolling mean with Pearson correlation coefficients. 
10. Plot the autocorrelations of each element. 
11. Calculate and plot time lagged cross-correlation to determine peak synchronicity178, with 
Spearman correlation coefficients. 
12.  Plot a heatmap of windowed time lagged cross-correlation. 
13. Plot heatmap of rolling window time lagged cross-correlation. 
14. Plot the instantaneous phase synchrony of E1 with E2, a measure of the moment-to-
moment synchrony of the compared time series179. The phase angle of each signal is 
extracted using the Hilbert transformation180 using a 3 sample data frame that has been 
passed through a narrow band filter (0.05-0.5Hz, Butterworth bandpass filter181). The 
angle is zero when both series are in phase, and phase coherence can be plotted in the 





3 U-RHYTHM: Development of the microdialysis sampling 
device 
3.1 Introduction 
Microdialysis is a minimally invasive technique that permits continuous sampling of the 
extracellular space. Modern microdialysis probes consist of narrow bore inlet and outlet 
tubing attached to a semi-permeable membrane, through which a continuous flow of fluid 
(perfusion fluid) is passed. The membrane mimics the function of a capillary blood vessel by 
allowing passive diffusion of analytes between the extracellular space and the perfusion fluid 
as it passes the membrane153. The fluid, which contains the diffused molecules from the 
extracellular space, is known as the microdialysate. The microdialysate is then recovered and 
its contents analysed. Traditionally, use of microdialysis has been restricted to experiments 
lasting a few hours, or for collection of few samples over longer periods. However, the 
development of a prototype method for ambulatory sample collection over the full 24 hour 
day117 gives rise to many possibilities including the characterisation of diurnal, circadian, and 
ultradian dynamic physiology in vivo. To be successful, the method needs to be translated 
from a prototype to a robust, reliable system feasible for general use in both clinical and 
research settings. In this chapter I will review the U-RHYTHM sampling system, describe 
improvements made to the prototype, identify its current limitations, and provide some 
suggestions for ways to potentially overcome these in the future. 
3.1.1 Application of microdialysis for human dynamic assessment 
Microdialysis has many inherent features that make it suitable for dynamic assessment in 
humans, principally because use is minimally invasive, no blood sampling is required, and 
unbound (free, active) levels of compounds can be assessed at tissue level. As no cells, large 
proteins or enzymes are present in the microdialysate fluid, no specific sample separation is 




at room temperature, or for long periods of time. For example, stability of glucocorticoids 
outside of blood plasma or serum has been demonstrated in hair182, and in saliva183 at 
ambient temperature for several weeks184. Concentrations of lactate and glucose in 
microdialysate are stable for at least 72 days when stored at -80 degrees185. 
However, in spite of the potential for dynamic analysis, most experiments in humans limit 
measurements to a handful of time points, or even just one or two147. In typical clinical 
experiments, microdialysis samples are obtained for no more than a few hours following a 
specific intervention, where tissue measurement is compared with plasma samples136. 
Limitations to the use of microdialysis over longer sampling periods have chiefly been related 
to practicalities. As microdialysate is produced continuously, investigators need to change 
sample vials by hand each time a new sample is collected. This makes it essentially impractical 
to perform whole day experiments, and consequently only a very few investigators have 
attempted this. Simmel et al. (2013) proposed microdialysis as a viable method for monitoring 
pharmaceutical drug levels over a several days in subcutaneous tissue146. In the proof-of-
principal trial, recovery of the antifungal drug voriconazole was monitored over a total of 87 
consecutive hours in 3 healthy volunteers using abdominal subcutaneous microdialysis146. 
Participants were allowed home between study visits and the authors reported that the 
method was well-tolerated. However, since microdialysate recovery was not automated, 
sample collection was restricted only to study visits, limiting the sampling resolution and the 




Table 3-1 Requirements of an ideal ambulatory microdialysis sampling system 
To make prolonged in vivo microdialysis viable, an effective but minimally intrusive method 
for collection of multiple microdialysis samples is required (Table 3-1). Part of the solution is 
to find a functional method for storing multiple samples collected over time. In human in vivo 
and isolated organ ex vivo experiments, Gowers et. al. (2018) collected and stored 
microdialysate containing glucose and lactate in 100cm sections of polyvinyl chloride (Portex) 
tubing185. Comparisons of stored sample with results from simultaneous real time analysis 
were generally in good agreement, although acute concentration changes detected in the 
online samples were attenuated in the ‘offline’ stored sample. The authors attributed this to a 
dispersion effect, presumably because stored samples were kept as a continuous column of 
fluid, not separated in any way185. 
In the same year as Simmel et al. (2013) reported the feasibility of multiple day microdialysis 
experiments,146 a novel method for automated microdialysis sample collection was published 
by Bhake et al. (2013)117. The paper described the use of a portable ‘sampler’, worn in a waist 
band, and connected to a commercially available microdialysis probe placed in abdominal 
subcutaneous tissue. The ‘sampler’ receivesd a continuous stream of microdialysate which is 
then transferred into a long spool of polytetrafluoroethylene (PTFE) tubing. However, rather 
than being stored as a continuous column, samples are formed by insertion of air bubbles at 
intervals of 10-20 minutes. Measuring each sample by immunoassay, a 24-hour profile of 
tissue free cortisol dynamics could be obtained without the need for any blood117. To validate 
High sampling frequency  
Relative recovery as close to 100% as possible 
Low risk to participants 






the technique, experiments in a small number of healthy adult males were performed, 
showing good agreement between Synacthen-stimulated or dexamethasone-suppressed 
cortisol measured simultaneously in plasma, tissue and saliva, with little or no delay between 
compartments, when sampled every 10 minutes119. Further studies in small groups of healthy 
male volunteers confirmed that ambulatory subcutaneous microdialysis profiles could be 
reproduced between participants, and in the same participant over several consecutive 
days186. 
In summary, it has been established that reproducible diurnal cortisol profiles can be 
obtainable using microdialysis in abdominal subcutaneous interstitial fluid. These profiles can 
be captured during ambulatory normal life using novel sampling technology that continuously 
collects and stores the microdialysis fluid. Evidence suggests that large changes in plasma 
concentrations are readily detected without substantial delay. 
3.1.2 From prototype to production 
Initially only a very small number of the ambulatory microdialysis sampling devices were built. 
These devices were used for testing and generation of proof of principle data and initial 
validation of the technique117,119,186. Each of these early ‘blue box’ devices were given a name 
based on the researchers that were testing them (Figure 3-1). However, it quickly became 
obvious that to complete larger scale clinical trials, more devices were needed. Funding for a 
large multi-centre trial of the technology (ULTRADIAN Dynamic Hormone Diagnostics, 
NCT02934399) was awarded and due to commence in 2016. ULTRADIAN was a multi-
centre clinical trial whose purpose was to investigate adrenal steroid metabolodynamics using 
subcutaneous microdialysis, with the goal of defining new methodology for endocrine 
diagnosis and disease management. Coincident with retirement of the original device 
inventor, the process for manufacture and development of new samplers was contracted to 





Figure 3-1 One of the very first samplers built at the University of Bristol. Built by hand, these ‘blue box’ prototypes were 
named after the researchers that used them (this one is named “Chrissa”). 
The brief for DesignWorks was to replicate the original design and produce multiple new 
‘blue box’ devices for ULTRADIAN trial partners in Bergen, Bristol, Stockholm, and Athens. It 
was considered that this should be a straightforward task. However, it soon became apparent 
that this would be significantly more challenging than originally thought. 
• The original prototypes had been hand built and performance optimised on an individual 
sampler basis. 
• Design plans were not always available and reverse engineering of key components was 
necessary. 
• Many of the electronic components used in the original ‘blueprint’ devices were now 
legacy items and had to be replaced with modern alternatives whose performance had not 
been tested. 
The result of this combination of factors was the production of cloned ‘blue box’ samplers 
that were not fit for purpose. Sampling quality was highly variable with failure almost 
inevitably occurring after 12-14 hours as samples within the spool tubing became 




sampling over a full 24-hour period required for commencement of the ULTRADIAN clinical 
trials.  
 
Figure 3-2 Microdialysate fluid seen in the tubing of the collection spool. This is an example of poor-quality sampling. The 
fluid is fragmented into multiple small collections separated by variable length air gaps.  
A key reason for this was the inability of the sampling device to compensate for the 
cumulative build-up of pressure within the sample spool, caused by the repeated insertion of 
air bubbles. A work around of using shorter length spools and restricting sampling to 12-hour 
periods was dismissed as impractical. 
Since a device capable of producing 24-hour sample profiles without failure was crucial for 
the success of the ULTRADIAN grant, clinical trials were forced into delay, a major setback 
for the project. A solution was urgently needed, and so DesignWorks began a complete 
design and manufacturing process overhaul. In early 2017, a new fully functioning sampler 
prototype (Figure 3-3) was presented to the consortium and became available to test. The 
device was named ‘U-RHYTHM’. It was during this transition that I commenced my PhD 






Figure 3-3 The successor to the original ‘blue box’ microdialysis sampler, U-RHYTHM. The device was introduced in 2017 
after a complete design and manufacturing overhaul. U-RHYTHM finally offered the chance of robust, repeatable 
sampling performance over a full 24-hour period. 
3.1.3 Preparing for clinical trials 
Microdialysis samples generated by the U-RHYTHM device are low in volume due to the 
slow rate of perfusion of the microdialysis probe. The proposed steroid analysis panel was 
tested and optimised for a sample volume of 10 µL, which would be obtained in vivo at a 
probe infusion rate of 1 µL/minute, and sampling frequency of 20 minutes. This flow rate had 
been used successfully during development of the original sampler187 and in the published 
validation studies119,186. 
3.1.4 Adsorption affects recovery of free steroids  
A key objective of the ULTRADIAN clinical trial was to profile a broad variety of free adrenal 
steroids in subcutaneous tissue microdialysate. However, steroids are hydrophobic, and 
adsorption of hydrophobic compounds including steroids to laboratory plastic is a recognised 
problem188. Evidence suggests that the highly lipophilic (hydrophobic) compounds such as 
pregnenolone and progesterone are most significantly affected, but the choice of tube and 
type of vial are also very important, along with the material in which the steroids are 




analyte189, presumably because the peptides in solution compete for non-specific binding 
sites on the plastic surfaces. In the ULTRADIAN clinical studies, a microdialysis catheter with 
a molecular weight cut-off of 20kDa was chosen, meaning that in practical terms, molecules 
up to around 4-6kDa would be reliably recovered159. Larger molecules including peptides and 
proteins cannot cross the membrane, increasing the chance of lipophilic steroid adsorption. In 
addition, the ULTRADIAN sampling system contains multiple areas of surface contact where 
adsorption could occur. These include the probe material itself, extension tubing, internal 
surfaces within the sampler (see Appendix B), and the sample collection spool.  
Pilot work by collaborators in Bergen prior to the commencement of ULTRADIAN clinical 
trials confirmed that microdialysis samples retrieved from the spool were indeed affected, 
especially the most hydrophobic and lipophilic compounds. Direct infusion of a protein-free 
interstitial fluid surrogate (Ringer’s lactate containing cortisol, cortisone, androstenedione, 
17- hydroxy-progesterone (17-OH-P), and testosterone) into lengths of empty spool tube 
revealed substantial adsorption that was directly related to the length of tubing the sample 
had been exposed to - in other words, how far along the tube the sample had travelled. 
Recovery was much higher from 10cm tube sections (cortisol 94%, testosterone 87%) than 
sample that had passed through 300cm of PTFE (cortisol 43%, testosterone 11%). In a 
second experiment, interstitial fluid surrogate was sampled in vitro using a sampling catheter 
connected to a pre-U-RHYTHM ‘blue box’ sampler and spool. Recovery of cortisol and 
cortisone from the first sample in the spool was much lower (37% and 34% of the interstitial 
fluid surrogate) than the subsequent 4 samples (88-92% for cortisol and 94-107% for 
cortisone). Significantly, across all samples, there was no recovery of testosterone, and <5% 
recovery of androstenedione and 17-hydroxyprogesterone (unpublished data courtesy of Dr 
Paal Methlie, Haukeland University Hospital, Bergen, Norway). Since testosterone was at 
least partly recovered from samples of fluid directly injected into the spool, but not recovered 




hydrophobic compounds seems to occur both to the internal surfaces of the microdialysis 
sampling device as well as the spool tubing.  
A further experiment also undertaken in Bergen aimed to modify the surface of the sample 
tubing in an attempted to reduce the adsorption effect. Lengths of tubing measuring 250cm 
were pre-treated with either 0.002% bovine serum albumin (BSA), human interstitial fluid 
(expected to contain a small amount of low molecular weight peptides and other lipophilic 
compounds), or plain perfusion fluid (containing only electrolytes, and no hormones or 
peptides). Interstitial fluid surrogate (as described above) was then pumped through each 
piece of tube at 1µL/min for 26 hours. The tubing was then cut into sections to retrieve 
samples along its length. Sections treated with bovine serum albumin or human interstitial 
fluid showed substantially reduced adsorption and consequent improved recovery of 
testosterone, androstenedione, and 17-hydroxy-progesterone. By comparison, in the tubing 
treated only with plain perfusion fluid, recovery of these compounds was markedly reduced – 
no testosterone was recovered in the first 4 hours of samples, and no 17-hydroxy-
progesterone in the first 12 hours. Furthermore, when testosterone, androstenedione, and 
17-hydroxy-progesterone was eventually detected, concentrations were initially substantially 
higher than the reference (peak for testosterone 191%, androstenedione 227%, and 17-
hydroxyprogesterone 249%, Appendix B, unpublished data courtesy of Dr Paal Methlie, 
Haukeland University Hospital, Bergen, Norway).  
Based on these results, pre-treatment of the sample collection spools with bovine serum 
albumin was considered for all ULTRADIAN clinical samplings. However, the idea was 
ultimately abandoned because:  
1. Attempting to coat 5.0m of PTFE with albumin solution was a laborious task and 





2. The presence of BSA coating on the spool tubing surface caused microbubbles in the 
samples, affecting the sample quality, and making sample separation difficult.  
3. There was uncertainty about the stability of the BSA coat if left at ambient room 
temperature for prolonged periods of time. 
4. Both bovine and human serum albumin were found to be contaminated with trace 
amounts of adrenal steroids; only recombinant human albumin was pure.  
5. Coating the PTFE collection spool alone did not address the issue of binding in the 
manifold. 
6. Addition of albumin to the perfusion fluid as an alternative to coating the spool 
would significantly complicate the clinical procedure by introducing of potentially 
non-benign drug substance into otherwise bland, sterile perfusate.  
In summary, the material composition of the U-RHYTHM sampling system impacts on the 
recovery of lipophilic and hydrophobic compounds, which includes adrenal steroids. 
3.2 Aims and objectives 
My objective was to review and develop the prototype U-RHYTHM microdialysis sample to 
the point of being ready for formal certification as a clinical device, and a viable proposition 
for market use as a clinical and research tool. This chapter describes in detail: 
1. The development of methods and procedures for the use of the U-RHYTHM device 
including set-up, sampling procedures, and sample recovery. 
2. Audit and validation of sampler performance in vivo. 
3. Evaluation of the acceptability of the technique. 
4. Identification and further consideration of factors that might be contributing to 
inconsistent hormone recovery, including investigations into alternative perfusates and 
methods to reduce adsorption of lipophilic compounds.  
5. Investigation of a broad range of metabolites (amino acids, biogenic amines, acylcarnitine, 




a. Stability of metabolites (assessed by changes in concentration) following 
prolonged exposure to ambient environmental conditions as encountered during a 
simulated U-RHYTHM clinical sampling session, 
b. The extent (if any) of metabolite adsorption to the U-RHYTHM device and sample 
collection spool. 
1. It was hypothesised that hydrophobic metabolites and biogenic amines would be the 
most likely to be affected by prolonged exposure to ambient conditions, and that 
adsorption would affect concentrations of hydrophobic metabolites. 





3.3 The development of methods and procedures for the use of the U-
RHYTHM device 
3.3.1 Basic description of the U-RHYTHM sampling procedure 
Conducting a 24-hour sampling session involves completion of several steps, as outlined 
below: 
1. Preparation of the U-RHYTHM with a 5.0m spool of PTFE tubing which stores the 
microdialysis fluid samples collected during the sampling session (Figure 3-4). 
 
Figure 3-4 Example of spool cassette containing 5.0m of spool tubing. The spool attaches to the sampler using a Click-N-
Seal® microfitting (Diba Industries, Inc, CT, USA, top left of image). Due to the repeated insertion of air bubbles, pressure 
within the spool increases substantially over the sampling period. To prevent sudden depressurisation and sample 
damage, the tubing must be clamped close to the microfitting prior to disconnection from the U-RHYTHM sampler. In 
this Figure, a plastic Cole Palmer ratchet clip is being trialled. 
2. Placement of the microdialysis probe into the participant.  
3. Connection of the microdialysis probe to the U-RHYTHM device. 
4. Collection of microdialysis fluid samples. At a sampling frequency of 20 minutes, 72 
samples are produced every 24 hours, formed as a sequence of fluid columns each 
separated by air bubbles, within the spool tube. Samples move gradually further along the 
tube as new samples are added to the collection. 
5. Removal of the probe at the end of the sampling session. 




3.3.2 Improvements to the sampling process 
With the introduction of the U-RHYTHM device, several areas for improvement were 
identified for the process of conducting a 24-hour sampling session. These included 
standardising the setup and preparation of the device, formalising consistent operating 
procedures for starting and ending a microdialysis session, and introducing standardised 
methods for sample retrieval and processing.  
3.4 Test of sample viability by direct freezing in the spool 
Retrieval of samples from the sample spool is time consuming and requires training and 
expertise to perform properly (see next section). Currently this procedure is done at the site 
of sampling, which potentially restricts more generalised use of U-RHYTHM by non-expert 
users. Successful freezing of the microdialysis samples within the spool immediately after 
completing a session would add flexibility and appeal by allowing the spools to be safely 
shipped to a centralised location for processing and analysis. 
3.4.1 Procedure 
Tests (n=3) were performed using a single U-RHYTHM device fitted with 5.0m spools of 
sample tubing. For each test, a CMA 107 portable microdialysis pump was used to deliver T1 
perfusion fluid at the standard rate of 1µL/min. Samples were delivered to the spool for 26-
28 hours, and at the end of each test, the spool containing the samples was removed and 
frozen at -80ºC for at least 48 hours. 
3.5 Audit and validation of sampler performance  
3.5.1 In vitro volume recovery 
To ensure that the microdialysis sampler itself was not inhibiting the flow of microdialysate, 
the volume of sample produced every 20 minutes by the U-RHYTHM device was compared 
with a control infusion line in which no sampler was attached. Samples from the control line 




vials. The mean volume of the control samples was compared with the mean of the U-
RHYTHM samples using a two-tailed t-test assuming unequal standard deviations (Welch’s t-
test) at a significance level of p<0.05. 
3.5.2 In vivo estimates of volume recovery  
Estimations of sample volume recovery were calculated for each successfully completed 
sampling at the University of Bristol recruitment site. This was done by identifying individual 
samples within the spool tubing, measuring the sample length, and then using this 
information to calculate an approximate volume.  
The estimated volume of each measured sample was calculated according to: 
𝑉𝑜𝑙𝑢𝑚𝑒 =  𝜋 ×  𝑟2 × 𝑙  





Since the probe was infused at 1µL/minute and the sample separation frequency was 20 
minutes, the ideal measured sample length should be 25.46mm, if 100% of the sample 
volume was recovered.  
To investigate if there were significant differences in the volume of samples within each set 
of samples (within sampling variation), the mean lengths of each sample in the sequence were 
compared. Because repeated measures ANOVA cannot handle missing values, data were 
analysed by fitting a mixed model as implemented in GraphPad Prism 8.0 (GraphPad 
Software LLC, San Diego, USA). The mixed model uses a compound symmetry covariance 
matrix and is fitted using Restricted Maximum Likelihood (REML). In the absence of missing 
values, this method gives the same P-values and multiple comparisons tests as repeated 
measures ANOVA. In the presence of missing values (missing values assumed to be at 




assumed and so GraphPad Prism was asked to apply the Geisser-Greenhouse correction as 
part of the analysis. 
3.5.3 Sampling success rate 
The outcome of each clinical sampling session conducted as part of the ULTRADIAN clinical 
trials was recorded in a centralised database. To obtain a list of successful samplings from all 
sites, records were queried according to the following conditions: SAMPLING_DATE = 
>01/04/2017 AND GroupName EITHER “Patient” OR “Control” AND SAMPLING_SUCCESS = 1 
[“Yes”] AND “SAMPLE_APPROVAL_STATUS” = 1 [“Include”]. From this subset of records, the 
field “Comment” was then reviewed, further records were excluded if comments indicated 
that the sampling did not meet study criteria for inclusion.  
To identify sampling failures, records were queried according to the following conditions: 
SAMPLING_DATE = >01/04/2017 AND GroupName EITHER “Patient” OR “Control” AND 
SAMPLING_SUCCESS = 2 [“No”]; in addition records where SAMPLING_SUCCESS = 1 [“Yes”] 
AND SAMPLE_APPROVAL_STATUS ≠ 1 were also included as sampling failure. A flowchart 
of the process is included in Appendix C.  
In addition to recording success or failure, partners were requested to record in detail issues 
encountered during sampling sessions using an online reporting form (Microsoft Forms, 
Microsoft Office 365 Enterprise for Faculty, Microsoft Corporation), distributed from August 
2018. The form prompted confirmation that Standard Operating Procedures had been 
followed and allowed users to provide specific information about the suspected cause of 
sampling failure (Appendix D). Data from the form were exported into Microsoft Excel 
spreadsheet format for review. 
3.5.4 Safety profile 
All adverse events related to ULTRADIAN sampling were recorded in Clinical Record Forms 




insertion of the microdialysis probe since it involves skin puncture and the placement of a 
foreign body in subcutaneous tissue. Researchers were not expected to report minor 
discomfort during insertion of the probe, trivial or minor bleeding and/or very minor bruising 
around the insertion site. Participants were counselled during the consent process of these 
possible outcomes and the theoretical risk of infection at the puncture site, mitigated using 
aseptic insertion technique and sterilised equipment, and possible reaction to the adhesive 
material used to secure the probe.  
Attachment of the U-RHYTHM device to the microdialysis probe was not felt likely to 
increase risk, since the device otherwise has no physical contact with the participant, and 
internal design mechanisms prevent retrograde flow of perfusate (microdialysis fluid is 
prevented from flowing in the reverse direction).  
3.6 Investigation into factors influencing hormone recovery 
3.6.1 Effect of perfusion fluid on volume and relative recovery of cortisol and 
testosterone in vitro 
Hydrocortisone (as sodium phosphate, Amdipharm UK Ltd) and testosterone (Sigma Aldrich) 
were reconstituted in methanol and diluted to 20nmol/L and 800pmol/L respectively in 0.9% 
saline. Solutions of 10% (2-Hydroxypropyl)--cyclodextrin and 10% (2-Hydroxypropyl)--
cyclodextrin were made up in 0.9% saline (Wacker Chemie AG, Burghausen, Germany).  
The saline solution containing testosterone and hydrocortisone was divided into 3 sample 
vials, and a 20kDa microdialysis sampling membrane submerged in each vial. The vials were 
placed in water bath as described in the General Methods chapter. Membranes were then 
perfused with either 0.9% saline, 10% -cyclodextrin, or 10% -cyclodextrin. After discarding 
the initial 20 minutes of sample fluid, samples were then retrieved every 20 minutes. The 
mean volume of saline samples was compared with the mean volume of cyclodextrin samples 




Outliers in the recovered hormone concentration data were identified using an inbuilt 
method within GraphPad Prism 8 (ROUT, GraphPad LLC)190. The method was configured so 
the false discovery rate of outliers should not exceed 1%. Differences in the mean 
concentration of hormone recovered in the saline, β- and γ-cyclodextrin conditions were 
assessed using a Brown-Forsythe one-way analysis of variation (ANOVA) since equality of 
group variance was not assumed. Post-hoc multiple comparisons were performed using 
Dunnett’s modified t-test (Graph Pad Prism 8, GraphPad LLC).  
3.6.2 Adsorption of adrenal hormones to the internal surfaces of the U-RHYTHM 
device and spool 
Experiments were conducted to investigate the extent to which modification of the 
hydrophobic internal surfaces of the U-RHYTHM device (see Appendix B – Material 
composition of the U-RHYTHM sampling system, U-RHYTHM manifold and internal 
components) and the surface of the plastic sample spool might affect measurement of 
microdialysate cortisol.  
3.6.2.1 Preparation 
Two experiments were conducted, and the methods are described in detail in Appendix G. In 
summary, the first involved pre-treatment of the sampler connection tubing, the internal 
surfaces of a U-RHYTHM sampler, and the internal surfaces of 5.0m of sample collection 
tubing with a solution containing the synthetic glucocorticoid methylprednisolone (Solu-
Medrone, Pzifer Limited, Walton Oaks, UK). By doing this methylprednisolone might adsorb 
to and block non-specific binding sites on the plastic surfaces, preventing adsorption of other 
adrenal steroids (i.e. hydrocortisone). Methylprednisolone was chosen as it could easily be 
distinguished from hydrocortisone in the mass spectrum during sample analysis.  
The second experiment involved surface modification of the same sampling components with 




Aldrich, now Merck Life Science, Gillingham, UK). By modifying the plastic surfaces in this 
way adsorption of hydrophobic compounds (hydrocortisone) might be reduced.  
In both experiments treated systems were compared with a ‘native’ system without any 
modification. Experiment and control U-RHYTHM devices were brand new at the time of the 
first experiment (no clinical use) and thus were considered clean and uncontaminated. In 
between experiment 1 and 2, both samplers were cleaned with 100% ethanol and then rinsed 
with Millipore water to remove any residual hormone. 
3.6.2.2 Procedure 
Solutions containing hydrocortisone 10nmol/L (as sodium phosphate, Amdipharm UK 
Limited, London, UK) diluted in 0.9% saline were infused through the U-RHYTHM sampler 
and into the attached to sample spools. Sample spools were changed after 27 hours and the 
experiment continued for a further 27 hours (Figure 3-5). Aliquots (10µL) of the first 16 and 
final 6 samples in every spool were retrieved and frozen at -80°C prior to analysis.  
To assess the potential effect of hydrocortisone adsorption to the collection vials, aliquots of 
the reference sample were pipetted either into untreated polypropylene tubes, or tubes that 
had been incubated for 24 hours with 5% w/v poloxamer 407. The treated vials were rinsed 
with deionised water and allowed to air dry before the experiment commenced. 
Analysis of the samples was performed at University Medical Centre Groningen with a 
Waters Xevo TQ-MS triple quadrupole mass spectrometer using a validated method169 
optimised for measurement in microdialysate. Hydrocortisone recovery was expressed as a 
proportion of an internal reference standard, measured simultaneously. The proportional 
recovery should remain constant (unchanged) in all samples if there was no effect of the 





Figure 3-5 Schema for testing the effects of surface modification on recovery of hydrocortisone. The concentration of 
hydrocortisone in samples in U-RHYTHM devices and spool tubing pre-treated with either 1mmol methylprednisolone or 
5% w/v poloxamer 407 was compared with samples from an untreated control sampler, and untreated spool tubing. 
3.6.3 Investigation of the stability of metabolites at ambient temperature, and any 
effect of the U-RHYTHM device on recovery in vitro  
3.6.3.1 Preparation 
A reference quality control sample (the ‘infusion solution’) containing metabolites (21 amino 
acids, 21 biogenic amines, 1 monosaccharide, 40 acylcarnitines, 90 glycerophospholipids, and 
15 sphingomyelins, Biocrates AbsoluteIDQ® p180 targeted metabolomics kit, Biocrates Life 
Sciences AG, Innsbruck, Austria) was defrosted from -80ºC and immediately infused through 
a clean U-RHYTHM sampler, which was later connected to 5.0m of spool tubing. During the 
experiment, the temperature around the sampler and syringe containing the infusion solution 
was continuously monitored (HOBO Pendant® UA-002-08, Onset Computer Corporation, 
MA, USA). 
3.6.3.2 Procedure 
To assess the effect of time and ambient storage conditions on concentrations of 
metabolites, two reference samples of the infusion solution were obtained. The first was 
taken from the metabolite mix immediately after defrosting (QCbaseline), and the second from 
infusion syringe after exposure to ambient conditions, at the end of the experiment (QCend). 










To assess the acute effect of contact with the internal surfaces of the U-RHYTHM device on 
metabolite concentrations, sample was collected from the sampler outlet over the first 40 
minutes and then between 160-200 minutes, and immediately frozen at -80°C. 
To assess any subsequent effect of contact with the plastic spool tubing on metabolite 
concentrations, the device was then connected to an empty 5.0m PTFE sample spool, 
allowing the metabolite test solution to enter and form air-bubble separated samples. During 
this part of the experiment, the U-RHYTHM sampler was placed in a waist band and worn on 
the body for 20 hours to simulate conditions encountered during an ambulatory sampling. At 
the end of this period sampling was stopped and the device and spool were left to pressure 
equilibrate overnight, as per standard procedure. Samples for analysis of metabolites were 
retrieved from the spool as follows:  
1. The first 4 samples that entered the sample collection spool were merged into a 1 sample 
to represent samples with the most contact with the spool, since this fluid had travelled 
the longest distance along the spool tubing.  
2. The final 4 samples in the spool were merged into 1 sample to represent samples with the 
least spool contact, since these samples had travelled the least distance in the spool. 
Concentrations of metabolites in samples (volume 15µL) were analysed at the University of 
Surrey as described in General Methods. A significant change in metabolite concentration 
was defined as greater than 20% deviation from the baseline reference (QCbaseline). Mean 
differences in the concentration of metabolites were assessed using Wilcoxon matched-pairs 
signed rank tests (GraphPad Prism 8, GraphPad LLC). 
3.7 Evaluation of the acceptability of the technique  
It was important to gather feedback from participants about their experience with the U-
RHYTHM device since to be viable as a clinical tool, it needs to be both a convenient and 




Satisfaction Questionnaire” (Appendix E) was developed by members of the ULTRADIAN 
consortium for this purpose. The survey consisted of 8 Likert items symmetrically balanced 
between ‘Strongly disagree’ to ‘Strongly agree’ and an open text box for free comments. 
Participants were asked to complete the survey at the end of each sampling session. 
Questionnaire data were collected on paper forms and then entered using REDCap electronic 
data capture tools hosted at the University of Bristol191,192. REDCap (Research Electronic 
Data Capture) is a secure, web-based software platform designed to support data capture for 
research studies, providing audit trails for tracking data manipulation and export procedures. 
Exported data was downloaded in comma separated value (CSV) format and analysed in 
Microsoft Excel (Version 2007, Microsoft Corporation, Redmond, USA) and GraphPad Prism 
8 (GraphPad Software LLC, San Diego, USA). 
3.8 Results  
3.8.1 A standardised method for ambulatory sampling 
3.8.1.1 Standard operating procedure for U-RHYTHM sampling sessions 
To ensure consistency of process across all ULTRADIAN sampling sites, a standard operating 
procedure (SOP) for insertion of the microdialysis probe was produced (Figure 3-6). A 
complementary video SOP was also professionally filmed in Bristol and distributed to all 
partners for reference. 
1. Placement of the microdialysis probe should be periumbilical and in a horizontal position, 
with the location on the left or right of the umbilicus depending on the preference of the 
participant. 
2. Insertion of the probe through the skin should follow the probe manufacturer guidance 




3. The introducer needle should be inserted pointing toward the midline so that when the 
probe is placed, the direction of microdialysate flow through the membrane is from medial 
to lateral. 
4. Local anaesthetic, while not mandated, should be offered to all participants, and where 
used, should consist of 1% lignocaine infiltrated at the entry and exit points. 
5. The syringe should be filled with 2.0-2.5mL of T1 perfusion fluid. Care must be taken to 
avoid air bubbles in the syringe. The syringe must be gently placed in the pump housing 
without applying any force. The pump lid must always be closed by squeezing the sides of 
the lid.  
6. Closing the pump lid will initiate a preprogramed pump flush sequence. This lasts for 5 
minutes and must be completed before the probe is attached to the U-RHYTHM device. 
7. The pump should be fixed to the side of the sampler using Velcro® or similar adhesive. 
8. The sampler and pump should be placed in an appropriately sized flexible waist band 
(Limber Stretch Hip Hug™, Limber Stretch, Egham, Surrey, UK) with the band positioned 
around the hips so that it does not cover the probe site. The base of the sampler faces 
toward the abdomen of the participant with the pump placed on top.  
9. The fit of the band should be snug enough that the sampler and pump do not move easily. 
The exact position of the sampler and waist band should be adjusted to the comfort and 




Figure 3-6 The U-RHYTHM microdialysis sampling system being worn by a healthy volunteer. The site of the 
subcutaneous microdialysis catheter membrane is marked with a solid black line. The microdialysis pump (inside the 
waist band, concealed and adjacent to the U-RHYTHM device) pumps perfusion fluid through the catheter in the 
direction of the black arrow. The waist band is positioned on the hips so that the probe site is not covered. In this 
sampling from 2018, the extension tubing that connects the probe to the U-RHYTHM device has been fixed without the 
formation of a loop, which increases the risk of accidental disconnection (white arrow).  
3.8.1.2 Improvements to sampling procedures 
Table 3-2 Summary of improvements made to U-RHYTHM connection processes and procedures. 
Original procedure Revised procedure Outcome 
Connect extension tubing to U-
RHYTHM at the time of 
sampling start. 
Pre-fit extension tubing prior to 
sampling. 
Saves time during clinical procedure. 
Reduces risk of accidental 
disconnection at the sampler inlet. 
Use plain FEP tubing to connect 
the probe to U-RHYTHM. 
Reinforce the extension tubing 
with a silicone sleeve. 
Eliminates the risk of extension tube 
kinking. 
Strengthens the connection of the 
extension tube to the sampler. 
Linear connection of probe to 
extension tubing 
Strain relieving loop formed to 
protect connection 
Reduces the chance of accidental 





3.8.1.3 Summary of issues related to connection of the probe to the sampler. 
Several issues related to the extension tubing were identified and addressed (Table 3-2).  
1. The connection between the probe and the extension tubing is the most fragile part of 
the system, and the part at most risk of failure during a clinical sampling session. The 
diameters of the probe outlet and extension tubing are very narrow (0.38mm and 0.5mm 
respectively) and at risk of kinking.  
2. Connection of the extension tubing to the probe and to the sampler requires the use of 
very small microtube adaptors and connectors (MAB8, Microbiotech/se, Stockholm, 
Sweden). Attaching the probe to the extension involves soaking the connector in 100% 
ethanol and then carefully joining the two ends (Figure 3-8). This process is difficult due 
to the small size of the probe tube and connector. It is also difficult to ascertain if the 
tubing is adequately attached as the connector is partly opaque. The tubing must be 
pushed completely into the connector to ensure a secure fit and eliminate dead space.  
3. Attaching the extension tube to U-RHYTHM is also difficult as it involves first pushing an 
ethanol-soaked adaptor onto the metal fluid inlet pin located on the device, and then 
threading the tube through the adaptor (see Figure 3-7). This needs to be done quickly as 
the adaptor shrinks and quickly becomes non-pliable as the ethanol evaporates. There is a 
risk of damage to the adaptor as it is pushed onto the pin. If the extension tubing is not 
pushed adequately inside the inlet, the tubing can kink and obstruct flow. If strain is 
placed on the extension tubing, there is a high chance of disconnection particularly if this 
occurs soon after fitting. 
3.8.1.4 Solution: Pre-fitted, reinforced extension tubing with a strain loop 
1. The extension tubing should be attached to the metal fluid inlet on the U-RHYTHM 
sampler prior to the sampling session. Once thoroughly dried, 15cm of silicone tubing 
(0.5mm ID x 0.5mm OD, Appleton Woods, Birmingham, UK) soaked in petroleum ether 
(60/80, Fisher Scientific, Loughborough, UK) should be threaded over the extension 





Figure 3-7 Silicone reinforcement of sampler connections. Prior to a clinical sampling session, the U-RHYTHM device is 
prepared by pre-attaching the extension tubing to the metal fluid inlet (black arrow) using a pink MAB8 adapter (also 
indicated by the arrow). The extension tubing and connector are then sleeved with silicone (indicated by the white arrow) 
to strengthen the connection and prevent kinking of the extension tube. 
2. Risk of disconnection caused by linear traction on the extension tubing was reduced with 
use of the silicone sleeve. Testing on the bench indicates that it was practically impossible 
to dislodge the extension tube from the sampler even with strong jerking force.  
3. Risk of connection failure between the probe and extension tube can be partially 
mitigated by the formation of a strain relieving loop. The loop is then secured with a 
transparent dressing (Tegoderm™) which allows the connection to be directly visualised 
throughout the sampling session (Figure 3-8). Formation of the loop slightly reduces the 





Figure 3-8 Use of a strain relieving loop to protect sampler connections. The loop has been formed at the site of 
connection between the probe and the extension tube. The tubing adaptor is indicated by the arrow – the probe attaches 
to the green side and the extension into the pink side. The extension tubing is covered with a silicone sleeve which is then 
joined to the U-RHYTHM device (right arrow). 
Original procedure Revised procedure Outcome 
Inaccurate timing of samples. Longer air gap every 9 
samples. 
Provides reference points for 
timing of samples. 
Leave device with spool 
attached until sample harvest. 
Clamp and remove spool on 
completion of sampling. 
Expedites sampler cleaning. 
Allows rapid assessment of 
sampling success. 
Spool unwound in a straight 
line on the laboratory bench. 
Creation of a spool cutting 
worksheet with track and grid 
lines. 
Saves space. 
Easier, more ergonomic 
procedure. 
Allows the spool to be 








Table 3-3 Improvements made to U-RHYTHM end-of-sampling and sample processing procedures. 
3.8.1.5 Issues related to end of sampling and microdialysis sample retrieval. 
Several issues related to the end of sampling and sample retrieval procedures were identified 
and addressed (Table 3-3).  
1. The presence of internal dead space within the U-RHYTHM device introduces a time lag 
between the arrival of fluid at the sampler from the probe, and the eventual deposition of 
that fluid into the sample spool. Any variation in the flow rate of incoming microdialysate 
fluid will result in inaccurate timing of samples.  
2. Repeated insertion of air bubbles over the sampling period results in a large build-up of 
pressure within the sampling spool which gradually dissipates over 8-12 hours. Removing 
the spool from the sampler while pressure is high results in retrograde movement of 
samples within the spool, potential loss of fluid, and disintegration of many or all the 
remaining samples.  
3. The sampler cannot be cleaned or reused while the spool remains attached, and success 
(or failure) of the sampling session cannot be assessed until the spool is removed and 
unwound. 
Spool fixed to sheet or bench 
with tape during sample 
processing. 
Use magnets to fix tubing to 
spool sheet and isolate 
samples. 
Reduces time taken to process 
spool. 
Tape-free system less messy. 
Reduces risk of accidental 
sample loss during cutting or 
transfer. 
Transfer of tube containing 
sample to storage microvial by 
hand. 
Create an adaptor for hands-
free sample transfer. 
Reduces chance of accidental 
sample loss. 
Increases speed of sample 




4. The procedure for assessment of the spool was clumsy as it involved unwinding the spool 
in a straight line along a 4-metre bench space. Samples were taped in place and retrieved 
by hand delivery of to the collection vial. This procedure clearly needed substantial 
revision due to the impractical space required, the lack of systematic evaluation of 
sampling quality, and the risk of accidental sample loss during cutting of the sample tube 
and transfer of the sample to the collection vial.  
3.8.1.6 Solutions: Timing markers, spool clamping, and standard procedures for sample 
assessment. 
1. U-RHYTHM was reprogrammed to insert a ‘double length’ bubble every 3 hours. Since 
samples are generated every 20 minutes, there will be 9 samples between each double 
length air bubble. The exception is prior to the first double bubble, which has fewer 
samples because it takes time to fill the sampler dead volume when sampling first 
commences (see Appendix B, Estimation of manifold volume).  
2. The total dead space volume consists of the sum of the pre-sampler components 
(microdialysis probe outlet and extension tubing, 4.2µL) plus the internal volume of the 
sampler. Sampler internal volume was estimated to be 77.8 ± 14.4µL based on repeated 
measurements of 6 individual U-RHYTHM samplers, however there was considerable 
variation between devices (range 60.6-102.9). Based on these assessments, at a fixed flow 
rate of 1µL, a sample recovered at the membrane surface would reach the entry to the 
sample spool 64.8-107.1 minutes later.  
3. Immediately after completion of sampling, the spool should be clamped and then removed 
to expedite U-RHYTHM cleaning, immediate reuse of the device, and to allow rapid 
assessment of sampling quality. A pair of ratchet haemostat forceps apply sufficient force 
to occlude the tubing and prevent sudden depressurisation but use of two clamps is 
recommended in case one pair is accidently dislodged. A mini plastic tubing clamp (Cole 




4. Unwinding the spool and fixing the tube on a single sheet of paper is a more practical use 
of workspace and allows the entire sampling to be photographed in a single frame (Figure 
3-9). The paper sheet is placed on a magnetic board and a series of magnets (Figure 3-10) 
placed along the tubing to secure the unwound tubing.  
5. The sample set is assessed by the following process: 
1. Count number of samples and check position of double bubbles. 
2. Measure length of individual samples. 
3. Identify any features that might indicate a sampling issue. 
a. Missing samples. 
b. Poor air bubble separation. 
c. Presence of microbubbles within sample fluid. 
d. Short, long, or inconsistent sample lengths. 
4. Photograph spool. 
5. Harvest samples. 
3.8.1.7 Solution: Sample harvesting improvements 
Microdialysis fluid samples are isolated by cutting through the middle of adjacent air bubbles. 
This creates a free section of tubing approximately 30mm long. To move this safely to the 
sample vial, a special adaptor was developed to enable ‘hands free’ transfer (Figure 3-10). The 
adaptor was formed by taking a short piece of Portex® polyethylene tubing (2.45mm ID, 
3.70mm ED). The Portex® tubing was heated over a flame to form a shrunken cylinder flared 
at one end. The non-flared end was fixed to a blunt metal needle attached to a retracted 
2.5mL luer lock syringe. The flared end of the adaptor is used to ‘grab’ sections of spool tube 
containing sample, as illustrated. The seal formed between the piece of tubing containing the 
microdialysis sample and the adaptor connected to the air-filled syringe prevents the sample 




gently on the syringe plunger. 
 
Figure 3-9 Evolution of the sample processing sheet. A: The first revision allowed a complete spool to be unwound on an 
A2 size sheet of paper. Samples were fixed to the sheet with laboratory tape. B: Introduction of a ‘tapeless’ method using 
a metallic backboard and magnetic strips cut with grooves to hold the spool tubing. C: Final iteration with commercially 








Figure 3-10 Sample transfer adaptor. (A) Heat modified Portex® tubing (arrow) attached to a 2.5mL syringe is pushed on 
to the section of spool containing the sample (indicated by the horizontal bracket). The sample can then be transferred to 
the collection vial safely and ‘hands free’. (B) Spool magnet. Grooves in the base of the magnet fit over and secure the 
tubing to the sample sheet. When it is time to retrieve and decant the samples, magnets can be placed over the sample 
fluid column (as shown) and the sample safely isolated by cutting through adjacent air bubbles. 
3.8.2 Effect of whole spool freezing on sample quality. 
Of the 3 spools, 2 were frozen once spool pressure had dissipated, and 1 frozen while the 
spool was still pressurised, with haemostat forceps clamping the tube. Spool 1 and 2 were 
frozen for 48 hours and spool 3 for 72 hours. 
All spools were defrosted at room temperature for not less than 30 minutes prior to sample 
quality assessment. At this point removal of the haemostat forceps from the spool that was 
frozen pressurised resulted in immediate expulsion of the final sample in the tubing. This 
indicates that pressure was still high in the spool despite the freeze/thaw process. Otherwise 
the physical structure of the sample sequence remained intact with no fragmentation or 






3.8.3 U-RHYTHM sampler performance  
3.8.3.1 Consistency of sample volume in vitro 
One control sample was identified as an outlier and excluded due to very low volume (<4µL). 
The mean volume of the remaining control samples (19.34µL, SD=0.91, n=44) was not 
different to the volume of samples that passed through the U-RHYTHM sampler (19.59µL, 
SD=1.10, n=54), indicating no independent effect of the U-RHYTHM sampler on recovered 
sample volume (Welch’s t=1.238, p=0.2186). 
3.8.3.2 Consistency of sample volume recovery in vivo. 
A total of 9320 samples from 132 successful clinical microdialysis studies were included for 
analysis. There were 184 missing values. The mean sample length was 22.8mm (range 2-94, 
SD=2.9, coefficient of variation 12.7%, Figure 3-11) corresponding to 89.5% of ideal, or an 
estimated mean volume of 17.9µL/sample. The sampling with the shortest mean sample 
length was 16.3mm, predicting an average sample volume of 12.8µL. 
In the first 27 samplings, the sporadic presence of ‘merged’ samples was identified – samples 
that were twice expected length (generally >40mm) with absence of an air bubble separating 
the sample. This was eventually diagnosed as being due to a hardware fault on the U-
RHYTHM circuit board, causing intermittent failure of the bubble pump. Affected devices 






























Grand mean all samples
 
Figure 3-11 Mean length of samples in 132 consecutive successful sampling events. Samplings were conducted in Bristol 
between April 2017 and March 2020. Error bars indicate the standard deviation of the mean for that sampling. The 
overall mean sample length was 22.8mm (SD = 2.9), represented by the horizontal dashed line, and represents an 
estimated mean volume recovery of 89.5%. 
Figure 3-12 shows the mean lengths of consecutive samples, where sample 1 was the first 
sample produced in a sampling session, and sample 72 the final sample inserted into the 
sample spool. There was no evidence for a difference in the length of samples within a 
sampling session (Mixed-model ANOVA [F(14.9, 1915)= 1.42, p=0.0899]). 
















Figure 3-12 Consistency of sample length within a sampling session. Mean ± SD length of consecutive samples obtained 
from sampling sessions in Bristol (n=132) are shown. The overall mean of 22.9mm is shown by the horizontal dashed line. 
There was no evidence for a difference in the length of samples within a sampling session (Mixed-model ANOVA F(14.9, 




3.8.3.3 ULTRADIAN sampling success rate  
Between 1 April 2017 and 10 March 2020, 649 sampling events were recorded in the 
ULTRADIAN database, of which 483 (74.4%) were classified as successful (Table 3-4). The 
highest success rate was in Bristol (132/160 procedures, 82.5%) and the lowest in Stockholm 
(84/129, 65.1%). For 15 procedures (2.3%) there was insufficient data available to classify 
success or failure; all these procedures were completed in Athens.  
Site Success n (%) Failure n (%) Unclassified n(%) Total 
Bristol 132 (82.5) 28 (17.5) - 160 
Athens 115 (74.2) 25 (16.1) 15 (9.7) 155 
Stockholm 84 (65.1) 45 (34.9) - 129 
Bergen 152 (74.1) 53 (25.9) - 205 
 483 (74.4) 151 (23.3) 15 (2.3) 649 
Table 3-4 Outcome of ULTRADIAN sampling procedures using the U-RHYTHM device, by sampling site. Success was 
defined as completion of the sampling period, and recovery of a usable sample set. The outcome of 15 procedures was 
unclassified as information about these samplings was not available at the time of database retrieval. 
3.8.3.4 Reported issues related to sampling events. 
Between 15 August 2018 and 9 March 2020, 110 events were reported. The majority were 
sampling failures (58%, n=64). In 17 cases, there was no recovery of any samples (empty 
spool). The remaining were inadequate for analysis due to one or more of the following 
issues: short samples (n=25), microbubbles in the sample fluid (n=12), samples merged (9%,), 
or incorrect number of samples retrieved (n=35). 
Of the 46 non-sample related events, 52% (27/46) were attributed to consumable 
malfunction (probe failure n=13, accidental disconnection of extension tubing n=14), and 
26% caused by infusion pump malfunction (n=11). Only 3 reports were directly attributed to 
malfunction of the U-RHYTHM itself (list in Appendix D). On one occasion sampling failed 
due to user error (pump flow rate incorrectly set). Four non-critical incidents were reported 




3.8.3.5 Safety profile 
There were no serious adverse events reported at any of the ULTRADIAN study centres. A 
total of 15 minor adverse events were reported: greater than expected bruising/haematoma 
(n=6), discomfort at probe site (n=2), local skin reaction to adhesive dressing (n=7). 
3.8.4 Factors influencing adrenal hormone recovery. 
3.8.4.1 Effect of perfusion fluid type on volume recovery using the microdialysis probe in a water 
bath 
 
Figure 3-13 Effect of perfusate type on recovered sample volume.  The ideal sample volume of 20µL is indicated by the 
dotted horizontal line. Grey circles represent individual sample volume measurements. The mean sample volume 
recovered with saline perfusate was significantly lower than for samples collected using perfusate containing cyclodextrin 
(p<0.0001). There was no evidence for a difference in volume recovery between cyclodextrin types (p=0.560).  
Samples were collected using saline, HP--cyclodextrin, and HP--cyclodextrin perfusates 
(n=18 in each group). When probes were perfused with 0.9% saline, the mean recovered 
sample volume was 16.54µL (SD=3.97), or 82.7% of expected. Volume recovery with either 
type of cyclodextrin was increased compared with saline (mean difference 15.78µL, 95% C.I 























































conditions (HP--cyclodextrin samples 31.76µL, SD=6.35 vs. HP--cyclodextrin 32.88µL, 
SD=5.07, [Welch’s t=0.589, p=0.560], Figure 3-13). 
3.8.4.2 Effect of perfusate type on the relative recovery of hydrocortisone using the microdialysis 
probe in a water bath 
Several outliers were detected in the measurements of hydrocortisone in saline perfusate 
samples (n=3), HP--cyclodextrin samples (n=2), and HP--cyclodextrin samples (n=5). These 
samples were removed prior to further analysis.  
There was no evidence for a difference in the mean hydrocortisone concentration between 
the perfusate types (Brown-Forsythe ANOVA test [F*0.1741 (2, 43.40), p=0.8408]). The 
mean concentration of hydrocortisone was 15.84nmol/L (SD=6.38, n=16) in 0.9% saline, 
16.12nmol/L (SD=7.37, n=17) in HP--cyclodextrin, and 14.73nmol/L (SD=6.68, n=14) in HP-
-cyclodextrin.  
By contrast, there was very strong evidence for the treatment effect of 10% cyclodextrin on 
recovery of testosterone (Figure 3-14, Brown-Forsythe ANOVA [F*4407 (2, 41.44), 
p<0.0001]). The mean testosterone concentration in 0.9% saline perfusate was 516pmol/L 
(SD=174.1, n=18), compared with 6812pmol/L in HP--cyclodextrin (SD=290.9, n=18) and 





Figure 3-14 Effect of perfusate type on the in vitro recovery of testosterone. The mean difference between 0.9% saline 
and HP--cyclodextrin is 6292pmol/L (95% C.I.6125—6466, p<0.0001) and between 0.9% saline and HP- -
cyclodextrin 432.9pmol/L (95% C.I. 262.4-603.3, p<0.0001). 
3.8.4.3 Effect of methylprednisolone and poloxamer 407 pre-treatment on the recovery of 
hydrocortisone in vitro 
3.8.4.3.1 Methylprednisolone (n=1) 
Figure 3-15 shows the recovered concentrations of hydrocortisone in samples retrieved from 
a sampler and spool that had been pre-treated with 1mmol/L methylprednisolone, compared 
with a sampler and spools that had not.  
There was an upsloping gradient in the relative concentration of hydrocortisone between the 
first and last samples in each sampling spool - changing the spool for a new one resulted in a 
sharp fall in the recovered concentration of hydrocortisone, regardless of treatment 
condition. The effect was most pronounced where both the spool and manifold were 
untreated (refer from sample 73, open circles).  

















































Figure 3-15 Effect of methylprednisolone pre-treatment on recovery of hydrocortisone in vitro.  Concentrations are 
expressed as relative to an internal standard. A U-RHYTHM device which had been pre-treated with 1mmol/L 
methylprednisolone solution (M+, black circles) was compared with an untreated control (M-, white circles), with samples 
from each device collected into treated (S+) and untreated (S-) spools. Spools were changed after 27 hours of continuous 
sampling (vertical dashed line). There is a strong concentration gradient between the first and last samples collected in 
each spool, regardless of the treatment condition. 
3.8.4.3.2 Poloxamer 407 (n=1) 
Figure 3-16 shows the effect of 5% w/v poloxamer 407 on the relative recovery of 
hydrocortisone, comparing a treated U-RHYTHM sampler and sample spools with an 
untreated control. Hydrocortisone recovery is expressed as a proportion of an internal 
reference standard.  
Exposure of the perfusate to untreated spool tubing (Sampler 1, filled circles, left of vertical 
dashed line and Sampler 2, open circles, right of the vertical dashed line) is associated with a 
marked reduction in hydrocortisone recovery, affecting at least the first 9 samples in each 
spool. Pre-treatment of the internal volume of the sampler (Sampler 1, filled circles) seems to 




407 show no such drop in concentration (Sampler 1, filled circles, right of vertical dashed line, 
and Sampler 2, open circles, left of vertical dashed line).  
































Figure 3-16 The effect of poloxamer 407 pre-treatment on recovery of hydrocortisone in vitro. Recovery of 
hydrocortisone is substantially reduced in at least the first 9 samples entering untreated spools (S-, filled circles, left of 
dashed line, and open circles, right of dashed line). By contrast, samples entering poloxamer treated spools (S+, open 
circles, left of dashed line, and filled circles, right of the dashed line) are unaffected. Pre-treatment of the manifold (M+) 
attenuates the adsorption effect when samples contact untreated tubing (compare sampler 1: black circles sample 1-10 
with sampler 2: open circles sample 72-82). There is no difference in the concentration of hydrocortisone recovered in 
the final samples entering the spools, regardless of treatment condition (p=0.639). 
The mean concentration of the final 6 samples entering the tubing was not different between 
treated and untreated spools or U-RHYTHM devices (ANOVA [F(3, 20) = 0.574, p=0.639]). 
There was evidence to suggest a small amount of adsorption may occur when sample contact 
polypropylene sample vials (mean concentration difference between poloxamer 407 treated 





Finally, there was evidence that the concentration of hydrocortisone in final samples to enter 
the spool was higher than the reference solution, as measured in untreated vials (mean 
difference 0.183, 95% CI 0.146 – 0.220, [t(8) = 11.36, p<0.001]).  
3.8.5 Influences on the recovery of metabolites in vitro.  
In the reference sample, 153 metabolites were detected and met validation criteria for 
inclusion (21 amino acids (100% of total), 21 biogenic amines (100%), 13 acylcarnitines (33%), 
84 glycerophospholipids (95%), and 14 sphingomyelins (93%)). The mean coefficient of 
variation (CV) of all samples retrieved was 16.6% (range 7.0-144.3). Amongst amino acids the 
CV was 12.5%, glycerophospholipids 13.1%, sphingomyelins 14.2%, acylcarnitines 20.2%, 
and biogenic amines 30.2%. A full list of all metabolite changes is given in Appendix L. 
3.8.5.1 Effect of ambient storage conditions on metabolite concentration. 
The total exposure time of the metabolite solution to ambient conditions was 48 hours. The 
ambient temperature ranged from 21.4ºC (laboratory bench during equilibration) to 34.0ºC 
(overnight, while the U-RHYTHM was being worn in the waist band). 
There was no evidence for a difference in the overall concentration of metabolites in the 
infusion solution at baseline (QCbaseline) compared with the same sample solution at the end of 





Figure 3-17 Effect of ambient storage on metabolite concentrations. Reference metabolite solution was measured 
following 48 hours of exposure to ambient temperature conditions. Results are expressed as the percentage difference in 
concentration compared with the baseline reference sample. The grey shaded area represents ±20%. Metabolites with 
particularly large changes are labelled individually on the figure (e.g. DOPA/dopamine). 
However, substantial changes in individual metabolite concentrations were evident (Figure 3-
17, Appendix L). Of the amino acids, glutamate increased by +36.8%. In the biogenic amines 
there were substantial increases in 5 compounds: asymmetric dimethylarginine (ADMA) 
+23%, symmetric dimethylarginine (SDMA) +27%, creatinine +103%, methionine sulfoxide 
+26%, and taurine +21%. There was complete loss (>99%) of DOPA and dopamine, and a 
44% decrease in serotonin. Amongst the acylcarnitines, free carnitine (C0) increased by 
+36.1%, hexanoic acid (C6) by +23.6%, and acetylcarnitine (C2) decreased by 21.7%. 
Amongst the 84 glycerophospholipids, there were 3 substantial increases (2 
lysophosphatidylcholines and 1 phosphatidylcholine) and 8 substantial decreases (5 
lysophosphatidylcholines and 3 phosphatidylcholines). There was no substantial change in the 




















































































































































































































































































































3.8.5.2 Effect of contact with the U-RHYTHM device and sample collection spool. 
3.8.5.2.1 Amino acids 
 
Figure 3-18 Effect of the U-RHYTHM sampler and spool on amino acid concentration. Relative concentrations of amino 
acids were compared to baseline after (A) 40- and 200-minutes of contact with the U-RHYTHM device alone, and (B) in 
the first samples to have entered the spool compared with the final samples collected. Panel A: Contact with the U-
RHYTHM device is associated with a relative decrease in most amino acid concentrations in both 40-minute (open bars) 
and 200-minute (filled bars) samples, except for glutamate which was increased in both. Panel B: Amino acids, except for 
asparagine (Asn), measure at or above the baseline reference concentrations, in both samples with the least (open bars) 
and most (filled bars) exposure to the sample spool.  
There was an overall mean increase of 14% (SD=7.3) in all amino acids in the ambient control 
sample. Contact with the U-RHYTHM device alone resulted in a generalised small decrease in 
amino acid concentrations, at least over the first 200 minutes of contact (Figure 3-18, A). 
Following contact with the sample collection spool, concentrations of amino acids were 
slightly (most) or substantially (glutamate) increased (Figure 3-18, B). The exception was for 
asparagine (Asn) which was 18% lower in the sample most exposed to the spool tubing. The 
overall mean concentration of amino acids in the least spool exposed sample increased 
































































































































3.8.5.2.2 Biogenic amines 
 
Figure 3-19 Effect of the U-RHYTHM sampler and spool on biogenic amine concentration. Relative concentrations were 
compared to baseline after (A) 40 minutes- (open bars) and 200 minutes (closed bars) of contact with the U-RHYTHM 
device alone, and (B) in samples with the least exposure to the spool (open bars) compared with the most exposed 
samples (closed bars).  
Figure 3-19 shows the relative concentrations of biogenic amines in samples recovered from 
the U-RHYTHM device alone (A) and from the device and spool (B). DOPA, dopamine, 
creatinine, and serotonin all showed substantial changes in concentration compared with the 
baseline reference control – these metabolites also substantially changed in the ambient, 
non-U-RHYTHM exposed reference (Figure 3-17). In the spool samples, phenethylamine, 
spermidine, and spermine, were substantially lower in the spool exposed samples than both 










































































































































































































































































Figure 3-20 Effect of the U-RHYTHM sampler and spool on acylcarnitine concentration. Relative concentrations were 
compared to baseline, after (A) 40- (open bars) and 200-minutes (closed bars) contact with the U-RHYTHM device alone, 
and (B) in samples with the least exposure to the spool (open bars) compared with the most (closed bars).  
Figure 3-20 shows the relative changes in the concentration of acetylcarnitines when 
exposed to the U-RHYTHM device alone (A) and following contact with the spool (B). All 
acylcarnitines except C14 were lowest in the sample most exposed to the spool tubing (mean 
-25.8% of baseline reference, SD=26.6). 
3.8.5.2.4 Glycerophospholipids 
Contact with the U-RHYTHM device alone was generally associated with a small decrease 
change in phosphatidylcholine glycerophospholipids (Figure 3-21 A) but following contact 
with the spool tubing this trend was reversed with increased levels, particularly in the final 





















































































































Figure 3-21 Effect of the U-RHYTHM sampler and spool on phosphatidylcholine glycerophospholipid concentration. 
Relative concentrations were compared to baseline after (A) 40- (open bars) and 200 minutes (closed bars) of contact 
with the U-RHYTHM device alone, and (B) samples with the least exposure to the spool (open bars) compared with the 
most (closed bars). A: Infusion solution in contact with sampler alone was associated with a <20% reduction in 
metabolite concentration. B: Change in concentration of metabolites was most pronounced in samples with the least 
spool tubing contact compared with samples with the most contact. 
For the lyso-phosphatidylcholines contact with the device alone was associated with a 
generalised decrease in (Figure 3-22 A) but following contact with the spool there were more 
significant differences with significant increases in lyso-phosphatidylcholines C16-C20. The 
overall mean difference in lyso-phosphatidylcholines comparing the baseline reference with 
the final sample entering the spool was +49.3% (SD=38.7, Figure 3-22 B). By contrast, lyso-
phosphatidylcholines were less affected by exposure to ambient conditions alone (overall 
mean decrease -7.7%, SD=21.2). 
For the lyso-phosphatidylcholines, contact with the device alone was associated with a 
generalised decrease in relative concentration (Figure 3-22 A) but following contact with the 











































































































































































































































































































































































































































































































































































phosphatidylcholines C16-C20. The overall mean difference in lyso-phosphatidylcholines 
comparing the baseline reference with the final sample entering the spool was +49.3% 
(SD=38.7, Figure 3-22 B). By contrast, lyso-phosphatidylcholines were less affected by 
exposure to ambient conditions alone (overall mean decrease -7.7%, SD=21.2). 
 
Figure 3-22 Effect of the U-RHYTHM sampler and spool on lyso-phosphatidylcholine glycerophospholipid concentration. 
Relative concentrations were compared to baseline after (A) 40- (open bars) and 200 (closed bars) minutes of contact 
with the U-RHYTHM device alone, and (B) in samples with the least exposure (open bars) compared with the most (closed 
bars). A: Concentrations were reduced in the 200-minute sample compared with the 40-minute sample. B: Contact with 
the spool tubing was associated with substantial increases in the relative concentration of many lyso-
phosphatidylcholines, most pronounced in samples with the least spool exposure (open bars). 
3.8.5.2.5 Sphingomyelins 
Like the glycerophospholipids, sphingomyelins were lower in the 200-minute U-RHYTHM 
exposure sample than the 40-minute sample (Figure 3-23 A). Concentrations were 
substantially higher than the baseline reference control in both spool samples, especially in 














































































































































































































































































comparison, the concentration of sphingomyelins did not change substantially in the ambient 
control sample (-7.1%, SD=5.1). 
 
Figure 3-23 Effect of the U-RHYTHM sampler and spool on sphingomyelin concentration. Relative concentrations were 
compared to baseline after (A) 40 minutes (open bars) and 200 minutes (closed bars) of contact with the U-RHYTHM 
device alone, and (B) in samples with the least exposure (open bars) compared with the most (closed bars) exposure to 
the spool collection tube. A: Concentrations were reduced in the 200-minute sample compared with the 40-minute 
sample. B: Contact with the spool tubing was associated with increased concentrations of sphingomyelins, especially in 
the sample with least spool contact (open bars). 
3.8.6 Acceptability of the technique 
3.8.6.1 Participant feedback 
A total of 515 feedback questionnaires were retrieved from the four ULTRADIAN sampling 
sites. Of these, 9 were discarded due to empty data fields. Figure 3-24 shows a summary of 


























































































































































































0 25 50 75 100
Fitting was comfortable
Carrying sampler was easy
Normal activites maintained
Probe is pain free
Day noise acceptable
Easy to sleep with sampler
Night noise acceptable
Would wear again if asked
Strongly disagree Disagree Undecided Agree Strongly agree
 
Figure 3-24 Summary of responses to the ‘Device satisfaction questionnaire’ Data is shown from n=506 ULTRADIAN 
participants. Responses to each question item were answered using a 5-point Likert scale ranging from ‘Strongly disagree’ 
to ‘Strongly agree’. The number of response to each level on the scale are represented as a percentage of the total. 
Most people agreed that fitting the device was not too uncomfortable (95.3% agreed or 
strongly agreed, 1.0% undecided). The majority (79.6%) agreed or strongly agreed that 
carrying the device was easy, with 10.1% undecided, and 10.3% disagreeing or strongly 
disagreeing. While most (71.8%) agreed or strongly agreed that normal activities could be 
continued, 13.1% were undecided and 15.1% disagreed or strongly disagreed.  
For the vast majority, the sampling probe was painless during the sampling session (91.9% 
agreed or strongly agreed, 3.0% undecided). Daytime noise from the device was acceptable 
for most (91.5%). During the night, 12.2% disagreed or strongly disagreed with the statement 
that it was easy to sleep with the device (12.6% undecided), and 5% were significantly 
disturbed by noise from the sampler (4.0% disagreeing and 1% strongly disagreeing with the 
statement that night noise levels were acceptable). Overall, most participants would have 
been happy to wear the device again if they were asked (82.3% agreed or strongly agreed, 




3.8.6.2 Comment feedback from individual participants  
There were 150 comments left by participants. Since participants often made comments 
about more than one issue, 185 individual comment items were coded, summarised 
according to “Comment type” in Table 3-5 and presented in full in Appendix E. 
Comment type Frequency (n, %) Example 
Noise 8 (4.3) "a bit loud…particularly when sitting in a lecture or 
meeting" 
Sleep 15 (8.1) "I needed a bit longer period to fall asleep than 
usual" "could not sleep in my usual position on 
stomach" 
Other 20 (10.8) "It would be ideal to shower with the device in the 
future" 
Positive feedback about 
experience 
20 (10.8) "Very easy to wear. No problem with noise" 
Worry about device, lines 27 (14.6) "I was worried that I may have destroyed 
something" "I was worried that the tubings, lines 
and membrane may [become] loose" 
Size, bulk 44 (23.8) "it was big and bulky to have on"; "I would prefer a 
smaller device" 
Interference with routine, 
restriction of daily activity 
51 (27.6) "difficult to bend over and play with my kid" "it was 
difficult to bend over to put socks " 
Table 3-5 Free-text comments left by participants in the Device Satisfaction Questionnaire. Responses are summarised 
according to comment type. There were a total of 150 comments from which 185 comment items were coded.  
The most common complaint (n=51, 27.6%) was that the sampler partially interfered with or 
restricted normal daily routines. Comments included difficulty bending over to dress, 
difficulty finding a comfortable position while driving, and the need to adjust seat position to 
be comfortable while sitting at a desk. Negative comments around the size and bulk of the 




they felt the device was too large, felt heavy, or should be smaller. Approximately 15% of 
comments were specifically related to worries about the fragility of the device and 
connections during the sampling, including that their daily actions might inadvertently 
damage the system and cause the sampling to fail. One participant reported “I felt I had to be 
extra careful with every step I made”.  
Comments about interference with sleep were less common, accounting for just over 8%, 
such as a need to change from normal sleeping position, “I needed to sleep on my back or on 
the left side, I usually sleep on stomach”. The least common complaint, accounting for 4% of 
all comment items, was about the noise of the sampler. These participants were aware of the 
device sound during quiet lectures, meetings, and when visiting the cinema. There were 20 
comments (10.8%) that were classified as general feedback including suggestions for 
improvement “it could be less hot and sticky”, “waterproof it please”.  
Finally, there were 20 comments (10.8%) providing specifically positive feedback “easier than 
expected & more comfortable”, “before the research I was very nervous but it all went 
smoothly and I am happy to have participated”. 
3.8.6.3 Impact of differential use of anaesthetic across sampling sites 
Consortium members in Athens, Bergen and Stockholm strongly advocated for the routine 
use of local anaesthetic for all procedures. In Bristol, local anaesthetic offered but only used 
in the first 3 participants completing the ULTRADIAN protocol (<0.5% of all samplings).  
Since omitting anaesthetic may have had a negative effect on participant experience, the 
responses from participants in Bristol regarding comfort of fitting the probe, and pain from 
the sampling probe were assessed in comparison with the whole group. For item 1 “Fitting 
the device was not too uncomfortable”, 95.4% Agreed or Strongly Agreed compared with the 




sampling probe” 92.1% of participants from Bristol Agreed or Strongly Agreed compared with 
91.1% overall. 
3.9 Discussion 
3.9.1 A standard method for U-RHYTHM ambulatory microdialysis. 
Setting up the microdialysis probe, connecting to U-RHYTHM and successful retrieval of 
microdialysis samples remains a time consuming process involving many steps. Reviewing 
these steps identified several areas for improvement, which allowed for improvements and 
the standardisation of the procedure. The ability to systematically review and document the 
outcome of each sampling has made it possible to audit sampling performance accurately, 
and to identify causes for sampling anomalies.  
The performance of the system remains under constant review. Practical issues outstanding 
include the need to eliminate the use of tubing adaptors, and a better system for connection 
of the probe to the extension tubing. A particular concern is the large, variably sized internal 
dead space within the sampler. The presence of this space increases the lag time between 
physical acquisition of the sample at the membrane, and consequently the insertion of the 
sample into the spool tubing. With the current devices, this time is on average 80 minutes 
with some devices taking up to 103 minutes. Reducing this dead space to an absolute 
minimum must be a high priority in any future versions of the sampler. 
Sample harvesting remains a laborious manual task and users need time and practice to 
master the technique. It is my opinion that there is no further optimisation of the current 
method possible. Ideally, use of a plastic tubing spool as a sample reservoir should be 
abandoned in favour of a system that facilitates sample acquisition directly from the device 
into the measurement instrument; however, developing this would require considerable 
further investment. In the meantime, demonstration that a spool can be frozen and rethawed 




central processing facility, making the U-RHYTHM method more accessible to a broader 
range of users. 
3.9.2 Validation of the U-RHYTHM system performance in vivo 
Sample length measurements were used to estimate sample volume obtained during clinical 
samplings, thus providing a measure of real-world device performance. The measurement 
method provides an estimate of volume - the alternative method of weighing 72 individual 
samples per participant was not practical over the course of the study where hundreds of 
procedures were completed. The results indicate that U-RHYTHM performs very well in vivo. 
During clinical studies, good quality samples with consistent length and of sufficient volume 
for analysis were reliably produced with only a small variation in volume recovery between 
participants and sequential samples. 
3.9.3 Success rate depends on user experience 
The success rate of procedures was not equal amongst the sampling centres. Athens, Bristol, 
and Bergen were all familiar with microdialysis prior to the commencement of ULTRADIAN, 
but due to regulatory delays, Stockholm did not begin clinical studies until mid-2018, at least 
12 months after the other study sites. The higher failure rate observed at the Stockholm site 
reflects the complexity of the current U-RHYTHM procedures, which has a learning curve 
and needs close expert supervision when users are unfamiliar with the technique.  
3.9.4 Issues causing sampling failure 
There were several sources of error that lead to sampling failure. Preventable errors included 
disconnection of the probe connection with the sampler. Reinforcing the tubing with silicone, 
and protecting delicate connections by using strain relieving loops, are examples of solutions 
that were introduced as part of this project. The complete absence of samples in a spool 
suggests either failure of the probe or pump, or obstructed connections, rather than any 




failed samplings occurred because of problems with marketed consumables, namely the 
probe and microdialysis pump. Since there are currently no alternatives available, studies 
using these materials will continue to be necessary, at least over the short-to-medium term. 
In the long-term, integration of the perfusion pump into the sampling device itself would be 
ideal and would afford much greater control over sampling performance. Likewise, it would 
be desirable to commission a custom microdialysis probe that better fit the requirements of 
ambulatory procedures, namely with a longer probe outlet, eliminating the need for extension 
tubing.  
Issues with sample quality identified once a sampling has been completed were multifactorial. 
In this project, overlength samples encountered with some devices were caused by a 
hardware malfunction. In other instances, poor quality sampling will have been be related to 
impaired performance of the sampling membrane, which can be easily damaged during the 
insertion process, leaky connections, or air bubbles within the perfusion fluid. Inter-individual 
variation193 in the exact placement of the probe, body habitus, and daily activity are also 
certain to have contributed to some of the negative outcomes. In this project, sampling 
failures were systematically reviewed and, in most cases, the most likely cause could be 
identified. Where no reason is identified for a sampling issue, the U-RHYTHM device should 
be tested in vitro to ensure it is functioning as expected. 
3.9.5 U-RHYTHM sampling is safe 
Minor adverse events occurred in just 2% (15/649) of sampling events, and there were no 
serious adverse outcomes reported at any study site. It was expected that the U-RHYTHM 
sampling procedures would be safe, since apart from receiving the microdialysate fluid, the 
device otherwise has no physical contact with the participant, and internal design 
mechanisms prevent retrograde flow of perfusate. This finding validates previous work with 
the prototype ‘blue box’ sampler, which had also not been associated with any significant 




subcutaneous microdialysis in humans146,194. It is extremely reassuring that in the 
ULTRADIAN trials of more than 600 participants - where procedures were performed by 
multiple operators, and where the microdialysis process occurred almost exclusively 
unobserved due to the free-living, ambulatory nature of the studies - so few adverse events 
occurred. 
3.9.6 Factors affecting recovery at the sampling membrane 
Optimal sampling conditions would result in 100% recovery of sample volume, and 100% of 
the tissue concentration of the analyte(s) of interest. In current studies, volume recovery in 
vitro was 82.5%, and the estimated volume recovery in vivo was 89.5%. This indicates that 
there is, on average, a small net loss of perfusion fluid - around 1-2µL - across the membrane 
into the interstitial tissue space. This is consistent in magnitude with reports in the literature 
using similar procedures134,137. Volume recovery can be augmented by the addition of an 
osmotic agent to the perfusion fluid, a technique that is commonly employed when using high 
molecular weight cut-off membranes (100kDa and greater)157. Cyclodextrins were tested in 
these experiments as they are safe, naturally occurring cyclic oligosaccharides that not only 
have an osmotic effect but form inclusion complexes and solubilise hydrophobic target 
molecules195. Cyclodextrins are also advantageous as they do not interfere with liquid 
chromatography-based mass spectroscopy systems194. In one study, addition of 10% HP--
cyclodextrin increased sample volume in vitro by 10%, at a perfusion rate of 2µL/min125. In 
my experiments however, using a perfusion rate of 1µL/min, both 10% − and 10% 
 −cyclodextrin increased volume recovery by more than 150%. This degree of excess volume 
recovery is not acceptable and future experiments should trial a lower concentration (e.g., 
5%) to determine if volume recovery closer to 100% can be achieved. 
Relative recovery of hydrocortisone in vitro was not affected by the addition of either HP-- 
or -cyclodextrin, suggesting that cyclodextrin does not readily form inclusion complexes 




perfusate, significantly higher than the 56% reported by Sandeep et al196 (in that study the 
probe type was not specified and the perfusion rate was 0.3µL/min) and similar to Sun et 
al197 who reported 67-85% recovery of cortisol and 67-87% recovery of cortisone using a 
30mm concentric probe perfused at 1µL/min. Worryingly, in those experiments, significant 
differences in recovery were noted between 2 different probe batches197. Currently there is 
no ability to determine the in vivo relative recovery for individual participants, and in vitro 
performance of a membrane does not necessarily reflect true performance in vivo116. 
Methods for probe calibration and reducing potential variability in recovery between 
samplings requires further investigation. 
Testosterone was recovered from the water bath in all conditions and was substantially 
increased by the addition of cyclodextrin, particularly the HP-- form. The smaller inclusion 
pocket or cavity in the HP-- cylcodextrin198 seems ideally suited to capturing free 
testosterone, a property that has been exploited in the manufacture of sublingual 
testosterone therapies, for example199. While this is an encouraging finding, further 
experiments are needed to determine the optimal concentration that would avoid both 
excess relative recovery as well as sample volume. This is important because Dr Methlie’s 
experiments suggest that testosterone and other highly lipophilic steroids are entirely 
adsorbed to the surfaces inside the U-RHYTHM device - and never reach the sample 
collection tubing - when saline-based perfusate is used. HP--cyclodextrin has already been 
used safely to enhance recovery of highly lipophilic endocannabinoids in human adipose 
tissue125. Therefore, cyclodextrin to recover testosterone and other lipophilic adrenal steroids 
in vivo warrants further investigation. 
3.9.7 Poloxamer 407 reduces the adsorption of hydrocortisone to the sample 
collection tubing 
Two strategies were pursued to investigate and reduce adsorption of cortisol to surfaces in 




sites within the sampler itself and on the sample spool plastic, by pre-treating the entire 
length with a high concentration of the synthetic glucocorticoid methylprednisolone. This 
was completely ineffective. Next, a different approach was taken with the application of a 
non-ionic surfactant, poloxamer 407. Again, the sampler and the entire length of the sampling 
spool were treated. The results of this experiment were much more encouraging and support 
the previous findings of Dr Methlie that the most significant adsorption of hydrocortisone 
occurs on contact with the spool tubing, and lasts for multiple samples. Most importantly, 
pre-treatment with poloxamer 407 was highly effective at mitigating the effect. Poloxamers 
are safe, and inexpensive200. Poloxamer 407 is a so-called triblock copolymer formed by a 
central hydrophobic block of polypropylene glycol flanked by two hydrophilic blocks of 
polyethylene glycol. Poloxamers have previously been used to improve recovery of 
proteins201 by pre-treatment of microdialysis membranes prior to insertion202. The application 
of poloxamer to reduce adsorption of lipophilic compounds from a spool of tubing is novel, 
but it is clear from the current experimental results that it does indeed substantially reduce 
the affinity of PTFE plastic tubing for hydrocortisone at the very least. Further investigation 
of other hydrophobic compounds - in particular, testosterone, androstenedione and 17-
hydroxyprogesterone, which potently bind to hydrophobic surfaces - is warranted. However, 
the potentially negative consequence of reducing the hydrophobicity of the tube surface 
could be the undesirable effect of inhibiting recovery of more hydrophilic compounds. It was 
also noted that the concentration of hydrocortisone in the final samples to enter the spool 
were higher than the reference control, suggesting the possibility of contamination or ‘carry 
over’ from previous samples.  
3.9.8 Metabolite recovery from U-RHYTHM in vitro 
It is well established that preanalytical factors impact the quality and accuracy of 
measurements in samples for metabolomic analysis203. Processing delays and exposure to 




because these media contain enzymes and other molecules that allow metabolism to 
continue even after collection. In the present experiments the internal volume and sample 
collection spool of the U-RHYTHM sampler were exposed to a pure reference solution of 
free (non-protein bound) metabolites, intended as a realistic simulation of what might be 
contained in microdialysate in vivo. The concentrations of metabolites in samples exposed to 
the system were compared to the baseline reference sample, and a second reference that 
was kept at ambient temperature, but not exposed to the device or spool. The important 
findings were that amino acids were generally very stable, and little influenced by contact 
with the sampler or spool, even when kept at ambient temperatures, including during ‘on 
body’ ambulatory conditions, for 2 full days. Several biogenic amines were inherently 
unstable and degraded rapidly, independent of exposure to the device and spool. This is 
consistent with previous reports that contact with air, light and storage temperatures above 
freezing substantially affect stability of biogenic amine compounds204.  
Contact with the U-RHYTHM device and spool was most impactful on lipophilic compounds 
including the some glycerophospholipids and most sphingomyelins. Since these types of 
metabolites are extremely insoluble205 they are likely to have interacted with and adsorbed 
onto the hydrophobic surfaces of the U-RHYTHM system, particularly the plastic spool 
tubing. It is proposed that highly lipophilic compounds ‘smear’ onto the walls of the tubing as 
the sample moves progressively along. When a new sample enters the spool, it must pass 
through a section of tube previously exposed and coated with hydrophobic compounds, 
some of which ‘dislodge’ and mix with the new sample. The evidence for this theory is that 
concentrations of glycerophospholipids and sphingomyelins were most increased in the final 
samples to enter the spool, i.e., in the samples that had just passed through tubing exposed to 
and coated by multiple previous samples, and noting also that the same affect occurred with 




evidence in support of an alternative method for collecting microdialysate samples that does 
not involve spooled tubing. 
In summary, in its current form U-RHYTHM would be suitable for metabolomics studies of 
24-hour rhythms in amino acids and other relatively hydrophilic metabolites, but further 
optimisation would be needed to make recovery of inherently unstable (biogenic amines) and 
highly lipophilic metabolites (long chain acylcarnitines, glycerophospholipids, sphingomyelins) 
a viable proposition. 
3.9.9 U-RHYTHM is well tolerated 
Wearing the U-RHYTHM system is an unusual experience for most participants. They are 
asked to carry an experimental and potentially fragile device continuously for 27 hours, even 
while asleep. Participants are asked not to exercise vigorously, and are unable to shower, 
bathe or swim. Despite this, feedback was very positive with most participants managing to 
continue general daily activities, including sleep, without interference. One participant even 
reported riding a horse during the sampling period. However, the strongly positive feedback 
in all questions may have been influenced by an acquiescence bias in the survey. The 
questionnaire was flawed and should have been designed with a balance of equal positive 
and negative statements, rather than asking participants to disagree with positive statements 
only206.  
While feedback indicates that most normal daily activity can continue while wearing the 
device, several important issues were raised. Participants took issue with the size, bulk, and 
the perceived fragility of the device, and at times found that it made some aspects of the 
daily routine more difficult. A smaller, more robust system would make users feel more 
confident and would be less of a hindrance on routine activities. This should be a further 




The ability to sample during undisturbed sleep is a clear advantage of this microdialysis 
system. Feedback from participants indicates that for the majority the device did not disturb 
rest. Nevertheless, it would be useful to obtain an objective measure of sleep quality, ideally 
using a non-invasive method such as wrist actigraphy207, and compare sleep quality during 
nights with and without U-RHYTHM.  
Insertion of the microdialysis probe can safely be performed with or without use of local 
anaesthesia. In Bristol, where lignocaine was not used, the procedure was very well tolerated. 
Participants were equally comfortable with the procedure as participants at the other sites, 
who all received anaesthetic. Injection of local anaesthetic, while very safe, is not completely 
without risk208 and initially causes some discomfort before the lignocaine begins to take 
effect. Furthermore, deposition of local anaesthetic fluid, particularly if large volumes are 
used near to the probe membrane site, could potentially affect microdialysis due to dilution 
of the subcutaneous fluid161. Where anaesthesia is desired, a less invasive alternative would 
be preferable. Vapocoolants, for example, have been proven to reduce pain associated with 
intravenous cannulation, when applied immediately before the procedure209. Avoiding the 
use of injectable local anaesthetic would also reduce the time, cost, and complexity of the 
procedure. 
3.10 Summary and conclusions 
In this chapter, the further development and validation of a prototype ambulatory 
microdialysis sampling system has been described. The U-RHYTHM device is safe, well 
tolerated and operates with an success rate close to 75% during the period of device 
development. It produces good quality samples suitable for analysis using sensitive analytical 
techniques. Further improvement of the system is desirable, particularly optimisation of 
connections, reducing the manifold dead space, and simplification of the process for recovery 
of samples. Ergonomically, reduction in the size and bulk of the device would make it more 




Pre-analytical factors including the composition of the device manifold and spool clearly 
affect recovery of some analytes, notably highly lipophilic, hydrophobic compounds. In the 
long term, a redesign of the sample collection reservoir should be considered to overcome 
this issue.  
In its current state, the U-RHYTHM device is suitable for dynamic measurement of many 
types of small molecules including but not limited to less hydrophobic steroid hormones and 
hydrophilic metabolites. Surface modification with a non-ionic surfactant could potentially 
mitigate the adsorption effect of at least some hydrophobic compounds, and preliminary 
work indicates that use of cyclodextrin increases recovery of testosterone from a water bath. 
Cyclodextrin could be utilised with, or independently of tube surface modification to maintain 
solubility of hydrophobic compounds as they are recovered, and to prevent binding within 





4 Dynamics of 8 adrenal steroids in plasma and U-RHYTHM 
microdialysate 
4.1 Introduction 
In humans, the hormone cortisol is secreted with an anticipatory diurnal circadian rhythm – 
levels begin to rise from nadir concentrations in the early hours of the morning to peak 
around the time of waking – in preparation for the events of the coming day. However, 
adrenal hormones, and indeed hormones in general, are not released continuously - instead 
they are secreted in pulses that vary in amplitude and/or frequency over the 24-hour 
period48,210,211. In this chapter I will describe an initial validation of the U-RHYTHM sampler to 
measure a range of pulsatile and rhythmic adrenal hormones in subcutaneous tissue 
microdialysate, in comparison with simultaneous measurement of venous plasma.  
High frequency blood sampling studies in both animals45 and humans65,210, have revealed that 
the ultradian rhythm of glucocorticoids coincides with 60-90min secretory pulses of 
adrenocorticotropic hormone (ACTH) from the anterior pituitary54,56. Similarly, the 
mineralocorticoid hormone aldosterone, essential for maintenance of blood pressure through 
the regulation of sodium and potassium levels, is also secreted with both an ultradian and 
circadian rhythm, modulated by both ACTH and the renin-angiotensin system212,213. 
However, for any individual, the dynamics of the internal rhythmic environment may be 
influenced by multiple factors including chronotype214, the timing of food215, light91, sleep211, 
age and sex216, body weight217, mental218 or physical67 illness, pregnancy149, and of course by 
primary endocrine diease112. Hormone secretion in endocrine diseases continues to be 
dynamic. Pituitary Cushing’s disease111, adrenal Cushing’s syndrome112 and primary 
aldosteronism113 are all examples of pathologies characterised by disordered pulsatile 
secretion, rather than tonic hypersecretion. An altered diurnal rhythm of cortisol has been 




It is no wonder then that, for any particular individual, high levels of variation make random 
measurements essentially impossible to interpret, and are not recommended221. However, 
when it comes to clinical diagnosis, full 24-hour blood sampling protocols are not a practical 
solution as they are invasive, expensive and resource intensive. Instead, investigation of 
endocrine disease221–223 relies on single time point or limited dynamic analyses224, 
measurement of metabolites in urine225, or free hormone measurement in saliva183 - none of 
which can accurately capture intrinsic variation.  
While diagnostic approaches to endocrine conditions have not substantially changed for 
decades221 significant advances have been made in analytical science, particular the 
availability and performance of mass spectrometry-based measurement systems126. Mass 
spectrometry permits the simultaneous measurement of multiple analytes, including adrenal 
hormones, in small sample volumes. Morning fasted reference ranges of 16 adrenal 
hormones, measured in the same sample and determined by liquid chromatography-mass 
spectrometry (LC-MS)226 have recently been published, for example.  
The inclusion of multiple steroids could potentially improve the diagnostic power of a sample, 
reduce uncertainty, identify biomarkers, and reduce the need for additional diagnostic tests. 
Novel examples include the identification of subtypes of primary aldosteronism associated 
with glucocorticoid excess, identified through measurement of urinary glucocorticoid 
metabolites227. However, a recent study using a panel of 10 adrenal steroid in 222 single time 
point plasma samples did not outperform conventional tests for the discrimination of 
Cushing’s syndrome subtypes228, presumably because of the inability to capture intrinsic and 
interindividual dynamic variation. Likewise, while LC-MS examination of urine collections 
provide insights into overall changes in steroid production and metabolism229, urine is 
necessarily an integrated measure and cannot provide fine-grained detail about dynamic 




The ideal solution therefore might be a system that was able to not only capture multiple 
hormones, but the dynamics of the multiple hormones. Further, to reduce burden on health 
care systems, the procedure should be able to be performed as an outpatient, and not require 
intervention from the participant or patient during sample collection. Results from such a 
dynamic assessment could potentially lead to significant improvements in the speed and 
accuracy of endocrine diagnosis and monitoring of hormone diseases, such as Cushing’s and 
primary aldosteronism.  
The development of portable technology, described in detail in Chapter 3, has already proven 
able to passively capture samples for analysis of free cortisol, continuously over 24-hours or 
more, without the need for blood117,119,186. Distinct from measurements in blood, the U-
RHYTHM microdialysis system recovers free, rather than total concentrations of hormones, 
which include the fraction that bound to protein. For glucocorticoids this is extremely 
important since under normal conditions, most circulating hormones are bound to protein. 
Cortisol binds avidly to corticosteroid-binding globulin (CBG, 80%) and albumin (14%) leaving 
just 6% as the free portion230. By contrast, circulating free cortisone amounts to close to 25% 
of total cortisone231, while circulating free aldosterone represents approximately one third of 
the total232, with the remainder bound predominantly to albumin and CBG233. Sex hormone-
binding globulin regulates the free concentration of androgens and other sex steroids in all 
mammals234. Measurement of adrenal steroids using microdialysis and a low molecular weight 
cut-off microdialysis catheter therefore provides different information from blood samples 
for two important reasons:  
1. Proteins are too large to cross the membrane, and only the free, non-protein bound, 
biologically active portion is recovered116. 
2. Microdialysis provides a tissue-specific ‘view’ of hormone exposure which may not 




4.2 Aims and hypotheses 
The aim of the current studies was to examine and provide a preliminary description of the 
dynamic relationship of adrenal steroids, in and between plasma and subcutaneous interstitial 
fluid, using a targeted multiplex panel measured by high performance liquid-chromatography 
mass-spectrometry.  
It was hypothesised that cortisol, cortisone, and other adrenal steroids with similar solubility 
would be detected well in microdialysate, but that highly insoluble compounds including 
androgens would be poorly recovered. Further, it was hypothesised that adrenal hormones 




Healthy, non-smoking male and female volunteers (n=7) aged 18-68 and with a mean body 
mass index (BMI) of 25.5kg.m2  participated in this study as part of the healthy volunteer 
cohort of the ULTRADIAN clinical trial (NCT02934399) and following ethical committee 
review (IRAS 181429). Exclusion criteria were: BMI <16 or ≥30, use of estrogen containing 
oral contraceptive medication within the past 6 weeks, pregnancy or lactation, regular 
prescribed medicine, active medical conditions ongoing or within past 3 months, any history 
of endocrine disorder, current or recent use of oral, inhaled, parenteral or topical 
glucocorticoids within past 3 months, regular alcohol intake greater than 26 units per week, 
use of illicit substances, any use of potentially interfering herbal or over-the-counter 
supplements (St John’s wort, black liquorice, grapefruit juice) within 14 days, and abnormality 
of screening blood tests of renal function, haemoglobin, white cell count and differential, 
fasting glucose and glycated haemoglobin (HbA1c), liver function tests, thyroid stimulating 




4.3.2 Pre-sampling routine 
Participants were asked to maintain a regular bedtime, abstain from alcohol and all 
medication, and to avoid any strenuous physical activity for 48 hours prior to the sampling 
session. Participants were also asked to complete an activity diary, including record of food 
type and timing, sleep timing and subjective quality, commencing 24 hours prior to the 
sampling session.  
4.3.3 Sampling protocol 
On the morning of the sampling day, participants attended the research suite fasted. A 
standardised set of meals (Appendix H) was given to all participants providing 2225kCal (83g 
protein, 273g carbohydrate, 83g fat, 27g fibre) as breakfast (08:00), lunch (13:00), dinner 
(19:00) and a snack (22:00). Participants were given free access to water, tea, and coffee 
throughout the experiment. 
All participants provided a urine sample to exclude illicit substance use (SureScreen 
Diagnostics, Derby, UK) and in females, pregnancy (VWR International Ltd, Lutterworth, UK) 
prior to the commencement of sampling. 
Following breakfast, a 20kDa linear microdialysis probe was placed in the right periumbilical 
area and then connected to the U-RHYTHM sampler as described in Chapter 3. An 18g 
peripheral venous cannula was placed in an antecubital vein of the non-dominant arm and 
connected to the automated blood sampling system as described in the General Methods 
chapter47. 
Collection of blood samples began 80 minutes after commencing microdialysis sampling, 
coordinated with the timing of the U-RHYTHM bubble pump. During the procedure, 
participants remained on the study bed, except for visits to the toilet. Posture was noted at 




light were continuously monitored (HOBO Pendant® UA-002-08, Onset Computer 
Corporation, MA, USA).  
Room brightness was reduced to <10 lux as measured at the angle of gaze between 19:30-
23:00 and 07:00-09:00. Participants were asked to dim electronic devices and activate ‘night 
modes’ during these times. Room brightness was reduced to <5 lux during the sleep period 
(between 23:00-07:00).  
4.3.4 Sample acquisition 
Blood samples equalling 2.0mL in volume were collected every 20 minutes for 24 hours (72 
samples). Immediately after collection, the samples were centrifuged at 2000 RPM at 4ºC for 
5 minutes. Aliquots of the plasma were frozen at -20ºC until the end of the experiment and 
then at -80ºC until analysis.  
Microdialysis samples were retrieved from the U-RHYTHM sampler the day following the 
end of the sampling session. The first 80 minutes of samples in the spool were discarded 
after counting as they were considered likely to be affected by adsorption (see Chapter 3). 
The whole volume of each microdialysis sample was decanted into 300µL polypropylene 
sample vials (Microbiotech/se, Stockholm, Sweden) and then frozen at -80ºC.  
4.3.5 Sample analysis 
Immunoassay for plasma adrenocorticotropic hormone (ACTH) and multiplex analyses of 
adrenal steroids in plasma and microdialysate samples by LC-MS were performed at 
Haukeland University Hospital, Bergen, Norway (refer to General Methods). 
4.3.6 Data analysis 
Summary statistics were implemented in Stata 16.1 (StataCorp LLC, Texas, USA). Time series 
analysis was performed using a toolkit implemented in the NumPy (ver. 1.19.1), SciPy (ver. 
1.5.0), and Matplotlib (ver. 3.2.2) numeric libraries for Python (ver. 3.7.6), available at 




assistance and collaboration of Dr Eder Zavala and described in detail in Chapter 2 (General 
Methods). Cosinor analysis was implemented in Matlab R2019a (The MathWorks Inc., MA, 
USA) using code kindly provided by the laboratory of Professor Debra Skene (University of 
Surrey). 
Since the sample times in microdialysate and plasma were offset by 10 minutes, each series 
was interpolated creating two parallel time series with 10-minute sampling frequency. In the 
case of missing data, the maximum number of samples that could be interpolated was set to 
3. Time-lagged cross correlation was determined by incrementally shifting (lagging) one series 
relative to the other and repeatedly calculating the correlation between each profile. Each lag 
was 10 minutes, and the cross correlations were calculated to a maximum lag of 12 (120 
minutes) on either side of the centre. While there was no assumption about directionality it 
was considered likely that for most metabolites the direction would be from plasma to 
microdialysate. Since the sample populations were not assumed to be from a normal 
distribution, the strength of the cross correlation was evaluated using Spearman’s rank 
correlation (rs, where 1 = perfect correlation and -1 perfect anticorrelation). 
Dynamic correlation between time series was examined using rolling window mean 
correlation and instantaneous phase synchrony. First, rolling window aggregation was 
performed on the standardised (Z-scored) time series using a Gaussian window of size=6 
samples (60 minutes), generating a normally distributed mean value at each time point. Next, 
the Gaussian means were correlated using a rolling window correlation function, with a 
window size of 6 samples (60 minutes). The strength of the correlation was assessed using 
Pearson’s correlation coefficient rp, where 1 = perfect correlation and -1 perfect 
anticorrelation.  
Coherence between hormone time series was examined using instantaneous phase 
synchrony, which measures the moment-to-moment synchrony, or phase similarity, of paired 




Butterworth bandpass filter181). Next the phase of each time series signal was extracted using 
the Hilbert transformation180 and expressed as an angle between 0-360 degrees (or -π to π 
radians). When the difference between the angles is zero, both signals are in phase. The 
phase coherence was plotted as the instantaneous phase synchrony (IPS), which is equal to 
the angular difference between each time series subtracted from 1. Therefore, if the IPS is 0 
there is no coherence between the series; conversely if the IPS is 1 then the series was 
perfectly coherent (both time series were in phase with each other). 
Correlations were considered statistically significant when p<0.05. 
4.4 Results  
The data for 4 of 7 participants was available for review at the time of writing of this thesis. 
Participant demographics are shown in Table 4-1. 
ID Age BMI Sex Screening BP 
1 26 24.3 M 128/76 
2 26 22.9 M 105/71 
3 33 27.4 F 111/75 
4 24 27.3 M 118/90 
Mean 27.3 25.5  115/78 
Table 4-1 Demographics of participants who underwent 24-hour concurrent plasma and U-RHYTHM microdialysis 
sampling sessions. Data from 4 of 7 participants was available. BMI = body mass index (kg.m2), blood pressure (BP) = 
mmHg. 
4.4.1 Technical success rate 
A complete set of plasma samples was obtained for participants 1 and 2. Technical issues 
with the automated blood sampling system resulted in an incomplete collection for 
participant 3 (56/72) and 4 (69/72).  
Microdialysis sampling was technically successful for all 4 participants. The spool for 




and 1 very long sample (sample 26). All samples were of good quality for participant 2-4. For 
participant 4, unfortunately 12 samples were accidently dislodged from the sample plate 
(sample 1-8, 11, 13, 14, 16) during the harvesting procedure. Because the correct sequence 
of these samples could not be confirmed, they have been omitted from analysis (n=60/72 
samples included). 
4.4.2 Steroids recovered in both plasma and microdialysate 
For each participant, detection of steroids was classified into 3 categories: good (more than 
75% of samples contain valid measurements), acceptable (50-75% of samples contain valid 
measurements), poor (<50% of samples) for both plasma and microdialysis (Appendix K). 
There were 8 compounds with acceptable or good recovery in both plasma and 
microdialysate. Cortisol (F), cortisone (E), corticosterone, and dehydroepiandrosterone sulfate 
(DHEAS) were measurable in >95% of all samples in both plasma and microdialysate. 
Aldosterone was detected in all plasma samples. In microdialysate aldosterone was detected 
in over 90% of samples for participant 2 and 3, in 55.6% of samples for participant 1, but only 
21.3% of samples for participant 4. For 18-hydroxycortisol (18-OH-F) there was recovery in 
all plasma and microdialysis samples for every participant. Allo-tetrahydrocortisol (aTHF) and 
tetrahydrocortisol (THF) were recovered in all plasma samples, in >90% of samples for 
participant 1,2, and 4, and in approximately 50% of samples for participant 3.  
While there was good measurement of the androgen and progestogen steroid hormones 
androstenedione, testosterone, 17-hydroxyprogesterone (17-OH-P), and 
dehydroepiandrosterone (DHEA) in plasma, these compounds were universally absent in all 
microdialysis samples and are not presented here.  
4.4.3 Relationship between plasma and microdialysate 
Summary statistics of the mean, standard deviation, and range of concentrations detected in 




 Plasma U-RHYTHM microdialysate 
  Mean SD Min Max Mean SD Min Max 
Aldosterone 158.92 90.27 23.00 492.00 17.62 9.85 6.87 62.36 
Cortisol 142.04 83.94 18.56 340.82 2.18 1.90 0.18 8.28 
Cortisone 32.59 15.48 5.90 65.26 2.00 1.35 0.25 6.47 
18-OH-F 1.09 0.72 0.14 3.51 0.140 0.152 0.082 0.750 
aTHF 8.34 7.04 0.74 34.91 0.63 0.47 0.07 2.40 
THF 3.90 2.37 0.52 11.27 0.35 0.29 0.05 1.33 
DHEAS 4436.28 1060.24 2244.01 6755.05 15.62 8.69 2.28 38.49 
Corticosterone 2.68 3.19 0.13 20.25 0.103 0.079 0.081 0.612 
Table 4-2 Summary statistics of hormones measured every 20 minutes over 24 hours simultaneously in plasma and U-
RHYTHM microdialysate. The mean, standard deviation (SD) and range of each hormone are shown. Aldosterone = 
pmol/L, cortisol/cortisone=nmol/L, 18-hydroxycortisol (18-OH-F) =nmol/L, aTHF/THF = nmol/L, DHEAS = nmol/L, 
corticosterone = nmol/L, see main text for abbreviations. 
4.4.4 Relationships between ACTH and cortisol in plasma and microdialysate 
 
Figure 4-1 Comparison of ACTH against cortisol in plasma and tissue. ACTH (solid black lines), cortisol in plasma (pF, red 
dashed lines) and microdialysate (mF, teal dotted lines) are shown for the 4 participants, sampled every 20 minutes for 
24-hours. Vertical dashed lines indicate standardised meal teams [breakfast 0800, lunch 1300, dinner 1900, snack 
2200]. The grey shaded area indicates the sleep period [<10 lux, 2300-0700]. Plasma cortisol lags ACTH by a mean 
17.5 minutes (10-30). There is a strong and significant correlation between plasma and tissue cortisol (mean rs = 0.828, 




Total plasma cortisol ranged between 18.56-340.82 nmol/L (mean 142.04, SD=83.94) and 
free cortisol in microdialysate between 0.18-8.28nmol/L (mean 2.18, SD=1.90). In all cases, 
plasma ACTH showed a diurnal rhythm with superimposed ultradian secretion episodes 
(Figure 4-1). There was a stronger correlation of ACTH with plasma cortisol (mean Spearman 
correlation rs=0.864, range 0.748-0.939) than with cortisol in interstitial fluid samples (mean 
rs = 0.665, range 0.516-0.868). Across the four participants, plasma cortisol was also more 
closely synchronised with ACTH (mean lag 17.5 minutes, range 10-30 minutes) than 
interstitial cortisol (mean lag 87.5 minutes, range 60-100 minutes).  
4.4.5 Cortisol in plasma and microdialysis fluid 
 
Figure 4-2 Comparison of cortisol in plasma and microdialysate. Standardised values of plasma cortisol are represented 
by solid red lines (pF), and microdialysate dashed teal lines (mF). Vertical dashed lines represent meals and evening snack 
[08:00, 13:00, 19:00 and 22:00] and the shaded grey area the sleep period [23:00-07:00]. Individual coefficients and p-
values of the correlations are printed on each profile. 
Tissue cortisol profiles showed a characteristic asymmetric diurnal rhythm, dominated by a 




significant correlation between tissue and plasma cortisol (mean rs = 0.828, range 0.779-
0.873) although tissue cortisol lagged plasma cortisol by a mean of 55 minutes (range 40-70).  
Rolling mean cross-correlation (Figure 4-3) revealed that there were differences in the 
strength of the correlation between plasma and tissue cortisol across the sampling period. 
During the first part of the sampling, there was poorer correlation between the tissue and 
plasma measurements, especially for participant 1 and 2 (Figure 4-3 left and right top panels). 
The time of maximum correlation occurs during the later afternoon or evening when there is 
little dynamic change in the plasma signal, as cortisol concentrations in both plasma and 
tissue fall toward the nadir.  
The mean ratio of plasma cortisol:tissue free cortisol was 91.2 (SD=26.7), indicating that the 
free microdialysis cortisol was approximately 1.1% of corresponding total plasma levels. 
  
   
Figure 4-3 Rolling mean correlation of cortisol in plasma and microdialysate. The upper part of each figure shows 
standardised rolling means of plasma cortisol (pF, red lines) compared with tissue cortisol (mF, teal dashed lines). 




4.4.6 18-hydroxycortisol in plasma and microdialysate 
Plasma 18-hydroxycortisol was detected at a mean concentration of 1.09nmol/L (SD=0.72) 
compared with 0.140nmol/L ([140pmol/L], SD=0.152) in microdialysis samples.  
Plasma 18-hydroxycortisol was very strongly and significantly correlated with ACTH (mean rs 
= 0.889), plasma cortisol (mean rs = 0.977), and microdialysate cortisol (mean rs = 0.792). 
Plasma 18-hydroxycortisol lagged ACTH by a mean of 17.5 minutes (range 10-30).  
 
Figure 4-4 Microdialysate 18-hydroxycortisol is better correlated and synchronised with plasma ACTH than 
microdialysate cortisol. Example profiles of ACTH (solid black line), microdialysate 18-hydroxycortisol (mOHF, red dashed 
line) and microdialysate cortisol (mF, teal dotted profile) are shown here. The Spearman correlation of ACTH with 18-
OH-F was 0.799 (p<0.001) compared with cortisol 0.658 (p<0.001). 18-OH-F lagged ACTH by 20 minutes compared 




Microdialysate 18-hydroxycortisol also correlated very strongly with ACTH (rs = 0.804, range 
0.727 – 0.853) and with microdialysate cortisol (rs= 0.842, range 0.753 – 0.908). 
Microdialysate 18-hydroxycortisol lagged ACTH by a mean 37.5 minutes (range 20-50 
minutes samples (Figure 4-4).  
 
Figure 4-5 Comparison of 18-hydroxycortisol in plasma and microdialysate. Red lines shown plasma values (pOHF) and 
teal dashed lines microdialysate (mOHF). Vertical dashed lines represent meals and evening snack [08:00, 13:00, 19:00 
and 22:00] and the shaded grey area the sleep period [23:00-07:00]. The profiles are very highly correlated (mean 
Spearman correlation rs = 0.927, range 0.900-0.951). Individual coefficients and p-values of the correlations are printed 
on each profile. Plasma leads microdialysate by a mean 17.5 minutes (range 10-30 minutes). 
18-hydroxcortisol was very highly correlated between plasma- and interstitial fluid samples 
with plasma leading microdialysis by a mean 17.5 minutes (Figure 4-5).  
4.4.7 Cortisone in plasma and microdialysate 
Cortisone ranged between 5.90-65.26nmol/L (mean 32.59, SD=15.48) in plasma compared 
with between 0.25-6.47nmol/L (mean 1.35, SD=2.00) in microdialysate. The rhythm and 
relationship between cortisone measured in the plasma and microdialysate is shown in Figure 




rs = 0.792). Plasma cortisone lead microdialysate by a mean of 57.5 minutes (range 20-80 
minutes). The mean ratio of plasma to microdialysate cortisone was 19.3:1 (ratio 14.5-23.7) 
indicating that on average in these samples, the recovered tissue free cortisone was about 
5% of total plasma cortisone. 
 
Figure 4-6 Comparison of cortisone in plasma and microdialysate.  Standardised profiles in (plasma, solid red lines, pE 
and microdialysate, dashed teal lines, mE) are shown. Vertical dashed lines represent meals and evening snack [08:00, 
13:00, 19:00 and 22:00] and the shaded grey area the sleep period [23:00-07:00]. The profiles are well correlated 
(mean rs = 0.792). Individual coefficients and p-values of the correlations are printed on each profile. Plasma cortisone 
leads microdialysate by a mean 57.5 minutes (range 20-80).  
4.4.8 Dynamic relationship between cortisol and cortisone 
In both plasma and microdialysate, cortisol lead cortisone by no more than 10 minutes 
suggesting that there is typically no more than a 10-minute delay between changes in either 
tissue or plasma cortisol and corresponding shifts in cortisone. In plasma, the mean ratio of 
cortisol:cortisone was 4.18:1 (range 2.34-7.27, SD = 1.02, Figure 1-7, red solid lines). Both 





In microdialysis samples the mean ratio of cortisol:cortisone was 1.02, (0.52-5.03, SD = 0.56, 
Figure 1-8, teal dashed lines). During the late afternoon and evening, tissue cortisol fell below 
tissue cortisone in all participants. For participants 1 and 2, the combination of rising levels of 
cortisone and falling levels of cortisol during the first 3 hours of sampling has resulted in a 
disproportionately high ratio during the first part of sampling (Figure 1-8, top two panels). 
 
Figure 4-7 Ratios of cortisol:cortisone in plasma and microdialysis samples (plasma pF:pE, solid red lines, microdialysate 
mF:mE, teal dashed lines). Vertical dashed lines represent meals and snack [at 13:00, 19:00, 22:00 and 08:00] and the 
shaded area indicates the sleep period. Individual ratio mean (µ) and standard deviations (σ) are shown on each plot. 





4.4.9 Metabolites of cortisol 
 
Figure 4-8 Standardised profiles of allo-tetrahydrocortisol (aTHF) in plasma and microdialysis samples (plasma - red solid 
lines, microdialysate -teal dashed lines). Vertical dashed lines represent meals and snack [at 13:00, 19:00, 22:00 and 
08:00] and the shaded area indicates the sleep period. The Spearman correlation and associated p-value is printed on 
each individual profile. Plasma aTHF leads microdialysis by a mean of 50 minutes (range 10-70 minutes). 
Allo-tetrahydrocortisol (aTHF, Figure 4-8) ranged between 0.74-34.91nmol/L (mean 7.04, 
SD=8.34) in plasma and between 0.07-2.40nmol/L in microdialysate (mean 0.63, SD=0.47). 
Tetrahydrocortisol (THF, Figure 4-9) ranged between 0.52-11.27nmol/L (mean 3.90, 
SD=2.37) in plasma and between 0.05-1.33nmol/L in microdialysate (mean 0.35, SD=0.29). 
The mean ratio of aTHF:THF in plasma and microdialysate were similar (2.1 vs 1.8). 
aTHF and THF were highly correlated and synchronised within plasma (mean rs = 0.987, 
range 0.983-0.990, peak synchrony at lag=0), and microdialysate (mean rs = 0.924, range 
0.851-0.977, peak synchrony at lag=0).  
Allo-tetrahydrocortisol and tetrahydrocortisol were also highly correlated between plasma 




0.785)). The mean lag between plasma and microdialysis measurements of aTHF was 50 
minutes (range 10-70) and 47.5 minutes THF (range 10-80).  
 
 
Figure 4-9 Standardised profiles of tetrahydrocortisol (THF) in plasma and microdialysis samples (plasma -red solid lines, 
microdialysate - teal dashed lines). Vertical dashed lines represent meals and snack [at 13:00, 19:00, 22:00 and 08:00] 
and the shaded area indicates the sleep period. The Spearman correlation and associated p-value is printed on each 
individual profile. Plasma THF leads microdialysis by a mean 47.5 minutes (range 10-80). 
4.4.10 Corticosterone  
Plasma concentrations of corticosterone ranged between 0.13-20.25nmol/L (mean 
2.68nmol/L, SD=3.19) compared with 0.081-0.612nmol/L (mean 0.103, SD=0.079) in 
microdialysis samples (around 3.8% of plasma total concentration). Like other ACTH-driven 
glucocorticoids, a diurnal rhythm with predominant secretion beginning between 01:00 and 





Figure 4-10 Standardised profiles of corticosterone (CCS) in plasma and microdialysis samples (plasma - red solid lines, 
microdialysate - teal dashed lines). Vertical dashed lines represent meals and snack [at 13:00, 19:00, 22:00 and 08:00] 
and the shaded area indicates the sleep period. The Spearman correlation and associated p-value is printed on each 
individual profile.  
4.4.11 Aldosterone 
Aldosterone in plasma ranged between 23- 492pmol/L (mean 158.9, SD=90.3) and between 
6.87-62.36pmol/L (mean 17.62, SD=9.85) in microdialysis samples. Microdialysate free 
aldosterone concentrations were therefore approximately 11% of total plasma levels. 
Aldosterone was not detected in all microdialysis samples, with the poorest recovery in 
participant 4 – this participant also had the lowest mean concentration of plasma aldosterone 
of all the participants (Figure 4-11). Tissue free aldosterone secretion was significantly 
correlated with plasma (Figure 4-12). The pattern in both plasma and microdialysate (where 
detected) was episodic secretion that reaches the highest amplitude during and toward the 
end of the sleep period (Figure 4-12). Pulses of aldosterone occur both independently of 




nadir, plasma ACTH pulses become highly synchronous with large amplitude, pre-wakening 
pulses of aldosterone in both plasma and microdialysate samples (Figure 4-13). 
 
Figure 4-11 Aldosterone in plasma and microdialysate (plasma [pAldo] – red solid lines, microdialysate [mAldo] - teal 
dashed lines), detected in pmol/L concentrations. Not all microdialysis samples contained measurable concentrations of 
aldosterone, especially participant 4 (lower right). Vertical dashed lines represent meals and snack [at 13:00, 19:00, 





Figure 4-12 Standardised profiles of aldosterone in plasma and microdialysate (plasma – red solid lines, microdialysate - 
teal dashed lines). Vertical dashed lines represent meals and snack [at 13:00, 19:00, 22:00 and 08:00] and the shaded 






Figure 4-13 Phase synchrony of ACTH and aldosterone. Filtered profiles of ACTH (red solid lines) and plasma aldosterone 
(teal dashed lines) are shown in relation to their phase coherence (phase synchrony, solid black line). Vertical dashed lines 
indicate meal and snack times, the grey shaded area is the sleep period.  
Phase synchrony increases toward 1 when the magnitude and direction of changes in each hormone are aligned (rising or 
falling). When hormone changes are discordant, phase synchrony falls toward 0. Aldosterone secretion episodes occur 
both in and out of phase with ACTH secretion pulses, with strong interindividual variation evident in these 4 profiles. 
Aldosterone is most closely phase aligned at the time of the pre-wakening ACTH pulses. Lowest coherence occurs in the 
late afternoon and early evening, most clearly seen in participant 1 (top left), where phase synchrony is low throughout 
the day, and falls to zero between approximately 19:00 and 21:30. By contrast, for participant 3 (bottom left) ACTH 
secretion episodes are temporally associated with aldosterone secretion episodes throughout the 24-hour sampling 
period, resulting in many periods in which the two hormones are phase aligned. 
4.4.12 Dehydroepiandrosterone sulfate (DHEAS) 
Concentrations of dehydroepiandrosterone sulfate (DHEAS) ranged between 2234-
6755nmol/L in plasma and between 2-38nmol/L in microdialysis samples. Overall, the 
correlation between the two compartments was low (Figure 4-14). All four plasma profiles 
were significant for cosine fit, indicating daily rhythmicity of plasma DHEAS. The acrophase 




 Mesor Amplitude Acrophase (hh:mm) F P value 
1 5779 756 16:15 43.831 <0.001 
2 3128 573 16:15 138.070 <0.001 
3 5041 654 13:50 30.841 <0.001 
4 3826 545 15:40 19.397 <0.001 
Table 4-3 Cosinor fit of DHEAS profiles in plasma. Each participant has a daily rhythm as evidenced by the strong, 
significant fit to cosine curve (p<0.001). Rhythm mesor and amplitude are measured in nmol/L, and the acrophase (peak) 
of the rhythm is given in 24-hour clock time.  
 
Figure 4-14 Standardised profiles of DHEAS in plasma and in microdialysate (plasma – red solid lines, microdialysate - 
teal dashed lines). Vertical dashed lines represent meals and snack [at 13:00, 19:00, 22:00 and 08:00] and the shaded 
area indicates the sleep period. The Spearman correlation and associated p-value is printed on each individual profile. 
4.5 Discussion 
This chapter presents the results of an initial investigation into the dynamic correlation of 8 
adrenal steroids detected both in blood plasma and abdominal subcutaneous tissue fluid over 
24 hours. All but one (cortisol) have never been described in this way before. Samples were 




RHYTHM. The data in this chapter represent, to my knowledge, the first such sampling study 
of its kind. There are several significant findings that will be discussed. 
4.5.1 Detection of diurnal and ultradian rhythms in U-RHYTHM profiles 
The significant and unique advantage of the present study was the ability to measure and 
quantify multiple adrenal hormones in the same microdialysis sample, and to compare these 
with simultaneous plasma measurements. For most hormones, there was very good to 
excellent correlation of 24-hour profiles between plasma and microdialysate. Diurnal rhythms 
of cortisol, cortisone, 18-OH-cortisol, aTHF/THF, corticosterone and aldosterone were 
present in both tissue and plasma, and for DHEAS in plasma.  
With a sampling frequency of 20-minutes, ultradian pulses were observed in several plasma 
hormones, including ACTH, cortisol, corticosterone, and aldosterone. The most novel finding 
was the highly dynamic ultradian rhythm of 18-hydroxycortisol in both plasma and 
microdialysis samples, to be discussed further below. By contrast, the ability to detect smaller 
pulses of cortisol in microdialysate was not demonstrated, particularly during the daytime 
hours.  
In an earlier study of 8 healthy volunteers using an previous version of the prototype 
microdialysis sampler, cortisol was measured by immunoassay every 10 minutes in plasma 
and subcutaneous tissue over 24-hours186. Ultradian oscillations of cortisol were observed as 
expected in plasma, but as in the current study, temporally related pulsations were blunted or 
absent in the subcutaneous tissue samples, which represented a more smoothed, diurnal 
profile186. The authors speculated that this could be as a result of assay limitations at the 
concentrations found in tissue, smoothing related to the integrated nature of microdialysis 
sample collection compared with instantaneous time points in plasma, or related to local 
tissue factors such as protein binding by corticosteroid binding globulin186. In the only other 




studies in 23 lean and obese pregnant women and 7 healthy controls, with analysis by 
immunoassay for cortisol. Again, the expected diurnal rhythm was clear in all samplings, and 
while they claimed to have detected pulsatile secretion in the microdialysis samples149, the 
frequency of the pulses was acknowledged to be significantly lower than the reported 60-90 
minute frequency in plasma or serum44,47. The authors speculated that this may have been 
related to the sampling frequency149.  
In the current study, for cortisol, the cross-correlation determined lag between plasma and 
microdialysate was 40-70 minutes, comparable to Bhake et al. who reported a lag of 5 
samples (50 minutes) when sampling at a 10 minute frequency186. The steroid with the 
highest lag was corticosterone, in which the profile in microdialysate lagged plasma by 70-
130 minutes. In the current study, dynamic assessment using techniques of cross correlation 
and phase synchrony revealed that alignment of hormones in the plasma and microdialysate 
depends on the hormone itself, the magnitude of flux in the plasma compartment, and the 
time of day the sample is obtained. For example, microdialysate cortisol measurements 
obtained during the first few hours of daytime sampling are a much poorer reflection of the 
plasma values than an equivalent sample taken in the afternoon or early evening. Thus, the 
current findings indicate that while diurnal variation is well captured for cortisol 
measurements, microdialysate represents a time shifted and distorted view of concurrent 
plasma dynamics.  
4.5.2 Contributors to the differences between plasma and microdialysate 
As evidenced in previous studies, increasing the sample frequency did not improve the ability 
to measure ultradian cortisol pulsations in the microdialysate186, and neither did the use of a 
highly sensitive mass spectrometry method as described in the current study. Therefore, it is 
my opinion that there are likely to be several other contributors to differences in plasma and 
microdialysate dynamic profiles – steroid solubility, the interaction of these hydrophobic 




interaction with the subcutaneous matrix, and the possibility of local tissue metabolism 
affecting the relationship between cortisol and cortisone. 
The perfusate used for microdialysis is a saline (water) based solution containing no proteins 
or lipids and the observed differences between plasma and microdialysate correlate with the 
solubility of each steroid in water. For 18-hydroxycortisol this is 1.34g/L compared with 
0.2g/L for cortisol, 0.14g/L for cortisone, 0.15g/L for aldosterone, and just 0.046 g/L for 
corticosterone205. As the most insoluble compound detected, corticosterone was also the 
compound with the largest computed delay between plasma and tissue, while for 18-
hydroxycortisol the lag between plasma and tissue ranged from just 10-30 minutes. The 
solubility of extremely hydrophobic steroids testosterone and 17-hydroxyprogesterone are 
only 0.023g/L and 0.029g/L respectively; these were not recovered in any microdialysis 
samples. Strategies for improving the recovery of highly insoluble compounds were discussed 
in Chapter 3, and have been successfully implemented for the in vivo recovery of 
endocannabinoids194. 
The second significant influence on the recovery of adrenal steroids is likely to be artefactual 
and related to the interaction of recovered compounds with hydrophobic plastic surfaces. In 
Chapter 3, it was described and demonstrated that adsorption to surfaces within the sampler 
and collection spool significantly impact all lipophilic compounds, a class effect for adrenal 
steroids, with the most highly lipophilic (insoluble) being most affected. In the present studies, 
the first samples collected were those with the poorest correlation between the 
compartments. These samples were also the first to contact the sampling device and most 
exposed to the plastic collection spool. The relatively more hydrophilic 18-hydroxycortisol 
was much less affected, presumably because it was able to remain soluble and interact less 
with the hydrophobic sampler surfaces. This may also partly explain the fact that in rodents, 




detected with intra-adrenal45 and subcutaneous tissue microdialysis151 – in those studies 
samples were collected without the use of a ‘U-RHYTHM’ device.  
A further explanation for differences in the lag and correlation of steroids between plasma 
and microdialysate relates to the compositions of the interstitial environment. In a cohort of 
205 men and 137 women aged 18-70, ultrasound determined mean skin thickness at the 
waist was <2mm and while there were no sex differences in abdominal skin thickness, skin 
was significantly thicker with a BMI in obese range (2.2mm) than those who were 
underweight or with normal BMI (1.78 and 1.88mm respectively)235. The microdialysis probes 
used with the U-RHYTHM device are placed superficially, approximately 1-2 mm below the 
skin surface, and therefore are potentially influenced by proximity to subcutaneous fat, 
especially in people with increased BMI, although this was not a factor in the present study. 
As described in the introduction to this thesis, the interstitial space is a complex environment 
containing collagen matrix, proteins and charged particles that could potentially influence the 
transit time of molecules from capillaries through the interstitial fluid161. Although unproven, 
it is possible that corticosteroid-binding globulin (CBG) is present in the interstitial matrix - if 
this were true it could capture diffusing free cortisol and thus reduce recovery by 
microdialysis. Recovery of CBG-bound cortisol would be technically challenging due to the 
molecular weight and structure of CBG236, at the very least requiring the use of a much larger 
cut-off microdialysis membrane.  
Finally, it is possible that recovery is also influenced by local metabolism of glucocorticoids, 
particularly the dynamic interconversion of cortisol to cortisone. In the plasma, the overall 
mean ratio of cortisol:cortisone was around 4.2, comparable with a median ratio of 4.9 
measured by LC-MS in single morning time point samples (reported by Eisenoffer et al.226). 
Thus cortisol is dominant in circulating plasma, with the large proportion bound to plasma 
proteins, especially corticosteroid binding globulin234. In contrast to the plasma, the 




cortisol:cortisone that was maintained very close to 1:1, and in all participants the ratio fell 
below 1 overnight, meaning that for substantial periods, free cortisol was lower than 
cortisone in the tissue. Cortisol is in constant equilibrium with the biochemically inactive 
cortisone, through interconversion modulated by 11β-hydroxysteroid dehydrogenase (11β-
HSD) enzymes. The isoforms of these enzymes are expressed differentially throughout the 
body237 meaning that local tissue exposure to glucocorticoids can be regulated through the 
selective interconversion between the inactive and active forms238. The machinery for 
interconversion of cortisol with cortisone is present in and around subcutaneous tissue. 
Previous studies have identified the cortisol activating isoform 11β-HSD -1 within all layers 
of the epidermis239 and within subcutaneous adipose tissue240 while the inactivating form 
11β-HSD-2 is present around sweat glands but not in epidermis241. Adipose tissue is an 
endocrine organ242 and endocrine pathology can alter adipose tissue deposition and local 
tissue glucocorticoid exposure through overproduction of 11-β-HSD-1243. Skin samples from 
patients with primary aldosteronism show pathological alterations compared with healthy 
controls, including significantly increased 11-beta-HSD-2, glucocorticoid and 
mineralocorticoid receptor expression244. Thus there are a number of factors that might 
differentially affect the pattern of local free cortisol recovery in healthy, normal weight 
participants compared with those who have elevated BMI245,246 or endocrine diseases. 
4.5.3 18-hydroxycortisol as an interstitial biomarker of adrenal steroid production 
The high frequency measurement of 18-hydroxycortisol in these 4 healthy participants 
represents, to my knowledge, the first ever 24-hour dynamic profile of this steroid in humans 
or any other mammal. It is clearly regulated by ACTH, confirming previous reports247. Most 
significantly, however, is its presence in the microdialysis samples of all participants, and its 
high correlation with plasma – 18-hydroxycortisol in microdialysate was a superior predictor 
of both plasma cortisol and ACTH than microdialysate cortisol. Previously, little attention has 




hallmark of glucocorticoid remediable hyperaldosteronism229 but in health, plasma 
concentrations are significantly lower than those of cortisol, and it has no known biological 
activity248. There is a small sex difference in the median plasma concentration when 
measured between 08:00-10:00 (1.41nmol/L in females compared with 2.02nmol/L in 
males)226 but such single time point samples do not reflect the dynamic range of the hormone 
clearly observed in the current work. 18-hydroxycortisol is commonly described as a ‘hybrid 
steroid’ as its molecular structure shares features from both the adrenal zona glomerulosa 
and zona fasiculata248, and since it requires both aldosterone synthase and 17α-hydroxylase 
enzymes for production248. Recently, there has been interest in its potential clinical utility as a 
biomarker for unilateral aldosterone producing adenoma249. In the setting of ambulatory 
microdialysis, 18-hydroxycortisol appears to be a key steroid of significance, whose profile 
may provide essential information about the secretion dynamics of both ACTH and cortisol, 
at least in healthy volunteers. In pathological states, there is clear potential to explore its use 
as dynamic diagnostic marker to distinguish, for example, adrenal from ACTH dependent 
Cushing’s syndrome, and aldosterone producing adenoma from bilateral adrenal hyperplasia 
or ‘essential’ hypertension248.  
4.5.4 Aldosterone and ultradian dynamics 
In the current study, wide inter-individual variation in the frequency and mass of aldosterone 
pulses was observed even in controlled sampling conditions with little physical activity and a 
standard diet. The common finding was that the largest amplitude pulses occurred overnight, 
during the sleep period, and synchronised with the pre-waking ACTH/cortisol surge. These 
findings are consistent with those of Charloux et al. (1999, 2001)212,213 who found pulsatile 
secretion of plasma aldosterone was associated with renin activity during sleep, and with 
pulses of cortisol during the day213, suggesting a dual regulation of aldosterone secretion. 
When sleep was deprived, there was blunting of the usual overnight secretion of both 




plasma renin in either plasma or microdialysate for comparison. In future studies, 
measurement of renin, particularly if it were possible in microdialysate, along with an 
objective index of sleep would be extremely helpful. 
In addition to the pulsatile profiles of 18-hydroxycortisol in microdialysis fluid, the periodic 
secretion of aldosterone detected in microdialysate clearly shows that ultradian hormone 
oscillations are detectable with U-RHYTHM, even at 20-minute sampling. In plasma, 
aldosterone concentrations are affected by a number of factors including sodium intake and 
medication250. Suspicion of abnormal secretion is usually based on ratios with plasma renin, 
since single time point samples of aldosterone are typically meaningless - random morning 
values in the plasma of 525 volunteers, half of who had hypertension, ranged for 20-
620pmol/L226. In the current study, microdialysate concentrations of aldosterone were in the 
low pmol/L range in all participants, and in many samples, no aldosterone was detected. It is 
suspected that the combination of both low circulating concentrations in healthy, 
predominantly supine rested states251 and the low solubility of aldosterone are likely to be 
the key contributors to the low recovery of aldosterone by U-RHYTHM microdialysis, at least 
in these volunteers.  
4.5.5 Ratio dynamics as potential biomarkers 
In the current study, a diurnal rhythm in the ratio of cortisol to cortisone could be observed 
(Figure 4-7). Calculation of the ratio applied to high frequency sampling in plasma makes it 
obvious that a lunch meal at 13:00 was associated with a relative increase in cortisol over 
cortisone. Time of day is clearly important as the same effect was not observed with the 
dinner meal at 19:00. These findings are consistent with the finding of Follenius et 
al.(1982)252 who studied 30 male volunteers and found that an identical meal given at 13:00 
produced a larger and more consistent cortisol response than at 20:00. No effect of meals on 
microdialysate cortisol can be observed but post-prandial rises in 18-hydrocortisol following 




The cortisol:cortisone ratio is commonly used as a tool for assessing 11-β-HSD activity 
through measurement of urine metabolites253 and there is little published regarding temporal 
changes in the ratio in plasma or other fluids in healthy people. Nomura et al. (1997)254 
described daily variation in plasma cortisone, cortisol, and in the ratio of cortisone:cortisol in 
a cohort of 10 healthy volunteers. While they claim that the ratio remained constant during 
“waking hours” the study was limited by a less than 24 hour collection time, and a 2 hourly 
sample frequency254. Moller et al. (2016) found diurnal variation in cortisol, cortisone and 
other adrenal steroids and androgens in a cohort of 10 healthy pre-menopausal women 
measured 4-hourly in blood for 24 hours255. The ratio of cortisol:cortisone ranged between 
4.4 between 06:00-10:00 and 2.7 between 18:00-22:00255, broadly similar to the 
observations in the current cohort. In the 24-hour microdialysis profiles, cortisol fell to very 
low levels, below that of cortisone, overnight. Data from further samplings across a broader 
range of age, body mass index and health conditions are needed to determine if this is a 
significant finding. THF/aTHF are intermediate compounds in the metabolism of cortisol256 
and in urine have been used with tetrahydrocortisone (THE) as a method of evaluating 11-β-
HSD-2 activity257. THE was poorly recovered in microdialysate and not reported here in these 
4 participants.  
4.5.6 Corticosterone and DHEAS 
Despite its very low solubility, recovery of corticosterone was possible in all participants, with 
a similar asymmetric diurnal rhythm to that of cortisol and other glucocorticoids. While 
corticosterone is the major active glucocorticoid in rodents, it has traditionally thought to be 
biological inactive in humans. However, the recent finding that corticosterone can suppress 
ACTH and improve the tissue metabolic profile in patients with Addison’s disease258 suggests 
the compound is a potentially important biomarker, and tissue profiles could be used as a 
monitoring tool if corticosterone was administered therapeutically. Finally, DHEAS 




rhythm in primates259 and diurnal rhythms in humans260,261 more likely related to circadian 
variation in serum albumin rather than intrinsic adrenal activity.262 Absolute quantities of 
DHEAS are higher in women and fall with age263 and with a larger cohort of samples, it may 
be possible to determine if concentrations of DHEAS in microdialysate show similar sex and 
age related differences. 
4.6 Conclusions 
Since the steroid metabolomes of blood and urine reflect different biochemical and metabolic 
pathways264, so too should we expect differences in the steroid metabolome of interstitial 
fluid compared with blood plasma and other tissues. This chapter presents the results of a 
first of its kind proof of principle trial. Here, the 24-hour dynamic correlations of 8 adrenal 
steroids detected simultaneously in plasma and in free form in U-RHYTHM microdialysis 
samples were presented. All steroids except DHEAS were well correlated, with 
microdialysate 18-hydroxycortisol being the best predictor of plasma ACTH/cortisol 
dynamics. Ultradian variation was most apparent in the blood samples while microdialysate 
profiles tended to be smoothed and lag changes in plasma. The loss of fidelity in microdialysis 
sampling is likely to be a result of the combination of the low solubility of adrenal steroids, 
the effect of adsorption, and the interaction of the subcutaneous tissue matrix with 
compounds as they diffuse from plasma into the interstitial space. Further experiments are 
needed to determine if any of these effects can be mitigated safely during in vivo sampling.  
With a limited number of participants these results need to be interpreted with some caution 





5 A pilot study of high-resolution daily metabolite changes in 
plasma and U-RHYTHM microdialysate  
5.1 Introduction 
Metabolomics is the comprehensive study of the small molecular weight products of 
metabolism (metabolites) in biological specimens265. Since metabolites can also represent 
substrates of metabolism, metabolomic profiles can provide detailed information about 
phenotypes in healthy and unhealthy metabolic states266,267. In this chapter, I will present 
demonstrative, proof-of-principle evidence that multiple metabolites can be recovered using 
the U-RHYTHM subcutaneous interstitial microdialysis sampler, providing meaningful profiles 
that correlate highly with the dynamic changes in plasma. 
Metabolomic approaches have been incorporated into an increasingly wide range of human 
studies. These include identifying potential biomarkers of disease such as osteoarthritis268, 
connective tissue disease269, inflammatory bowel disease270, and glucocorticoid excess271. 
Importantly, there is a complex and intertwined relationship between the intrinsic circadian 
timing system and the metabolome30,33,69. Many metabolites exhibit rhythmic daily 
changes29,115,272 which are strongly influenced by sleep status28,273,274 and the timing of food75. 
For example Isherwood et al. (2017) found significant differences in both the concentration 
and daily timing of metabolites between lean and obese participants with and without 
diabetes, emphasising the importance of considering time of day, and the limitations of single 
time point sampling for the measurement of highly dynamic systems168. 
Studies of variation in the metabolome typically sample at a frequency of 2-4 hourly29,115,168. 
Rapid changes in metabolites, such as those related to food consumption275 or which occur at 
the boundaries of sleep onset or offset, cannot be accurately assessed in this way. Further, 
there is evidence of significant interindividual variability5 in the timing and amplitude of 




resolution profiling of metabolites could therefore be extremely useful. It would help not only 
to understand normal interindividual variation, but also facilitate detailed exploration of the 
processes by which, for example, sleep disruption and mistimed food contribute to adverse 
health outcomes72,168,276. High frequency sampling in metabolomics studies has been limited 
by the difficulty and expense of admission to a specialist research unit, cannulation of a vein, 
on-hand retrieval of multiple samples, and supervision by dedicated specialist staff. Since 
metabolites are small molecules, the technique of microdialysis presents itself as an attractive 
alternative, which would allow blood-free and minimally invasive measurement of a wide 
range of metabolites in tissue. The feasibility and success of the microdialysis technique for 
targeted measurement of the adrenal metabolome has already been presented in Chapter 4. 
It has previously been demonstrated that amino acids are able to freely cross the membrane 
of a 20kDa microdialysis probe120, and remain stable at both ambient conditions and when 
exposed to the U-RHYTHM ambulatory microdialysis system in vitro (Chapter 3).  
Amino acids are an important group of metabolites whose normal rhythms are affected by 
food277, time of day272, sleep and sleep deprivation114,115,272,273. Further, free amino acids have 
been successfully recovered by microdialysis in humans. Small trials have reported their 
measurement in the subcutaneous tissue of neonates120 and children278, and in adult skeletal 
muscle135,162. However, microdialysis has never been used to characterise complete daily 
rhythms of amino acids, or indeed any other non-hormonal metabolite. 
5.2 Aims and hypotheses 
The purpose of the current study was twofold. Primarily it was aimed as a proof-of-principle 
study to generate data for future studies. The main goal was to determine the composition of 
metabolites recoverable in subcutaneous interstitial tissue fluid, using a targeted approach 





1. To compare the range and type of metabolites that can be recovered in both plasma and 
U-RHYTHM subcutaneous microdialysate samples. 
2. To generate first-of-their-kind high resolution daily metabolite profiles over 25 hours 
using 20-minute sampling, a targeted metabolomics approach, and a 16:8 wake/sleep 
routine with standardised meals. 
Based on previous reports120,275 and the experimental evidence discussed in Chapter 3, it was 
hypothesised that water soluble, polar metabolites such as amino acids should be efficiently 
recovered and show rhythms influenced by food and sleep timing, while the recovery of more 
non-polar (lipophilic) metabolites was less certain.  
5.3 Methods 
5.3.1 Participants and pre-sampling routine 
Healthy non-smoking male volunteers aged 18-35 (n=3) were invited to participate following 
local ethics committee review (Health Sciences Faculty Research Ethics Committee, 
University of Bristol, UK). Exclusion criteria were: regular use of prescription medication, 
over-the-counter supplements or vitamins, active medical conditions within past 3 months, 
abnormal screening blood tests (full blood count, renal function, liver function, thyroid 
function), recent shift-work or trans-meridian flight within the past 2 weeks, sleep disorder 
(Pittsburgh Sleep Quality Inventory (PSQI) >5, Epworth Sleepiness Score (ESS) >9), extreme 
chronotype (Horne-Östberg Morningness-Eveningness Questionnaire (MEQ) <30 or >70279), 
or major depressive symptoms (Beck Depression Inventory (BDI) >9). 
To ensure a regular routine, 7 days prior to sampling participants were asked to maintain a 
consistent sleep/wake schedule [23:00-07:00] with sleep diaries, daily activity, and light 
exposure monitoring for confirmation. Ambient light exposure measured in lux and triaxial 
motion counts were counted in 30 second epochs (MotionWatch 8, CamNTech Ltd, 




caffeine and caffeine containing drinks, vigorous exercise, all medications, and bright light in 
the evenings/night for 72 hours prior to the sampling session. Participants completed a 
detailed diary documenting all food intake for 24 hours prior to sampling. 
5.3.2 Sample acquisition 
On the day of the experiment, participants arrived fasted. A standardised set of meals 
(Appendix H) was given to all participants providing 2225kCal (83g protein, 273g 
carbohydrate, 83g fat, 27g fibre) as breakfast (08:00), lunch (13:00), dinner (19:00) and a 
snack (22:00). In addition to the study meals, participants were given free access to water. All 
participants provided a urine sample to exclude illicit substance use (SureScreen Diagnostics, 
Derby, UK). 
The microdialysis probe was placed in the right periumbilical area and connected to the U-
RHYTHM sampler as described in Chapter 3. Sample retrieval began no earlier than 2 hours 
after the breakfast meal and continued until 75 consecutive plasma samples were obtained 
(25 hours).  
During the sampling procedure, participants remained on the study bed. Posture was noted 
at each blood sampling point as ‘sitting’, ‘semi recumbent’, or ‘recumbent’. Ambient room 
temperature and light were continuously monitored (HOBO Pendant® UA-002-08, Onset 
Computer Corporation, MA, USA). Room brightness was reduced to <10 lux as measured at 
the angle of gaze between 19:30-23:00 and 07:00-09:00. Participants were asked to dim 
electronic devices and activate ‘night modes’ during these times. The sleep period occurred 
between 23:00-07:00 when the room lights were switched off (room brightness <4 lux).  
5.3.3 Sample processing and analysis 
Peripheral venous blood samples for metabolomics and cortisol were drawn at 20 minute 
intervals and melatonin at hourly intervals using an automated blood sampling system 




heparin tubes and immediately centrifuged at 4ºC for 5 minutes at 2000 RPM. Separated 
plasma for metabolomics was then placed immediately on dry ice until the end of the 
experiment and then stored at -80°C. Plasma for cortisol and melatonin was frozen at -20°C 
before storage at -80°C.  
The whole volume of each microdialysate sample was retrieved from the U-RHYTHM spool 
following overnight equilibration at the end of the experiment. All samples were included 
(none were discarded) and were stored at -80°C prior to analysis. 
Analysis of samples was performed at the University of Surrey. For the in laboratory protocol, 
plasma melatonin and cortisol were measured in duplicate by radioimmunoassay280 with all 
samples measured in the same run. The limit of detection for the melatonin assay was 
3.9pg/mL and the inter-assay coefficient of variation (CV) 22.2% at 8.2pg/mL, 10.4% at 
33.2pg/mL, 9.3% at 88.8pg/mL, and 9% at 121.4pg/mL. The limit of detection for the cortisol 
assay was 1.7nmol/L with inter-assay CV 11.2% at 67.7nmol/L, 11.0% at 520nmol/L and 
8.8% at 884nmol/L. Targeted quantification of metabolites was done using the 
AbsoluteIDQ® p180 kit (Biocrates Life Sciences AG, Innsbruck, Austria) according to the 
methods described in Chapter 2. At each 20-minute time point 10µL of plasma and 15µL of 
microdialysis fluid were used for measurement of the metabolites.  
5.3.4 Data analysis 
Dim light melatonin onset was calculated using the 25% threshold method as described by 
Sletten et al.280 Briefly, the 25th centile of the melatonin range was determined by adding the 
value of the limit of quantification or detection to 25% of the mean of the 3 highest 
melatonin measurements in the profile. Outlier measurements in the metabolite profiles were 
identified using a principal component analysis (SIMCA-P, v13.0, Sartorius AG, Goettingen, 
Germany). Analysis to test for linear change or daily rhythmicity (cosine fit) was performed on 




Professor Debra Skene (University of Surrey) and implemented in MATLAB 2019a (The 
MathWorks, Inc., Natick, Massachusetts, USA). Only metabolites recovered in both plasma 
and microdialysate of more than one participant were included for this analysis (n=24). 
Where a metabolite was significant for cosine fit (p < 0.05) the clock time of the acrophase 
was calculated. Metabolite data was extracted as both raw data and as standard scores (Z-
scores) where 𝑍 =  
𝑥− ?̅?
𝑆
, ?̅? is the sample mean and 𝑆 is the sample standard deviation.  
Summary statistics of the raw data were implemented in Stata 16.1 (StataCorp LLC, Texas, 
USA). Statistically significant differences between groups of metabolites were assessed using 
a Brown-Forsythe one-way analysis of variation (ANOVA) since equality of group variance 
was not assumed. Comparisons of metabolite concentrations between participants was done 
using the Mann Whitney U test, a non-parametric test of the means of independent samples. 
Time series analysis including cross correlation was implemented in the NumPy (ver. 1.19.1), 
SciPy (ver. 1.5.0), and Matplotlib (ver. 3.2.2) numeric libraries for Python (ver. 3.7.6), available 
at http://www.scipy.org and https://www.python.org. The code was written with the 
assistance and collaboration of Dr Eder Zavala and described in Chapter 2 (General Methods). 
Since the sample times in microdialysate and plasma were offset by 10 minutes, each series 
was interpolated creating two parallel time series with 10-minute sampling frequency. In the 
case of missing data, the maximum number of samples that could be interpolated was set to 
3. Time-lagged cross correlation was determined by incrementally shifting (lagging) one series 
relative to the other and repeatedly calculating the correlation between each profile. Each lag 
was 10 minutes, and the cross correlations were calculated to a maximum lag of 12 (120 
minutes) on either side of the centre. While there was no assumption about directionality it 
was considered likely that for most metabolites the direction would be from plasma to 
microdialysate. The significance of the cross correlation was evaluated using Spearman’s rank 




assumed. Standardised profiles of individual metabolites were plotted for reference, and to 
allow visualisation and comparison between the participants.  
5.4 Results 
5.4.1 Demographics  
Table 5-1 provides summary demographic information. Profiles of cortisol and melatonin are 
shown in Figure 5-1. 
Table 5-1 Demographics of male volunteers completing 25-hour simultaneous plasma and microdialysis sampling.  Age = 
years, BMI=body mass index (kg.m2), PSQI = Pittsburgh Sleep Quality Index, ESS = Epworth Sleepiness Score, MEQ (HO) 
= Morningness-Eveningness Questionnaire (Horne Östberg), DLMO= dim light melatonin onset. 
5.4.2 Technical success rate 
There were technical issues with the sample collection for participant 1. The microdialysis 
probe failed to flush following insertion, requiring replacement with a second probe in 
adjacent tissue. Secondly, the automated blood sampling device failed to draw adequate 
samples, requiring manual collection of blood from the peripheral cannula at each time point. 
Sampling for participant 2 was uneventful. For participant 3, the probe required a second 
flush due to flow obstruction at point of connection with the sampler. Adequate volume 
microdialysis samples were retrieved in all cases. 
ID Age BMI PSQI  ESS MEQ (HO) DLMO 
1 26 27.2 3 5 45 22:38 
2 30 24.4 1 3 65 21:56 
3 34 21.4 1 4 63 21:41 





Figure 5-1 Plasma cortisol and melatonin profiles. The mean of duplicates is shown - error bars have been omitted for 
clarity. Vertical dashed lines represent the timing of meals [08:00, 13:00, 19:00], and the evening snack [22:00]. The 
shaded area represents the sleep period (light levels <5 lux).  
Lunch was associated with an increase in cortisol secretion for participant 1 (closed circles) and 2 (open squares) but not 
participant 3 (stars), while the evening meal was associated with a large secretion episode for participant 2 but not 1 or 
3. For participant 1 and 3, the evening snack occurred at the nadir concentration of cortisol and was associated with a 
small cortisol secretion episode. The breakfast meal was associated with a small rise in cortisol in all participants.  
5.4.3 Metabolites recovered 
In plasma, 138 metabolites were recovered constituting 20 amino acids, 10 biogenic amines, 
12 acylcarnitines, 84 glycerophospholipids, and 14 sphingolipids. In microdialysate, 35 
metabolites were recovered constituting 20 amino acids, 9 biogenic amines, 5 acylcarnitines, 
and 2 glycerophospholpids. A summary of these recovered metabolites is provided in Table 
5-2 and a full list of all metabolites recovered is provided in Appendix L.  
Participant 1 2 3 
 Plasma IF Plasma IF Plasma IF 
Amino acids 20 20 20 18 20 1 
Biogenic amines 9 9 10 4 10 5 
Acylcarnitines 12 5 9 2 9 1 
Glycerophospholipids 83 1 84 1 84 1 
Sphingolipids 14 0 14 0 14 0 
TOTAL 138 35 137 26 137 8 
Table 5-2 Count of metabolites meeting criteria for inclusion in plasma and microdialysate (IF) of 3 healthy volunteers. 
No cause for the low recovery of metabolites in the interstitial fluid of participant 3 was identified. 































All metabolites detected in interstitial fluid were also detected in plasma, except for 
methionine sulfoxide, which was detected in microdialysate of participant 1 but below the 
limit of quantification in plasma. Only metabolites that were detected in both microdialysate 
and plasma were considered for further analysis.  
 Plasma [µmol/L] Microdialysate [µmol/L] 
 n Mean ± SEM Min Max n Mean ± SEM Min Max 
ALA 210 384.11 ± 6.02 183.00 686.41 148 191.27 ± 10.8 31.40 501.66 
ARG 213 114.69 ± 1.81 62.70 184.28 149 49.55 ± 3.13 8.29 121.22 
ASN 211 52.08 ± 0.64 33.42 78.68 149 24.99 ± 1.47 4.51 59.79 
CIT 212 41.13 ± 0.38 26.82 59.30 149 15.8 ± 0.9 3.23 34.52 
GLN 213 771.53 ± 6.95 535.50 1107.00 149 305.01 ± 14.67 92.20 654.04 
GLU 213 53.28 ± 1.32 16.50 108.00 73 26.15 ± 0.66 16.12 36.99 
GLY 213 261.99 ± 3.4 163.77 415.00 149 127.94 ± 6.6 33.50 288.54 
HIS 213 98.94 ± 0.93 66.69 132.00 149 41.34 ± 2.2 10.10 89.68 
ILE 213 83.25 ± 1.72 36.00 157.25 147 36.75 ± 2.67 0.40 104.38 
LEU 213 165.29 ± 3.19 78.90 296.59 149 76.12 ± 5.48 2.20 220.33 
LYS 213 242.17 ± 3.77 119.00 376.92 148 88.77 ± 4.88 16.00 194.25 
MET 213 29.1 ± 0.49 14.60 51.14 146 11.31 ± 0.82 0.19 33.08 
ORN 213 66.37 ± 0.78 41.01 101.00 226 20.75 ± 1.11 3.40 59.72 
PHE 213 68.74 ± 0.85 43.70 100.00 149 27.21 ± 1.62 4.31 62.25 
PRO 213 261.72 ± 3.77 132.24 405.00 149 117.54 ± 5.56 34.60 260.85 
SER 213 115.75 ± 1.25 76.64 163.92 149 58.28 ± 2.85 16.80 124.71 
THR 211 123.85 ± 1.47 78.50 187.31 149 61.3 ± 3.41 14.60 145.41 
TRP 139 66.59 ± 0.9 39.62 97.60 73 11.64 ± 0.34 6.99 17.52 
TYR 213 70.07 ± 1.04 38.70 113.00 149 30.4 ± 1.86 4.46 77.56 
VAL 213 260.44 ± 3.24 172.18 408.00 149 106.79 ± 5.66 24.50 254.90 
T4-OH-P 214 12.97 ± 0.25 6.32 25.60 147 5.61 ± 0.21 1.74 13.54 




 Plasma [µmol/L] Microdialysate [µmol/L] 
 n Mean ± SEM Min Max n Mean ± SEM Min Max 
C0 214 35.46 ± 0.38 17.15 49.90 225 16.53 ± 0.77 3.04 35.88 
C2 212 3.5 ± 0.04 2.19 6.47 225 1.25 ± 0.06 0.39 2.66 
Table 5-3 Mean and concentration range of metabolites detected in both plasma and microdialysate  samples (number of 
samples =n, concentration in µmol/L ± standard error of the mean). The full names of each metabolite are provided in 
the table in Appendix L.  
Table 5-3 shows the mean, standard error of the mean, and range of individual metabolites 
measured in both tissue types. There was no difference in the overall concentration of amino 
acids, trans-4-hydroxyproline (t4-OH-PRO), taurine, free carnitine (C0), or acetylcarnitine (C2) 
in the plasma of the three participants (ANOVA F(2, 67.51) = 0.124, p=0.884). 
Concentrations of metabolites in the microdialysate of participant 3 were very low with many 
below the limit of quantification. By comparison, concentrations were significantly higher in 
the microdialysate of participant 1 than 2 (U=88, p<0.001). The ratio of total metabolites 
measured in plasma compared with the same metabolites in microdialysate was 1.68:1 for 
participant 1, and 4.99:1 for participant 2. The ratios for individual metabolites are provided 




5.4.4 Assessment of preanalytical sample quality 
 
Figure 5-2 Ratios of the aminos acids glutamine/serine (GLN/SER) as markers of sample quality in plasma (solid lines) and 
microdialysate (dashed lines) in all 3 study participants. A plasma fasting ratio of GLN/SER below 4.71 (horizontal 
dashed line) was identified as marker of poor preanalytical sample quality by Anton et al. (2015). The microdialysis data 
for participant 3 is shown for illustrative purposes – for that participant, microdialysate GLN and SER did met criteria for 
inclusion due to very low concentrations in the samples. Meals are marked with vertical dashed lines; the main evening 
meal was at 19:00. The sleep period is indicated by the shaded area. 
A number of preanalytical factors influence sample viability in metabolomics studies203. Anton 
et al. (2015) found that a fasting serum ratio of glutamine/serine (GLN/SER) of less than 4.71 
was predictive of poor preanalytical sample quality281, and so those ratios were calculated 
and are shown in Figure 5-2.  
For participant 1 and 2, which were successful samplings in both microdialysis and plasma, 
and for participant 3 in plasma, no fasting values (defined as the sleep period until the 
breakfast meal) fell below the threshold of 4.71. Metabolite ratio changes in plasma and 
microdialysate of successful samplings were weakly but significantly correlated with each 
other. Ratios in both tissue types were influenced by feeding status with values of the ratio 




purposes since both glutamine and serine were below the limit of quantification and these 
metabolites were excluded from further analysis. 
5.4.5 Metabolite ratios  
Since the absolute concentration of metabolites in microdialysate were significantly different 
between participants, ratios of metabolites were calculated to determine if the proportionate 
recovery of metabolites was the same. The kidney plays an important role in the metabolism 
and interorgan exchange of amino acids282 and three pathways of amino acids metabolism 
were examined: conversion of citrulline to arginine283, phenylalanine to tyrosine284, and the 
exchange of glycine to serine285. Finally the ratio of free carnitine to acetylcarnitine was 
examined as a marker of fatty acid metabolism286.  
5.4.5.1 Citrulline-arginine metabolism  
 
Figure 5-3 Relationship of citrulline (CIT) with arginine (ARG) expressed as ratios in plasma (solid lines) and 
microdialysate (dashed lines) in n=2 participants. Meals are marked with vertical dashed lines; the main evening meal 
was at 19:00. The sleep period is marked as the grey shaded area. For participant 1 (left) the mean ratio ± standard 
deviation was 0.33±0.05 in plasma and 0.30±0.04 in microdialysate. For participant 2, the mean ratio was 0.47±0.09 
in plasma and 0.37±0.1 in microdialysate. CIT:ARG ratios in both participants were significantly correlated (p<0.0001). 
Figure 5-3 shows the ratio of citrulline to arginine (CIT/ARG) in the plasma and 
microdialysate samples of participant 1 and 2. The ratios are strongly and significantly 
correlated. Both the amplitude and overall mean of the ratio is higher for participant 2 than 1. 




5.4.5.2 Phenylalanine-tyrosine metabolism 
 
Figure 5-4 Relationship of phenylalanine (PHE) with tyrosine (TYR) expressed as ratios in plasma (solid lines) and 
microdialysate (dashed lines) in n=2 participants. Meals are marked with vertical dashed lines; the main evening meal 
was at 19:00. The sleep period is marked as the grey shaded area. For participant 1 (left) the mean ratio ± standard 
deviation was 0.87±0.08 in plasma and 0.92±0.08 in microdialysate. For participant 2, the mean ratio was 0.91±0.08 
in plasma and 0.90±0.09 in microdialysate. PHE:TYR ratios in both participants were significantly correlated (p<0.001). 
Figure 5-4 shows the dynamic ratio of phenylalanine with tyrosine (PHE/TYR) in plasma and 
microdialysate. While ratios were highly correlated and similar in magnitude, the direction of 
ratio change within the sampling periods was different. For participant 1, the ratio increased 
after the lunch meal [13:00], while for participant 2 the opposite occurred, with a sharp fall in 
the ratio. For participant 1, there was a steady decrease in the ratio overnight, beginning to 
rise after breakfast [08:00] while the opposite occurs in participant 2, with a steady increase 
in the ratio overnight. 
5.4.5.3 Glycine-serine metabolism 
Figure 5-5 shows the dynamic ratios of glycine with serine (GLY/SER) in plasma and 
microdialysate. Ratios in plasma and microdialysate were significantly correlated within each 






Figure 5-5 Relationship of glycine (GLY) with serine (SER) expressed as ratios in plasma (solid lines) and microdialysate 
(dashed lines) in n=2 participants. Meals are marked with vertical dashed lines; the main evening meal was at 19:00. The 
sleep period is marked as the grey shaded area. For participant 1 (left) the mean ratio ± standard deviation was 
1.96±0.15 in plasma and 2.23±0.14 in microdialysate. For participant 2, the mean ratio was 2.09±0.21 in plasma and 
2.09±0.26 in microdialysate. GLY:SER ratios in both participants were significantly correlated (p<0.001). 
5.4.5.4 Acetylcarnitine-free carnitine metabolism 
 
Figure 5-6 Relationship of acetylcarnitine (C2) with free carnitine (C0) expressed as ratios in plasma (solid lines) and 
microdialysate (dashed lines) in n=2 participants. Meals are marked with vertical dashed lines; the main evening meal 
was at 19:00. The sleep period is marked as the grey shaded area. Mean ratios ± standard deviation for participant 1 
(left) were similar in plasma (0.1±0.02) and microdialysate (0.07±0.01). For participant 2 (right), the mean ratios were 
also similar in plasma (0.1±0.03) and microdialysate (0.08±0.03), and significantly correlated (p<0.0001). 
Figure 5-6 shows differences in the ratios of acetylcarnitine (C2) to free carnitine (C0) in 
plasma and microdialysate of participant 1 and 2. Ratios are similar in magnitude but poorly 
correlated for participant 1, while ratios are strongly correlated and similar in magnitude for 





5.4.6 Assessment of rhythmicity  
Table 5-4 Metabolites with a daily rhythm or linear trend in plasma and microdialysate samples. Bold clock times 
indicate daily rhythmic metabolites (significant fit to cosine curve at p<0.05), asterisks (*) signify metabolites significant 
for a linear trend (p<0.05), and dashes (-) not significant for either model. The full names of each metabolite are given in 
Appendix L-V. 
Cosinor analysis identified 21 metabolites with a significant daily rhythm in the plasma of at 
least one participant (Table 5-4), and 5 metabolites rhythmic in all 3 participants (arginine, 
lysine, tyrosine, C2, and t4-OH-PRO). In microdialysate, all metabolites were rhythmic in at 
least one participant, and 20/24 were rhythmic in at least 2 participants. The predicted 
acrophase of all daily rhythmic metabolites occurred in the evening or biological night, with 
most occurring after the time of dim light melatonin onset. The acrophase was later in 




Microdialysate acrophase  
 
1 2 3 1 2 3 
ALA * - * 04:48 -  
ARG 02:34 22:51 23:34 05:20 00:49  
ASN 01:06 20:08 * 04:59 22:31  
CIT 00:05 21:42 - 04:22 23:25  
GLN * - * 05:43 02:21  
GLU 21:38 - - 04:00 
 
 
GLY 03:42 - * 05:33 02:15  
HIS 02:23 - - 05:29 01:28  
ILE - - - 04:31 23:44  
LEU 02:06 - 01:57 05:40 -  
LYS 02:16 21:46 01:09 05:30 23:49  
MET 02:18 - 00:09 05:50 22:32  
ORN - 20:40 - 05:17 23:05 19:47 
PHE - - 22:40 05:20 00:18  
PRO 19:50 17:24 - 04:34 19:01  
SER 02:53 - - 05:50 00:39  
THR 03:30 - 02:40 05:20 01:14  
TRP 01:53 - 23:38 05:17 
 
 
TYR 04:21 18:53 00:38 05:43 21:44  
VAL - 21:13 02:11 05:05 00:23  
C0 * - 05:19 05:36 06:14  
C2 04:33 22:21 05:04 05:56 02:49 06:24 
T4-OH-P 02:27 22:26 02:16 03:19 23:38 19:00 




Several plasma metabolites identified as non-rhythmic by cosinor fit were significant for a 
linear trend (non-zero slope) in at least one participant. These were alanine, glutamine, 
glycine, free carnitine (C0), and taurine. 
5.4.7 Correlation of plasma metabolites with microdialysate samples 
 
1 2 3 
 
rs Lag (min) rs Lag (min) rs Lag (min) 
ALA 0.656 30 0.831 10   
ARG 0.612 40 0.798 10   
ASN 0.375 30 0.759 10   
CIT 0.162 - 0.560 50   
GLN 0.369 90 0.304 0   
GLU -0.121 - - -   
GLY 0.651 30 0.556 10   
HIS 0.404 40 0.505 10   
ILE 0.557 40 0.797 10   
LEU 0.496 30 0.952 10   
LYS 0.458 0 0.696 10   
MET 0.571 20 0.721 10   
ORN 0.487 0 0.767 10 0.296 50 
PHE 0.308 10 0.613 20   
PRO 0.348 10 0.850 10   
SER 0.433 20 0.660 20   
THR 0.573 30 0.758 10   
TRP 0.485 10 - -   
TYR 0.650 30 0.649 20   
VAL 0.320 40 0.671 10   
C0 0.211 70 0.226 10   
C2 0.539 10 0.558 20 -0.449. 120 
T4-OH-P 0.890 0 0.814 0 0.808 50 
TAU 0.096 - 0.182 -80 0.325 20 
Table 5-5 Spearman rank cross-correlation of plasma with microdialysate profiles of metabolites. Bold correlation 
coefficients (rs) are significant to p <0.0001, and bold italics p<0.05. The lag (in minutes) shows the time shift that would 
result in the highest correlation between each profile. Lags with positive numbers indicate that plasma leads 
microdialysate.  
Table 5-5 shows the Spearman correlation coefficients of metabolite profiles in plasma with 
microdialysate, and the time lag (in minutes) of peak correlation between plasma and 




(T4-OH-PRO, Figure 5-7) while the correlation of taurine was weak in all 3 participants 
(Figure 5-8). 
Excluding taurine, metabolite profiles in microdialysate were delayed from plasma by mean 
32.3 minutes (range 0-130) for participant 1, and 12.9 minutes (range 0-50) for participant 2. 
 
Figure 5-7 Profiles and Spearman correlation of trans-4-hydroxyproline in plasma (solid lines) and microdialysate (dashed 
lines). Results are plotted as standard scores (Z-score = number of standard deviations from sample mean). Vertical 
dashed lines indicate timing of meals and snack, the shaded area is the sleep period. The meal provided at 19:00 





Figure 5-8 Profiles and Spearman correlation of taurine  in plasma (solid lines) and microdialysate (dashed lines). Results 
are plotted as standard scores (Z-score = number of standard deviations from sample mean). Vertical dashed lines 




5.4.8 Amino acid profiles 
5.4.8.1 Essential amino acids 
 
Figure 5-9 Profiles and Spearman correlation of dietary essential amino acids histidine (HIS), lysine (LYS) and methionine 
(MET) in n=2 participants (left, right). Plasma (solid lines) and microdialysate (dashed lines) results are plotted as standard 
scores (Z-score = number of standard deviations from sample mean). Vertical dashed lines indicate timing of meals and 
snack, the shaded area is the sleep period. Food consumption was associated with rapid changes in both plasma and 
microdialysate 
Profiles of the dietary essential amino acids histidine (HIS), lysine (LYS) and methionine (MET) 
are shown in Figure 5-9; phenylalanine (PHE), threonine (THR) and tryptophan (TRP) are 
shown in Figure 5-10. All essential amino acids rose after food and fell during the overnight 
fast. There was significant correlation of all essential amino acids (individual correlation 





Figure 5-10 Profiles and Spearman correlation of essential amino acids phenylalanine (PHE), threonine (THR) and 
tryptophan (TRP). Trypotophan was not recovered in the microdialysate of participant 2 or 3; plasma profiles for these 
two participants are shown instead. Plasma (solid lines) and microdialysate (dashed lines) results are plotted as standard 
scores (Z-score = number of standard deviations from sample mean). Vertical dashed lines indicate timing of meals and 
snack; the shaded area is the sleep period. 
5.4.8.2 Branched chain amino acids 
Profiles of the nutritionally essential branched chain amino acids (BCAAs) leucine, isoleucine 
and valine are shown in Figure 5-11. There was significant correlation of the profiles in the 
plasma and microdialysate (coefficients and p-values printed on each Figure). Concentrations 






Figure 5-11 Profiles and Spearman correlation of the branched chain amino acids  leucine (LEU), isoleucine (ILE), and 
valine (VAL) in n=2 participants (left, right). Plasma (solid lines) and microdialysate (dashed lines) results are plotted as 
standard scores (Z-score = number of standard deviations from sample mean). Vertical dashed lines indicate timing of 
meals and snack, the shaded area is the sleep period. 
5.4.8.3 Non-essential amino acids  
The profile of citrulline (CIT) is shown in Figure 5-12. The profiles of arginine (ARG), glycine 
(GLY), proline (PRO), and tyrosine (TYR) and glutamine (GLN) are shown in Figure 5-13, and 
the profiles of alanine (ALA), asparagine (ASN), glutamate (GLU), serine (SER) and ornithine 
(ORN) in Figure 5-14. Except for glutamate, all metabolite profiles were significantly 






Figure 5-12 Profiles and Spearman correlation of citrulline  (CIT) in plasma (solid lines) and microdialysate (dashed lines). 
Values are plotted as standard scores (Z-score = number of standard deviations from the sample mean). Vertical lines 
indicate the timing of meals and snack, the shaded area indicates the sleep period. Compared with other amino acids, 
meals appear to have little effect on the concentrations of citrulline in either plasma or microdialysis 
In participant 1, glutamine, arginine and glycine appeared to accumulate during waking hours, 
before plateauing at night. Concentrations of most of the remaining amino acids in participant 
1 and 2 were strongly influenced by meals and fell or plateaued during the night/sleep 





Figure 5-13 Profiles and Spearman correlation of non-essential amino acids arginine (ARG), glycine (GLY), proline (PRO), 





Figure 5-14 Profiles and Spearman correlation of non-essential amino acids alanine (ALA), asparagine (ASN), glutamate 




5.4.9 Carnitine and acetylcarnitine 
 
Figure 5-15 Profiles and Spearman correlation of acetylcarnitine (C2) in plasma (solid lines) and microdialysate (dashed 
lines) of participant 1 and 2. Values are plotted as standard scores (Z-score = number of standard deviations from sample 
mean). Vertical lines indicate the timing of meals and snack, the shaded area indicates the sleep period 
 
Figure 5-16 Profiles and Spearman correlation of free carnitine (C0) in plasma (solid lines) and microdialysate (dashed 
lines) of participant 1 and 2. Values are plotted as standard scores (Z-score = number of standard deviations from sample 
mean). Vertical lines indicate the timing of meals and snack, the shaded area indicates the sleep period 
Profiles of the short chain fatty acids free carnitine (C0) and acetylcarnitine (C2) are shown in 
Figure 5-15 and Figure 5-16. There was better correlation of acetylcarnitine than free 
carnitine. There is little apparent similarity in the profile shape between participants. For 
participant 1 there appears to be an accumulation of free carnitine in microdialysate fluid, and 
accumulation of acetylcarnitine in both plasma and microdialysate during waking hours. 
5.5 Discussion 
In this first-of-its-kind pilot study, profiles of daily changes in metabolites were measured in 




and compared with plasma, using a targeted metabolomics approach. Samples were obtained 
from 3 healthy volunteers every 20 minutes for 25 consecutive hours during an in-laboratory 
routine, with standardised meals, minimal physical activity, and a consistent period of 
darkness and sleep. The principle aims of the study were met, with recovery of multiple 
metabolites in both plasma and microdialysate, and the hypotheses confirmed – the 
metabolites with best recovery were the amino acids, which are highly water soluble205.  
The results are significant in two respects. Firstly, this study demonstrates that metabolites, 
especially amino acids, can be recovered from subcutaneous interstitial fluid using an 
automated, portable sampling technique, generating daily profiles with significant and strong 
correlation with venous plasma. Secondly, sampling at high frequency has yielded extremely 
detailed information about daily changes in metabolite concentrations, particularly meals, in 
controlled normal conditions.  
5.5.1 Types of metabolites recovered 
In plasma, 138 metabolites were measured including amino acids, biogenic amines, 
acetylcarnitines, glycerophospholipids, and sphingolipids, similar to previous reports using the 
same method274. In microdialysate, fewer metabolites were recovered, being principally 
amino acids. A simple explanation for this difference with plasma could be that non-amino 
acid metabolites only exist in very low concentrations in abdominal subcutaneous tissue. In 
vitro work, described in Chapter 3, proved that acylcarnitines, glycerophospholipids and 
sphingolipids infused as a reference solution were recoverable from the U-RHYTHM device, 
albeit with altered concentrations. This suggests that adsorption must not be the primary 
reason for failure to recover these compounds in vivo. Amino acids are water soluble and 
circulate predominantly in free form, with only 5-10% bound to plasma proteins120 and as a 
tiny proportion complexed with metals287. By contrast, most fatty acids circulate in relatively 
low concentrations and bound to albumin288, and free fatty acids may not exist in significant 




exist predominantly in a free form278, were the only acetylcarnitines commonly detected in 
the microdialysate of all 3 participants. This finding is consistent with Hack et al. (2006) who 
reported the microdialysis measurement of free carnitine, acetylcarnitine, and a third short-
chain acylcartinine, hydroxybutyrylcarnitine, in a small paediatric trial of ketogenic diet for 
intractable epilepsy278. The authors do not specify if other acylcarnitines were detected in the 
samples, however.  
5.5.2 Differences in metabolite concentration between plasma and microdialysate 
Concentrations of plasma amino acids were similar between participants, and within the 
fasting range of amino acids previously reported in a cohort of 100 healthy volunteers289. 
Where recovered, microdialysate dynamic profiles were overall strongly and significantly 
correlated with plasma. However, there was a marked difference between the absolute 
concentration of metabolites measured in the subcutaneous interstitial fluid and the 
concentrations in plasma. The mean metabolite concentration in participant 1 was two thirds 
of plasma, but for participant 2 it was approximately 20%. To investigate further, ratios of 
amino acids were calculated and overall found to be consistent between plasma and 
microdialysis. Interindividual variation was evident in the profiles of the short chain fatty 
acids acetylcarnitine and carnitine; nevertheless, the magnitude of the ratio in plasma and 
tissue was almost identical in both participants, and within a healthy normal range as 
determined in morning venous plasma drawn from a cohort of 41 healthy adults290. This 
suggests that while the absolute concentrations of metabolites recovered were different 
between tissue and plasma, the proportion of metabolites that crossed the membrane and 
entered the microdialysate was the same between participants. Therefore, microdialysis 
measurements can be used as a valid method to compare between participants. 
The reasons for differences in microdialysate metabolite concentrations between participants 
will now be speculated on. Firstly, recovery of tissue amino acids at levels close to 100% of 




flow allows the perfusate to approach equilibrium with the surround tissue and improves 
relative recovery, but with the trade-off of reducing sample size, and therefore sample 
resolution.  
Only a few studies have previously attempted measurement of amino acids in human tissue 
using microdialysis – and none in healthy adult abdominal subcutaneous fluid. Perfusing at 
0.3µL/min, Rolinski et al. (2001) examined amino concentrations in thigh subcutaneous tissue 
of hospitalised neonates finding that the mean concentrations of taurine, serine, alanine, 
aspartate, glutamate, and ornithine were 85% of those in plasma, while the mean 
concentrations of valine, isoleucine, leucine, methionine, phenylalanine, tyrosine and arginine 
exceeded blood concentrations (115%)120. Sampling in skeletal muscle also at 0.3µL/min, 
McCormack et al. (2017) demonstrated dynamic changes in muscle amino acids in response 
to whey protein ingestion with post-prandial essential amino acids approaching 80% of 
plasma levels275. Therefore, in the current studies a slower perfusion rate may have increased 
the relative recovery of metabolites and potentially reduced differences between 
participants. In the present studies a flow rate of 1.0µL/min was used which in the end was a 
trade-off between achieving a reasonable relative recovery, guaranteeing an adequate 
volume of fluid for analysis, and the ability to maintain high frequency sampling.  
The trauma of probe insertion may also influence local tissue metabolite concentrations. Both 
Gutierrez et al. (1999) and McCormack et al. (2017) found that interstitial concentrations of 
multiple amino acids , especially taurine, glutamine and glutamate, significantly exceeded 
blood concentrations immediately after insertion of a microdialysis probe into skeletal 
muscle135,275. Insertion of the linear probe into abdominal subcutaneous tissue (as in the 
current study) is significantly less traumatic than insertion of a probe into skeletal muscle but 
it is interesting to note that taurine was among the metabolites with the weakest correlation, 




Thirdly, it may not be valid to generalise recovery of amino acids from muscle to results 
obtained from measurements in abdominal subcutaneous tissue. Interindividual variability in 
the diffusion of metabolites into abdominal subcutaneous fluid may be higher than other 
issues for example. There is no data currently available comparing amino acid concentrations 
between subcutaneous and other tissue types, but for the metabolism of glucose and lactate 
are different in muscle compared with subcutaneous adipose156, and comparison of paired 
venous and arterial samples taken across forearm muscles of healthy volunteers have also 
revealed small but significant differences in the concentrations of several metabolites 
including the amino acids291. Further studies would be needed to characterise if other factors 
such as body weight or body composition (which was not measured in this study) influence 
recovery. 
Following on from this, a potentially significant contribution to the differences in recovery 
between participants is methodological variation. In this study, microdialysis catheters were 
placed in a similar, but not identical areas of the abdomen, since catheters were placed 
without using ultrasound to confirm the depth of the probe. In a previous study of healthy 
adults, variability in the recovery of glucose and urea between two identical microdialysis 
catheters placed adjacent to each other in the same area of skin was close to 20%156. In a 
study of 65 women who completed two microdialysis sessions in skeletal muscle of the same 
arm, several months apart, there was poor intraindividual reproducibility of the relative 
recovery of small metabolites (lactate and glucose)134. Complicating that study was the use of 
high flow rate (5µl/min) – which can result in net removal of, rather than equilibrium with, 
substances in the interstitium, leading to inaccurate results and accentuating differences156. 
Quality control differences between probes can also affect performance. Sun et al. (2007) 
found inter-batch differences in the performance of microdialysis probes197 leading to 




In summary, there was good correlation of dynamic changes in metabolites between plasma 
and interstitial fluid. While the mean concentration of plasma metabolites was similar 
between participants, there was marked but proportionate variation in the recovered 
concentration of metabolites in the microdialysis fluid. Ratios of metabolites in plasma and 
microdialysate were consistent, providing confidence that dynamic changes and standardised 
profiles can be compared between individuals. Differences in absolute tissue metabolite 
concentration are likely to be due to methodological factors including the perfusion rate, 
methodological variation, the performance of the microdialysis probe, and potentially 
individual specific metabolism. Further work is needed to determine the relative contribution 
of each factor. 
5.5.3 Metabolite rhythmicity 
The current study was not done under either desynchronised or constant routine conditions, 
and is therefore was not able to unmask either endogenous circadian rhythmicity or rhythms 
masked by timing and content of meals292. Ang et al. (2012) conducted a study in 8 healthy 
males under similar physiological conditions, but provided hourly nutritional drinks during 
wakefulness rather than scheduled meals272. The authors found daily rhythmicity of 34 
metabolites, 6 of which were amino acids (methionine, tyrosine, proline, phenylalanine, lysine 
and leucine) and 1 acylcarnitine (acetylcarnitine, C2)272, all also rhythmic in the plasma and 
microdialysate of at least 1, but not all 3 participants in the current study. Since many other 
amino acids also showed a daily rhythm in the current study, the provision of food as 3 daily 
meals appears to have been a very strong determining factor. This is consistent with Skene et 
al. (2018) who found that the rhythmicity of the vast majority of metabolites is determined by 
externally imposed cues (food, sleep, activity, light exposure) rather than being under 
endogenous circadian control114. 
Despite conditions of identical food, activity, and lighting, interindividual variability in daily 




findings of Grant et al (2019) who in a study of 13 male and females, with otherwise similar 
demographics to the current study, found both linear and daily changes in polar metabolites 
(which include amino acids and biogenic amines) during a 40-hour period of constant 
waking115. Not only were no metabolites consistently rhythmic across all participants, but the 
timing of acrophases also showed wide variation115.  
5.5.4 Dynamic profiles as potential biomarkers of disease 
Amino acids were the most successfully recovered metabolites in the microdialysate and 
correlated well with sample-to-sample changes in plasma. Amino acids have been implicated 
as biomarkers of a variety of health conditions including osteoarthritis268, inflammatory bowel 
disease270 and Alzheimer’s disease293 and changes in amino acids have also been identified in 
number of metabolic health conditions including obesity168, insulin resistance294, and type 2 
diabetes295,296. The amino acid ratios tested in the current study - citrulline:arginine, 
phenylalanine:tyrosine, and glycine:serine - have been identified as markers of small intestine 
function following bowel resection297, as a screening marker for phenylketonuria298, and as a 
marker of cancer metabolism285 respectively. The additional dynamic information encoded in 
high resolution profiles of metabolites could be used to both improve existing biomarkers and 
lead to the discovery of new indicators that take into account intrinsic variation, the time of 
day, and the influences of food and sleep – none of which can be properly appreciated with 
single time point measurements.  
5.5.5 Limitations  
This study was designed as a proof-of-concept to demonstrate a possible application of U-
RHYTHM microdialysis technology. The main limitation therefore is that the population 
sampled was only 3 participants, all of whom were healthy males, so observations in this data 
set are not necessarily generalisable. Quantification of metabolites in the microdialysate was 
inconsistent between the 3 participants with large differences in both the number of 




which interindividual and/or methodological variation contributed to these differences 
remains unclear and is of concern. A barrier to further studies at the current time is the 
extremely high cost of metabolomic sample analysis, but clearly additional sample sets are 
needed to answer these questions and to establish a broad range of healthy normal variation. 
Secondly, the metabolites recovered in microdialysate were predominantly amino acids and 
therefore a significantly more limited ‘view’ of the metabolome than is currently possible with 
a targeted approach in venous samples. Refinement of the technique to optimise and enable 
recovery of other types of metabolites would make the method more attractive. Since the 
broader composition of the subcutaneous interstitial fluid metabolome remains essentially 
unknown, characterisation using an untargeted approach could be very useful as 
complementary method267 to potentially identify new metabolites and tissue-specific 
biomarkers. 
5.6 Conclusions 
This pilot study demonstrates that dynamic profiling of metabolites in subcutaneous tissue is 
possible and provides evidence that metabolite changes in abdominal subcutaneous 
microdialysate reflect changes occurring in venous plasma. Multiple metabolites, 
predominantly amino acids, were found to be dynamic, closely synchronised, and highly 
correlated between subcutaneous interstitial fluid and circulating venous plasma. Participants 
were healthy males provided with identical food, lighting, and environmental conditions. 
Despite this, there were differences in the tissue concentrations and dynamics of metabolites 
obtained. Metabolomic signatures appear to be highly individual. 
Mistimed food, sleep and activity in relation to the circadian clock is increasingly linked with 
long-term adverse metabolic health outcomes17,84. The results from this study provide the 
first evidence that 24-hour high frequency metabolomics could be used not only for 
establishing healthy normal variation but as a tool for identifying novel biomarkers for 




6 Sampling around the clock: U-RHYTHM measurement of 
melatonin and glucocorticoids combined with wearable 
technology 
6.1 Introduction 
Humans have evolved to live in a 24-hour light:dark cycle by adapting many aspects of their 
physiology to daily periods of rest and activity. Over time, these periods have become 
associated with internal hormonal, biochemical and behavioural processes that oscillate with 
daily rhythms. In this chapter I will describe how I have used the U-RHYTHM microdialysis 
sampling system in combination with digital wearable technologies to investigate how 
measures of internal daily timing (circadian hormones) could be related to peripheral 
measures of rhythmic physiology and behaviour (glucose, temperature, sleep patterns, 
physical activity, light exposure) in ‘real world’, free living conditions. As part of the 
investigation, I will describe for the first time, detection of full daily melatonin profiles by 
using U-RHYTHM ambulatory microdialysis technology, simultaneously with measurements 
of cortisol and cortisone. 
As described in the introduction to this thesis, coordination of circadian rhythms is 
maintained by a central pacemaker in the suprachiasmatic nucleus of the hypothalamus, but 
clock mechanisms are present in all peripheral tissues299. In humans, essentially all aspects of 
physiology are rhythmic, including the secretion of hormones, body temperature, glucose, 
activity and sleep300,301. Although circadian rhythms are endogenously generated, the external 
environment may profoundly influence them, particularly the timing of the light-dark cycle302 
and the timing of food75.  
A key marker of the endogenous circadian phase is the profile of the hormone melatonin. 




signals from the suprachiasmatic nucleus master clock304 and signals the onset of the 
biological night. In dim light conditions, melatonin begins to rise in the evening, in the hours 
before habitual sleep time, but with considerable interindividual variation305. During daylight 
hours, melatonin falls to very low levels. Sleep is closely associated with the rhythm of 
melatonin since sleep timing itself is under strong circadian control32. Disruption of 
melatonin, especially suppression by artificial light in the evening103, has been associated with 
adverse consequences including disturbed sleep306,307, and potentially toxic influences on 
energy308 and glucose85 metabolism. 
Measurement of circulating plasma melatonin remains the gold standard for assessment of 
endogenous circadian phase in humans94. Full profiling of melatonin requires admission to a 
specialist research unit and drawing of multiple blood tests, since until now, ambulatory 
sample collection cannot be obtained during sleep. The onset of melatonin in ambulatory 
settings is usually estimated by obtaining a partial profile in saliva during the hours leading up 
to habitual bed time94, which is less invasive the blood sampling, but requires active 
participation from the participant (physical collection of samples, altering light and body 
position if collecting in dim light conditions)309.  
Complementary, and in contrast to biological sampling, there has recently been considerable 
interest in the use of passively collected physiological information, used to estimate daily 
circadian and other rhythms in behaviour and physiology. Wearable devices can monitor daily 
rhythms of motor activity310 and this information can be used to predict sleep-wake patterns 
in the absence of invasive laboratory assessment207. While the rhythm of core body 
temperature must be assessed internally31, peripheral skin temperature rhythms171 may be 
useful as a less invasive alternative, at least in normally entrained individuals. In mammals, 
glucose has a daily rhythm under circadian regulation311 and with the advent of sophisticated 
wearable monitoring systems312, daily patterns of glucose can be examined in detail. Coupled 




an opportunity to potentially characterise the effect of the real world on a multitude of 
rhythmic processes314 outside of artificial laboratory settings. Since no two people are the 
same, understanding individual-level effects is a key goal in the development of more 
personalised approach to medicine and therapeutics315.  
However, only a few studies have attempted to measure rhythmic processes from multiple 
systems in real world settings. These studies have needed to rely on limited time point 
sampling and semi-invasive procedures such as rectal swabs and internal temperature 
measurements316,317. Most significantly, to date, no field studies have been able to combine 
biological measures of circadian time (melatonin and cortisol hormones) with rhythmic data 
from wearable devices, without limiting the sampling of hormones to a few limited time 
points.  
The goal of this current study was to test an ambitious protocol in which measurement of 
circadian hormones would be obtained at high resolution, over more than one day, without 
the need for participant intervention. Simultaneously, passive measurements of glucose318, 
skin temperature171, activity319, and light102 would be gathered using wearable sampling 
devices allowing observation of the multiple daily rhythmic processes during normal life. 
U-RHYTHM microdialysis technology has already been successfully used to measure dynamic 
tissue glucocorticoid patterns over multiple days186. Melatonin had not previously been 
investigated with the technique, but since it is a small molecular weight compound320, readily 
detected in saliva321, circulating in picomolar concentrations35, and with a water solubility of 
0.14g/L205 it seemed a good candidate for recovery by microdialysis. Further, melatonin 
containing solutions are stable for at least 48 hours in aqueous solutions even when stored at 
37°C, and across a range of pH322. Pilot data from a healthy adult male volunteer in dim light 
conditions demonstrated that melatonin was detectable in low picomolar concentrations in 
tissue microdialysis fluid, with concentrations correlating well with simultaneous 




6.2 Aims and hypotheses 
1. To demonstrate the ability to simultaneously measure melatonin, cortisol and cortisone in 
the same sample, over multiple days, using novel ambulatory microdialysis sampling 
technology. 
2. To demonstrate temporary suppression of melatonin levels by short-term bright light 
exposure given 1 hour before habitual bedtime. 
3. To determine the feasibility of measuring multiple physiological outputs using wearable 
devices in real-world settings. 
It was hypothesised that: 
1. In non-shift working, free living healthy volunteers, cortisol and melatonin onset and 
offset would be associated with the onset and offset of sleep. 
2. Melatonin secretion would be disrupted by the deliberate administration of bright light 
during the hour before bed. 
3. Daily rhythms in glucose, skin temperature, activity, and light exposure passively obtained 
from wearable technology could be visualised and mapped in relation to hormone 
rhythms, as a framework for further study into the relationships between rhythmic daily 
processes. 
6.3 Methods 
6.3.1 Participants  
Healthy non-smoking volunteers aged 18-38 (n=11) were invited to participate following 
local ethics committee review (Health Sciences Faculty Research Ethics Committee, 
University of Bristol, UK). Exclusion criteria were: body mass index (BMI) less than 18.0 or 
greater than 25.0kg.m2, regular use of prescription medication other than hormonal 
contraception, regular use of over-the-counter supplements or vitamins, active medical 




>5, Epworth Sleepiness Score (ESS) >9), and extreme chronotype (Horne-Östberg 
Morningness-Eveningness Questionnaire (MEQ) <30 or >70279). 
6.3.2 Study routine 
 
Figure 6-1 Study schema. Following a 7-day baseline period (day 0-6), participants completed two 48-hour continuous 
microdialysis sampling sessions, 1 week apart. On either night 1 OR night 2 of each cycle, participants were exposed to 
45 minutes of bright light, 1 hour prior to habitual bedtime. Sleep and activity monitoring continued throughout the 
study and consisted of actigraphy, continuous peripheral skin temperature monitoring, and self-reported sleep and 
activity diaries. Interstitial continuous glucose monitoring (CGM) was commenced on day 1 of the first microdialysis 
sampling session (day 7 on the timeline) and continued throughout the remainder of the study. 
Prior to sampling, participants were asked to maintain a consistent sleep/wake schedule for 7 
nights with sleep diaries, daily activity, and light exposure monitoring for confirmation. 
Ambient light exposure (measuring range 0-64000 lux) and activity (measured as triaxial 
motion counts) were recorded in 30 second epochs (MotionWatch 8, CamNTech Ltd, 
Fenstanton, UK, non-dominant wrist). Peripheral skin temperature was measured in 1-minute 
epochs using a consumer-grade sleep tracking device contained in a finger ring, worn on the 
non-dominant hand (Oura Health Ltd., Oulu, Finland, see General Methods for details and 
Appendix O for validation). Participants continued to wear the devices until the end of the 
microdialysis sampling protocol. Participants abstained from alcohol, vigorous exercise, all 
medications, and bright light in the evenings/night for 72 hours before microdialysis sampling 
commenced.  
6.3.3 Microdialysis sampling 
Each participant completed two sampling periods, with each sampling period lasting 2 
consecutive full days. Both sampling periods occurred on weekdays (commencing Monday-




On the first day of each sampling period, participants provided a urine sample to exclude 
illicit substance use (SureScreen Diagnostics, Derby, UK) and in females, pregnancy (VWR 
International Ltd, Lutterworth, UK). A 20kDa linear microdialysis probe was placed in the 
right periumbilical area and then connected to the U-RHYTHM sampler as described in 
Chapter 3. For comparison of hormones in saliva and microdialysate, participants were 
provided with sets of Salivettes® and instructed to collect these samples beginning 3 hours 
before habitual bedtime (at hourly frequency for 2 samples and every 20 minutes until 
habitual bedtime).  
During each sampling period, participants returned after approximately 27 hours for a check 
of wearable devices and replacement of the microdialysis infusion fluid and spool cassette, 
allowing sampling to continue for a second consecutive day.  
6.3.4 Glucose monitoring and meals 
On day 1 of the first sampling period, a continuous glucose monitor (CGM) was placed on the 
upper arm of the non -dominant side, recording interstitial glucose levels every 15 minutes 
until the end of the study (FreeStyle Libre Flash, Abbott Laboratories, Maidenhead, UK). 
During the microdialysis sampling periods, participants were asked to record all food and 
drink (except water) including portion size, using a food diary. Participants were free to 
choose the type and timing of meals. Tea, coffee, and other non-alcoholic drinks were 
permitted. 
6.3.5 Evening bright light exposure 
Participants received a 45-minute period of bright light within 1 hour of habitual bedtime 
randomised to either night 1 or night 2 of each sampling period. This was delivered using a 
head-mounted visor containing light-emitting diodes (LEDs) designed to reflect blue-
spectrum light off a holographic surface onto the retina323 (Luminette, Lucimed, Villers-Le-




laboratory testing by the author found that the mean brightness was 779 lux (SD ± 157), with 
measured lux highly dependent on the correct position of the visor (Appendix P). The correct 
position of the visor was demonstrated to every participant before use, and a pre-
programmed timer was provided to maximise compliance. 
6.3.6 Sample processing  
Microdialysis and saliva samples were retrieved and processed as described in the General 
Methods chapter. As the sampling resolution was 20 minutes, 72 samples were produced per 
24 hours. All samples were retrieved from the U-RHYTHM spool cassette.  
6.3.7 Hormone measurements and calculations 
Measurement of hormones in the microdialysate was performed using high-performance 
liquid chromatography mass-spectrometry (LC-MS) as described in Chapter 2. In several 
participants, melatonin was detected below the expected limit of quantification (LOQ) in 
some or most samples. In these cases, a limit of detection (LOD) threshold was used (where 
the LOD was approximately 1/3 of the LOQ).  
Non-dim light melatonin onset and melatonin offset for each sampling night were calculated 
using the 25% threshold method as described by Sletten et al. (2009)280. Briefly, the 25th 
centile of the melatonin range was determined by adding the value of the limit of 
quantification or detection to 25% of the mean of the 3 highest melatonin measurements in 
the profile. Onset and offset times were determined by linear interpolation from the nearest 
measured values in the profile. The melatonin period was calculated as the time in hours and 
minutes between the melatonin onset and the melatonin offset. The timing and magnitude of 
the pre-waking cortisol surge was calculated for each sampling day, and the cortisol onset 




6.3.8 Wearable data processing 
Light and activity data was downloaded from the MotionWatch using MotionWare 1.2.28-
1.2.47 (Cam- Ntech, Cambridge, UK). Data from the rings was transferred via Bluetooth 
technology using Apple iPad software provided by the manufacturer (Oura, Oura Health Ltd., 
Oulu, Finland). Time-stamped temperature and other data were downloaded in comma 
separated value (CSV) format from a cloud-based data service provided by Oura. Glucose 
data were downloaded using software provided by the vendor (FreeStyle Libre Glucose Data 
Management Software, v1.0, Abbott Diabetes Care Ltd, Oxon, UK) and extracted as time-
stamped CSV files. 
6.3.9 Statistics and visualisations 
Summary statistics were computed in Stata 16.1 (StataCorp LLC, Texas, USA). Mean 
differences were calculated using 2-tailed t-tests with Welch’s correction for unequal 
variance (significance level p<0.05). Tests for daily rhythmicity (cosine fit) were performed on 
standardised (Z-scored) mean profiles for each participant, using code provided by Professor 
Debra Skene (University of Surrey) and implemented in MATLAB 2019a (The MathWorks, 
Inc., Natick, Massachusetts, USA). Hormone and glucose profiles were analysed at the native 
sampling rate (20 and 15 minutes), while temperature and motion counts were meaned into 
5-minute bins. Where a profile was significant for cosine fit (p<0.05) the clock time of the 
acrophase was calculated. 
Graphical representation of the data was implemented in the NumPy (ver. 1.19.1), SciPy (ver. 
1.5.0), and Matplotlib (ver. 3.2.2) numeric libraries for Python (ver. 3.7.6), available at 
http://www.scipy.org and https://www.python.org. Processing of the data and the code for 





6.4.1 Characteristics of the study participants 
Eleven participants completed the study - 6 females and 5 males. Summary data for the 
participants is shown in Table 6-1. Sampling took place between April 2019 and February 
2020 and all participants were in the city of Bristol, United Kingdom.  
 Mean ± SD or No. (%) 
N 11 
Age (years) 27.23 ± 3.88 
Males 5 (45%) 
BMI 22.68 ± 1.42 
PSQI 2.17 ± 1.70 
ESS 3.75 ± 2.05 
MEQ (HO) 58.17 ± 8.65 
Table 6-1 Demographics of ambulatory study participants. BMI=body mass index (kg.m2), PSQI = Pittsburgh Sleep 
Quality Index, ESS = Epworth Sleepiness Score, MEQ (HO) = Morningness-Eveningness Questionnaire (Horne Östberg). 
6.4.2 Technical success rate available data 
All participants completed the protocol and there were no adverse events. There were no 
instances of device failure or accidental disconnection. For one participant, microdialysis 
sample collection was incomplete on one sampling day due to accidental obstruction of the 
microdialysis pump tubing. Poor quality microdialysis sampling was noted in at least one 
session for 3 other participants affecting 5 of the total 44 sampling days. These sessions were 
linked to the same batch of microdialysis probes. 
Microdialysis results were available for participant 1-9 (4 females, 5 males). For one 
participant, measurements of all hormones from 1 of 4 days and melatonin only from a 




One set of saliva samples was missed, the remaining 252 of 258 were collected. All missing 
saliva samples were from the same participant from a night without bright light exposure. 
Saliva results were available for participant 1-4. 
All participants wore the bright light visor for the full length of 45 minutes except for 
participant 1 during session 1 where battery failure shortened the session by 50% (worn for 
22 of 45 minutes). 
The continuous glucose monitor was accidently dislodged by participants on two occasions 
(affecting participant 2 and 3). In both cases, the sensor was replaced, and sampling was able 
to continue.  
6.4.3 Summary of hormone data 
 
Figure 6-2 Mean profiles of melatonin [pmol/L] obtained over 4 sampling days in n=9 study participants by automated 
ambulatory microdialysis. Profiles show interindividual variation in timing and amplitude of the daily rhythm. As 
expected, tissue melatonin concentrations rise during the evening, peak during the sleep period, and fall to low or 




Daily profiles of melatonin were obtained in all 9 participants (Figure 6-2), in addition to 
measurements of cortisol and cortisone (Figure 6-3).  
 
Figure 6-3 Mean profiles of cortisol and cortisone  [nmol/L] obtained over 4 sampling. Cortisol (left) peaks in the morning 
with nadir concentrations late in the evening or soon after midnight. Cortisone (right) shows a similar pattern of secretion 
but at a reduced amplitude.  
 
Mean ± SD Minimum Maximum 
Cortisol [nmol/L] 4.60 ± 4.69 0.87 27.71 
Cortisone [nmol/L] 3.30 ± 2.86 0.67 14.87 
Melatonin [pmol/L] 26.03 ± 22.39 0.46 125.67 
Melatonin range [pmol/L] 37.73 ± 26.04 6.23 111.27 
Melatonin onset 00:09 ± 0:59 22:00 02:27 
Melatonin offset 07:37 ± 1:08 05:34 09:57 
Peak cortisol time 07:57 ± 1:09 04:30 10:20 
Sleep time (hh:mm) 23:11 ± 1:24   
Wake time (hh:mm) 07:20 ± 1:13   
Table 6-2 Summary statistics of cortisol, cortisone and melatonin  in microdialysis samples. Mean, standard deviation 
(SD), minimum and maximum concentrations are shown for each parameter. The melatonin onset and offset (calculated 
as the 25% threshold), sleep and wake times, range and peak cortisol time are all reported in 24-hour clock time ± SD in 
hours and minutes.  
Table 6-2 shows summary statistics for cortisol, cortisone and melatonin as measured in 
microdialysis samples. In several participants, melatonin was detected at levels below the 




samples collected during waking hours (Figure 6-4). The melatonin range was significantly 
higher in females (53.9pmol/L) than in males (22.48pmol/L, mean difference 31.48pmol/L, 
[t=4.248, p=0.0003, 95% CI 16.2-46.8]).  
The mean time of melatonin onset was 58 minutes after the mean sleep time, melatonin 
offset 17 minutes after waking, and the peak of cortisol 37 minutes after waking (Table 6-2).  
 
Figure 6-4 Continuous profiling of hormones over 2 consecutive days.Profiles of melatonin (dark grey squares), cortisol 
(red circles), and cortisone (blue open circles) are shown for participant 9, a female. Melatonin was detected in almost all 
samples, including those obtained during daylight hours. The vertical yellow bar represents use of the bright light visor, 
grey shaded areas are sleep periods. The melatonin onset time on night 1 was 00:42 compared with 22:54 on night 2. 
6.4.4 Day-to-day stability of cortisol and melatonin profiles  
To determine if there was interparticipant variation in the time of peak cortisol secretion or 
melatonin offset between sampling days, a repeated measures analysis of variation (ANOVA) 
was performed. This showed no significant effect of the sampling day on cortisol onset time 
(F(3,21) = 1.51, p=0.2402), cortisol peak time (F(3,21) = 2.41, p=0.0955) or melatonin offset 
(F(3,21) = 2.80, p=0.0649). There was a strong alignment between phases of cortisol and 





Figure 6-5 Hormone plots aligned by cortisol onset time. Cortisol (top part of each panel, red, nmol/L) and melatonin 
(lower part of panels, blue, pmol/L) profiles are shown from 4 sampling days, except for participant 5 and 6 who had 
missing profile data. Time 0 (cortisol onset) is marked with a vertical dashed line. Solid line markers (squares and circles) 









Figure 6-5 (continued) Hormone plots aligned by cortisol onset time. Cortisol (top part of each panel, red, nmol/L) and 
melatonin (lower part of panels, blue, pmol/L) profiles are shown from 4 sampling days. Time 0 (cortisol onset) is marked 
with a vertical dashed line. Solid line markers (squares and circles) indicate the profiles in which the participant was 
exposed to pre-bedtime bright light. Participants 7-9 are shown on this page, and participants 1-6 on the previous page.  
6.4.5 Evening ambient light conditions 
Average ambient light exposure measured in the 3 hours prior to bedtime was 19.3 lux, 
(example Figure 6-6). There was a 4-fold difference between the participant with the lowest 
(10.5 ± 6.6) and highest (40.8 ± 46.3) light exposure (Table 6-3). 
ID Mean ± SD Min Max 
1 21.1 ± 11.5 5.2 46.9 
2 25.8 ± 18.2 6.0 101.7 
3 31.3 ± 17.6 2.5 54.5 
4 40.8 ± 46.3 5.2 175.8 
5 17.8 ± 4.7 9.6 29.2 
6 16.8 ± 8.8 1.7 34.6 






ID Mean ± SD Min Max 
8 22.3 ± 10.3 4.3 44.6 
9 19.3 ± 5.3 3.9 31.0 
10 14.3 ± 5.4 6.4 26.5 
11 10.5 ± 6.6 3.8 40.0 
TOTAL 19.3 ± 7.7 5.2 36.8 
Table 6-3 Mean exposure to environmental light during the 3 hours prior to habitual bedtime. Mean levels (lux) are 

































Figure 6-6 Environmental light exposure in relation to sleep periods and day length . Data is illustrative and from a single 
participant during a 54-hour sampling period. Light (in lux) is shown in yellow. Night is marked between sunset and 
sunrise (grey boxes), sleep in the purple shaded boxes, and melatonin secretion is shown as solid black lines. In this 
participant, the mean ambient light level was 21.1 lux (SD = 11.5) during the 3 hours prior to habitual bedtime. 
6.4.6 Effect of bright light intervention 
There was considerable day-to-day variation in the time of melatonin onset between 
participants, independent of the bright light exposure (Table 6-4). Overall, there was no 
evidence that for a difference in the time of melatonin onset on days without the bright light 
exposure compared with when it was used (t=-1.9541, p=0.0593). At an individual level, only 
participant 4 showed a significant delay in melatonin onset on both bright light exposure 




 Time difference of melatonin onset, by condition 
Participant Visor- vs non- Non-vs non- Visor-vs visor- 
1 (0:27) 0:24 0:05 
2 (1:21) 0:25 0:01 
3 0:17 0:36 0:01 
4 (1:45) 0:39 0:29 
5 - - - 
6 0:02 0:03  
7 (1:04) 1:35 0:11 
8 (0:49) 1:30 0:24 
9 (0:10) 0:27 0:28 
Mean difference (0:38) 0:42  0:12  
Table 6-4 Comparison of the time of melatonin onset by bright light exposure condition for each participant. Calculations 
were not possible for participant 5 due to missing data. Visor vs. non- visor: Times in (brackets) indicate phase delay and 
italicised times indicate phase advance of melatonin onset. There was a wide variation and ultimately no significant 
effect of bright light intervention on the timing of melatonin onset when comparing exposure nights vs. non-exposure 
nights (p=0.0593). Non- vs. non- visor: The mean time of melatonin onset varied by 42 minutes (SD = 0:32) between the 
two nights where the visor was not worn. Visor vs. visor: The mean time of melatonin onset varied by 12 minutes (SD = 
0:12) between the two nights in which the visor was worn. 
 
Figure 6-7 Example of melatonin suppression following deliberate bright light exposure.  In this 54-hour continuous 
profile from participant 4 (a male), bright light was delivered using a head mounted visor, 1 hour prior to habitual bed 
time (vertical yellow bar), on day 2 of the sampling protocol. During the period of light intervention, melatonin was 
temporarily suppressed in microdialysate (dark grey squares) and in saliva (grey ‘X’ symbols).The effect over both 
sampling sessions was a significant delay in melatonin onset (p=0.0161). Cortisol (red circles), cortisone (blue open 




6.4.7 Sleep disturbance associated with disrupted cortisol secretion 
Figure 6-8 shows a 54-hour hormone profile from participant 1 whose sleep pattern was 
disturbed during the second night of microdialysis sampling. Environmental noise delayed the 
onset of sleep by 250 minutes compared with the previous night and was associated with an 
altered pattern of cortisol, but not melatonin secretion. The early morning surge of cortisol 
was substantially lower in magnitude on the sleep-disturbed night, and was followed by a 
second, similar amplitude pulse, that anticipated waking after the delayed period of sleep.  
 
Figure 6-8 Abnormal secretion of cortisol associated with sleep delay. Hormones (melatonin, grey squares; cortisol, red 
circles; and cortisone, blue open circles) are plotted in relation to sleep periods (grey shaded area) over 2 consecutive 
days of continuous microdialysis sampling. On night 2 (right hand side of the panel) both the time of sleep onset and 
offset were delayed by several hours. The usual pre-waking surge in cortisol secretion, present on night 1 (left) was 









Figure 6-9 Biorhythm phase clocks. Coloured rays point to the time of the acrophase (peak) of rhythmic hormones 
(cortisol, cortisone, melatonin), peripheral skin temperature, glucose, motion, and ambient light exposure. The acrophase 
for each rhythmic process was calculated after confirming the daily rhythm by significance of cosine fit (p<0.0001). The 
shaded area indicates the time between the acrophase of melatonin and the acrophase of cortisol. Data for participant 












Figure 6-9 (continued). Coloured rays point to the time of the acrophase (peak) of hormones (cortisol, cortisone, 
melatonin), peripheral skin temperature, glucose, motion, and ambient light exposure. The acrophase for each rhythmic 
process was calculated after confirming the daily rhythm by significance of cosine fit (p<0.0001). The shaded area 
indicates the time between the acrophase of melatonin and the acrophase of cortisol. Data for participants 7-9 on this 
page, for 1-6 on the previous page. 
Significant daily rhythmicity of melatonin, cortisol, cortisone, glucose, skin temperature, 
activity, and light exposure was found for all participants (for all p<0.001, statistics and 
individual acrophase times can be found in Appendix Q). Biorhythm phase clocks for each 
participant are shown in Figure 6-9. Acrophases that occurred during sleep were melatonin 
(mean peak at 04:01, SD= 3:02), and peripheral skin temperature (02:43, SD=1:12). The 
acrophase of cortisol (09:32, SD=1:14) lagged cortisone (09:57, SD=1:28) by an average of 24 
minutes (SD=38 minutes). Peak light exposure (13:20, SD=0:43) and activity (14:57, SD=0:52) 






The mean time between the acrophase of melatonin and the peak of waking cortisol was 5 
hours 30 minutes (SD=56 minutes). The acrophase of peripheral skin temperature occurred 
on average 1 hour 18 minutes before the acrophase of melatonin, but with a large 
interindividual variation (SD=1 hour 32 minutes).  
6.4.9 Visualisation of rhythms as heat maps 
Figures 6-10 - 6-16 show the 7 rhythmic parameters plotted as daily heatmaps. 
Measurements were standardised as Z-scores to aide comparison of dynamic changes 
between participants, except for the heat map of light exposure (Figure 6-16), which was 
plotted on a logarithmic scale. For all plots, self-reported meals and snacks are represented as 
solid red circles, 25-75th centile range of bedtimes and get up times as black and white bars 





Cortisol begins to rise in anticipation of waking and peaking close to the time of habitual 
rising. Habitual bedtime occurs around the time of individual cortisol nadir (Figure 6-10). 
 
Figure 6-10 Tissue cortisol heatmap of 9 healthy volunteers measured during two 54-hour sampling periods, 1 week 
apart. Each cell represents a 20-minute sampling period. The meaned data from each participant is represented as 
standard scores (the Z-score is the number of standard deviations from the mean for that participant). Cortisol begins to 
rise several hours before waking and peaks around the time of habitual rising. The cortisol nadir occurs in the evening, 






The pattern of 24-hour cortisone secretion is very similar to that of cortisol, consistent with 
the close relation between the hormone and its metabolite. Cortisone begins to rise in the 
early morning, peaks around habitual rising time, and reaches its nadir at or just after habitual 
bedtime (Figure 6-11).  
 
Figure 6-11 Tissue cortisone heatmap of 9 healthy volunteers measured during two 54-hour continuous sampling 
periods, 1 week apart. Each cell represents a 20-minute sampling period. The meaned data from each participant is 
represented as standard scores (the Z-score is the number of standard deviations from the mean for that participant). 
The dynamic profile of cortisone is very similar to that of cortisol (Figure 7) with peak levels around the time of waking, 






Melatonin begins to rise late in the evening for most participants and does not reach peak 
levels for several hours after habitual bedtime. Melatonin falls to low levels at or soon after 
habitual rising time (Figure 12). 
 
Figure 6-12 Tissue melatonin heatmap of 9 healthy volunteers measured during two 54-hour sampling periods, 1 week 
apart. Each cell represents a 20-minute sampling period. Meaned data from each participant is represented as standard 
scores (the Z-score is the number of standard deviations from the mean for that participant). Melatonin is at its highest 
during the sleep period with maximum levels occuring several hours after habitual bed time. The disappearance of 





6.4.9.4 Peripheral skin temperature 
Peripheral skin temperature is strongly associated with time spent in bed. Habitual bedtime is 
consistently associated with an increased finger skin temperature which remains elevated 
throughout the sleep period before and falling quickly around the time of rising. During 
waking hours, finger skin temperature is much more variable (Figure 6-13). 
 
Figure 6-13 Peripheral skin temperature heatmap of 11 healthy volunteers measured throughout the study protocol. 
Measurements with a sampling frequency of 1 minute were obtained using a ring-based thermometer placed on a finger 
of the non-dominant hand. Each cell in the heatmap represents 5-minute mean data, and data from each participant is 
represented as standard scores (the Z-score is the number of standard deviations from the mean for that participant). 





6.4.9.5 Meals and glucose 
Participants did not eat at consistent set times, with meals scattered throughout the waking 
hours, and food intake close to bedtime was common (for example, participants 1 and 4, first 
and fourth ring from the centre). Highest levels of glucose occurred in the afternoon and 
evening with a clear diurnal rhythm – in all participants, the glucose minima occurred one to 
two hours prior to habitual rising times (Figure 6-14).  
 
Figure 6-14 Glucose heatmap of 11 healthy volunteers measured over 10 days using an interstitial continuous glucose 
monitoring system, placed in the skin of the non-dominant upper arm. Each cell represents a 15-minute sampling period, 
and mean glucose levels for each participant are presented as standard scores (the Z-score is the number of standard 
deviations from the mean for that participant). Highest levels of glucose occur during the mid-afternoon until bed-time, 






6.4.9.6 Physical activity 
Activity levels in this cohort of participants was overall generally low (Figure 6-16). Sleep 
periods were associated with minimal movement, as expected. Most participants reported 
waking episodes during the sleep period, for some participants this was a frequent 
occurrence (for example participant 3, third ring from the centre).  
 
Figure 6-15 Activity heat map of 11 healthy volunteers measured over 17 days using a wrist-based triaxial 
accelorometer sampling at 30-second epochs. Each cell in the heatmap represents 5-minute mean motion counts, which 
are presented as standard scores (the Z-score is the number of standard deviations from the mean for that participant). 
Overall, activity levels are low, reflecting the mostly sedentary lifestyle of participants and the request from study 
investigators not to engage in vigorous activity during the study protocol. The sleep period is associated with the lowest 





6.4.9.7 Ambient light exposure 
Figure 6-16 shows the light exposure heatmap for the 11 participants. Exposure to light 
levels between 10-100 lux were observed around bedtimes. A seasonal pattern of ambient 
light exposure is visible – there is more exposure to brighter light (green and yellow cells on 
the heat map) for participants 1-4 (inner 4 rings) who were sampled during the northern 
hemisphere spring and early summer, compared with participants in the outer rings who were 
sampled during autumn and winter, when day length was short. 
  
Figure 6-16 Light exposure heat map of 11 healthy volunteers measured over 17 days using a wrist-based integral light 
sensor. Each cell in the heatmap represents 5-minute mean data and is presented on a log10 scale. White unshaded areas 
correspond to 0 lux (complete darkness). Higher daytime light exposure levels are seen for participants 1-5 (inner 5 rings) 
who were sampled during the northern hemisphere spring and summer (April-July) compared with participants 6-11 





In this pilot study of 11 healthy male and female volunteers, a system for measurement of 
multiple dynamic and rhythmic physiological processes was successfully tested. The principal 
aim, to demonstrate full overnight melatonin profiles in ambulatory subjects simultaneously 
with cortisol and cortisone, was achieved. Tissue melatonin onset and offset were associated 
with sleep, but the bright light intervention hypothesis could not be proved. Multiple 
wearable devices were used together to gather detailed information about daily processes 
that were clearly rhythmic. These data were presented in novel ways to allow visualisation of 
minute-to-minute changes around the clock.  
6.5.1 Novel detection of in 24-hour profiles of melatonin in microdialysate fluid 
The principle aim of the study was to prove that complete melatonin profiles could be 
obtained in microdialysate, over multiple days, in multiple participants, and without the need 
for blood sampling. This was successfully achieved a subcutaneous microdialysis catheter 
coupled with a novel ambulatory sample collector (U-RHYTHM). Microdialysis detection of 
melatonin has been performed in vivo in rodent pineal glands324 but to the author’s 
knowledge, never before in human subcutaneous tissue. The achievement of detecting 
melatonin at very low concentrations and in small sample volumes in multiple microdialysate 
samples is unique, and a testament to the quality and sensitivity of the assay used for this 
study169.  
The typical method for measurement of melatonin is to sample it, or its metabolites, in blood, 
saliva, or urine. In non-laboratory settings, sampling time points are restricted to pre-bed 
measurements, or through lower precision integrated measurement in overnight urine 
metabolites94, since overnight sampling would disturb sleep. With a complete profile, multiple 
parameters can be estimated from the profile including both time of melatonin offset and 
onset, profile amplitude, and duration of the melatonin period. In the current study, where 




relative threshold method, allowing normalisation of differences in melatonin amplitude 
between profiles, thereby facilitating comparison between participants with markedly 
different melatonin secretion patterns94. Until now obtaining a full profile with the possibility 
of sleep has required admission to a research facility, placement of an intravenous cannula, 
and collection of blood. For this the microdialysis technique has clear advantages. Since the 
U-RHYTHM device is portable, sampling can continue throughout the night without 
disturbing sleep, and sampling can easily be done at home, or equally easily in a laboratory 
environment. The timing of food and drink does not interfere with sample collection, as it 
may do with saliva183, and compliance with sample collection is not an issue since 
microdialysis samples are obtained automatically and passively.  
The tissue-free melatonin profiles obtained in this study showed a clear and distinct 
nocturnal rhythm consistent with that previously rhythms in saliva325 and plasma90. The 
amplitude and shape of melatonin profiles varied more between participants and within 
participants than cortisol, consistent with the reported wide interindividual variation in 
melatonin secretion in humans325. The tissue melatonin amplitude was significantly higher in 
females, also consistent with previous findings in saliva and plasma19,92,95,326. These 
differences highlight important biological variability even in the healthy normal population 
and reinforce the importance of conducting research that includes both female and male 
participants.  
Free tissue concentrations were lower than typical total plasma concentrations321,327, which is 
not surprising since free plasma melatonin only accounts for approximately one quarter of 
total plasma melatonin328. Studies that collect complete free melatonin profiles in saliva under 
dim light conditions are rare but Burgess & Fogg (2008) reported mean peak concentrations 
of approximately 75pmol/L, higher than observed in the microdialysate samples in the 
current study, but not directly comparable due to the differences in methodology325. Using 




that free saliva melatonin was on average 36% higher than free plasma levels, hinting at the 
possibility of local production of melatonin in saliva169. With limited results currently 
available, the degree to which concentrations of free melatonin in microdialysate relate to 
free saliva levels currently remains unanswered but will be directed followed-up. 
Nevertheless, preliminary results from the pilot data (Appendix M) are promising and indicate 
there is high correlation between microdialysate and both plasma and saliva. Formal 
validation of free tissue melatonin against plasma, under dim light as gold standard 
conditions, is also a crucial next step. 
6.5.2 The impact of light on melatonin profiles 
In the current study, participants were deliberately exposed to 45-minute periods of bright 
light (approximately 800lux, equivalent to a bright office area) delivered by a head mounted 
visor, during the hour prior to habitual bedtime. Melatonin is extremely sensitive to 
suppression by light103, and is was hypothesised that the intervention would easily be of 
sufficient magnitude to affect melatonin concentrations. An easily acknowledged limitation of 
the visor was that compliance was based on self-report, and correct use was not observed by 
study investigators. Assuming that compliance was not an issue, for some participants 
melatonin profiles did appear to suppress following the intervention, but this was not 
consistent across all participants, and at a group level there was no significant difference in 
the time of melatonin onset between nights when the visor was worn and when it was not. 
There are likely to be several contributing factors to this result. Firstly, it is evident that the 
time of melatonin onset is equally variable on nights without visor exposure, and therefore 
there was no stable baseline for which to compare. In studies where the accurate 
determination of the unmasked endogenous period of melatonin is required, samples are 
collected in dim light conditions35. For example, in a study of volunteers comparable to the 
current cohort (healthy males and females age 18-30) exposure to room lighting (<200lux) in 




participants, compared with 8 hours of very dim light (<3 lux)100. In controlled dim light 
conditions, the onset of melatonin typically occurs in the hours before bedtime329 but in the 
current study, the average time of melatonin onset occurred almost 1 hour after bedtime, 
suggesting that for this group of participants, the phase of melatonin was already delayed by 
environmental light exposure. Even exposure to levels of light below 30 lux can substantially 
suppress melatonin in humans101,307 – the mean lux exposure during the 3 hours prior to 
bedtime in the present study was close to 20 lux, and in some participants was greater than 
40. Phillips et al. (2019) showed that under lit conditions, the delay of melatonin onset could 
be predicted by a dose-response curve –with 30 lux light exposure during the 4 hours prior 
to bed, the mean delay compared with dim light measurements was 77 minutes, and at 50 
lux, 109 minutes101. In a very recent study of 60 adults, the typical level of evening light 
encountered in participant’s homes was sufficient to suppress melatonin by up to 50%307, but 
importantly, there was wide individual variation in sensitivity, ranging from no suppression in 
some individuals to nearly 90% in others307. Finally, it has also been established that recent 
bright light exposure (such as daylight exposure) can reduce the sensitivity of melatonin to 
further suppression330,331, which would could also support the current findings. In summary, a 
combination of environmental light exposure, the visor intervention, and interindividual 
sensitivity are likely to have been significant contributors to the variation in timing of 
melatonin onset in the current participants.  
6.5.3 Daily cortisol profiles 
Daily rhythms in cortisol were clearly identified in all participants. There was less 
intraindividual variation in the timing and amplitude of cortisol secretion that for melatonin 
(Figure 6-5). The rhythm was remarkably stable from day-to-day, consistent with previous 
observations in controlled lab settings327. It was very interesting to note the marked 
disturbance in the profile of cortisol following acute sleep delay (Figure 6-8). Acute total 




conditions that disturb sleep, such as obstructive sleep apnoea, have been shown to lead to 
abnormal cortisol secretory dynamics65. In the study participant, surges in cortisol anticipated 
both the usual- and delayed-waking times, with an overall reduced amplitude, compared with 
the undisturbed previous night. Capturing the kind of abnormality seen in this participant 
would have been impossible without the high frequency sampling afforded by the U-
RHYTHM ambulatory sampler.  
6.5.4 A system for all day biosampling 
A key objective for this pilot study was to demonstrate ambulatory sampling of multiple 
physiological processes simultaneously, at high resolution, and with minimal input from the 
participant. The advantage of wearable devices, including the U-RHYTHM device, is that 
information is obtained passively, not requiring any input from the individual being sampled. 
This reduces burden to participants and aides continuous dynamic assessment333. Near real-
time tracking of rhythmic processes has produced data that will be suitable for machine 
learning and systems modelling techniques314, and a step toward a goal of truly personalised 
medicine317.  
The hypothesis that daily rhythms would be detectable in cortisol, melatonin, glucose, skin 
temperature, activity, and light exposure was proven. Using this information, acrophases 
could be calculated, and plotted in relation to each other, serving as a basis to begin 
describing normal variation in the phase relationships between rhythms. There appears to be 
a consistent and stable relationship between the secretion and offset of melatonin, and the 
onset and peak of cortisol both at an individual level (Figure 6-5) and as a group (Figure 6-8). 
My results agree with the findings of Weibel and Brandenberger (2002) who found that the 
onset of melatonin was phase locked to the quiescent, or period of low secretion, of cortisol 
in both day- and permanent night-shift workers, and it is also apparent that the offset of 




Together with the findings in the present study, this suggests the presence of high-level 
coordination of cortisol and melatonin secretion, at least in stable routine conditions. 
Distal body temperature rhythms were captured at high resolution throughout the sampling 
period providing revealing information related to coincidence of the timing of sleep in 
participants who maintained a regular day/night routine. Distal skin temperature is antiphase 
correlated with core body temperature301 with sleep onset associated with hypothalamic 
mechanisms that include vasodilation335 and consequent rises in peripheral skin 
temperature173,174,336 . By contrast, it is notable that peripheral body temperature during 
waking activity is much more variable than during sleep. Further exploration of potential 
correlates of waking finger temperature variation with environmental change and other 
measurements is desirable on the basis of recent evidence suggesting that changes in the 
ultradian oscillations in distal (finger) skin temperature could potentially predict surges in 
luteinising hormone43, and also work in mice demonstrating relationships between blood 
glucose and body temperature during the transition between normo- and hyperglycaemia.337 
6.5.5 Potential applications 
As well as documenting healthy normal variation, the technique of U-RHYTHM circadian 
phase hormone analysis combined with wearable device monitoring could be used to 
investigate the effect of shift work and other chronodisruptive behaviour on the alignment of 
body rhythms, and eventually to help guide interventions to maintain phases within ‘normal’ 
ranges. Fine-grain detail is strikingly represented in the circular heat maps (Figure 6-9-6-15)) 
where self-selected behaviours (bed and sleep times, meals, activity) can be visualised 
alongside intertwined endogenous processes (circadian hormones, daily rhythms in body 
temperature, the daily glucose rhythm and response to meals). The sampling system piloted 
here is highly flexible and could be adapted to include measurement of additional processes, 
including targeted or untargeted metabolomics in interstitial fluid, and measures of 




normal activities in the real world, but the system could equally be employed in laboratory 
environments with stricter controls on environmental conditions. 
6.5.6 Limitations 
This study was a proof of principle example of a further application of U-RHYTHM sampling 
technology, testing the feasibility of concurrent use of wearable passive sensors, with aim of 
being able to collect full daily profiles of melatonin in addition to cortisol and cortisone. For 
most of the study participants were simply observed – the primary objective was to collect 
data in as normal life conditions as possible, capturing ‘real world’ interindividual variation 
rather than attempting to establish causal links between processes. Where an intervention 
was attempted, the effect of environmental light and normal daily variation in melatonin 
secretion was underestimated, and the outcome confounded by the lack of a dim light 
control. Clearly, validation of melatonin measurements in microdialysate against plasma and 
saliva analysis are still needed. The study was in a small number of participants which limits 
the generalisability of the findings, and it would be useful to expand the study to include 
participants in older age groups for example, especially because as melatonin levels decrease 
with age338. Finally, these results represent an initial review, and further detailed analysis of 
the rhythmic processes and their interactions is planned. 
6.6 Conclusions 
Measurement of tissue free melatonin has been achieved for the first time in ambulatory 
healthy volunteers, without the need for blood sampling or participant intervention. Clearly 
seen are the powerful effects of individual variability and the environment on hormone 
profiles, which have been placed in the context of rhythms of sleep, activity, light exposure, 






7 Summary and conclusions 
Rhythms characterise the biology of all living things, having evolved to suit existence on a 
planet whose orbit and rotation define distinct periods of light, dark, and season. Rhythmicity 
occurs on a variety of time scales, from the rapid ultradian oscillations of internal biological 
processes, to daily circadian patterns of sleep and activity, and to the circannual patterns of 
migratory animals. These rhythms function together to create a dynamic environment which 
enables living things to adapt and anticipate change in the world.  
Traditional methods of scientific enquiry and health care diagnosis typically rely on the 
extrapolation of single or limited time point assessments, which by their nature cannot 
accurately capture dynamics. In this thesis I have argued that with the use of a novel 
ambulatory sampling system, U-RHYTHM, the dynamics of endocrine and metabolic systems 
can be studied without the need for laborious inpatient assessment. Studying dynamic data 
can provide useful information to identify both common and individual patterns, to gain new 
insights into the understanding of rhythmic physiology, and ultimately may lead to a more 
personalised approach to diagnosis and management of conditions caused by rhythm 
disruption.  
Specifically, I have: 
1. Described the further development and optimisation of a prototype, ambulatory 
microdialysis sampling device, U-RHYTHM, demonstrated its acceptability for use in 
human research, and identified areas of limitation (Chapter 3). 
2. Used the U-RHYTHM device to complete the first validation of the dynamics of multiple 
adrenal steroids in subcutaneous tissue (Chapter 4). 
3. Used the U-RHYTHM device to generate pilot data demonstrating the dynamics of daily 




4. Demonstrated the ability to measure full profiles of both glucocorticoids and melatonin 
simultaneously in U-RHYTHM microdialysis sample fluid, in free living ambulatory healthy 
volunteers over multiple days, in combination with a framework for collection and 
integration of rhythmic information sampled by wearable devices (Chapter 6). 
7.1 Use and acceptability of the U-RHYTHM prototype 
In Chapter 3 the history, development, use and potential limitations of the U-RHYTHM 
device were reviewed. The very first studies using microdialysis with an ambulatory sample 
collector were conducted using a hand-built prototype117,119,186 that could not be successfully 
reproduced for larger clinical trials. To address this problem the prototype was rebuilt using 
the same basic principles of action, but with substantial redesign and engineering overhauls 
to become the device known as U-RHYTHM. Over the course of this project, the 
microdialysis sampling process involving U-RHYTHM was reviewed in detail. Standard 
operating procedures were implemented allowing the technique to be used in four 
independent sampling locations, as part of the ULTRADIAN clinical trial. The U-RHYTHM 
sampler performed well in clinical situations, producing consistent volume samples across 
multiple successive sampling sessions, suitable for multiplex hormone analysis.  
Reassuringly, the U-RHYTHM sampling procedure is very safe – in over 600 sampling 
sessions there were no serious adverse events, and only a handful of minor events. It was 
also very well tolerated - even with potential bias in the feedback questionnaire, the response 
of almost all participants was positive. However, the failure rate was disappointing at just 
under 25%, over the 3 years of the ULTRADAN trial. While some degree of failure is to be 
expected with the development and application of a novel technique, to be a feasible 
proposition in the long term, this will need to improve. Several risk factors for failure have 
been identified, and actions taken to make the sampling procedure as secure as possible. 
Given the relative complexity of the current technique, it will be essential to ensure that 




or the U-RHYTHM microdialysis sampling system. Currently unmodifiable risks related to the 
performance and characteristics of the microdialysis probe and pump could be addressed by 
the production of custom materials – this would require substantially more investment, but it 
is my opinion that it would result in a significantly more robust and easier to use system.  
7.2 U-RHYTHM design affects the recovery of hydrophobic analytes 
The ability and reliability to detect hydrophobic analytes is influenced by the material 
composition of the U-RHYTHM device (Chapter 3). The surfaces within the internal volume 
of the sampler act as a sink, trapping extremely insoluble compounds (including testosterone), 
while the hydrophobic surfaces of the sample collection spool tubing also adsorb substantial 
amounts of lipophilic compounds. I was able to successfully mitigate this effect for 
hydrocortisone by modifying the U-RHYTHM plastic surfaces with a surfactant, and to 
augment recovery of testosterone in vitro by the addition of a complex-forming agent, 
cyclodextrin, to the perfusate. The logical next step is to now test these methods in vivo. 
What is unclear is whether such procedures would have any effect on the recovery of 
hydrophilic substances – for example, amino acids, which were not adsorbed. In any case, 
future versions of the prototype sampler need to consider addressing these issues, ideally 
abandoning the use of plastic tubing as a sample reservoir, and instead drawing inspiration 
from microfluidic technology339 and sophisticated anti-biofouling methods that completely 
prevent sample contact with solid surfaces340. Evidence from the clinical validation studies 
suggests that in vivo, the pre-analytical effect of the U-RHYTHM sampling system on the 
recovery of cortisol, cortisone and other steroids persists for several hours, and for current 
studies with the device, samples obtained in the first period of the session need to be 




7.3 Recovery of adrenal steroids 
In Chapter 4, I presented the metabolodynamics of adrenal steroids detected in participants 
who completed 24-hour plasma and microdialysis sampling. A total of 8 compounds were 
reliably detected in both plasma and in U-RHYTHM microdialysis samples, 7 of which have 
never previously been described in this way. Cortisol showed a robust diurnal rhythm, 
confirming previous findings117,119,149,186. In addition, diurnal rhythms of cortisone, 
corticosterone, tetrahydrocortisol, and allo-tetrahydrocortisol were also present in 
microdialysate samples. All were well correlated with plasma, but with blunted or absent 
ultradian features compared with blood-sampled profiles, likely due to several factors related 
to steroid solubility, adsorption effects, and potentially local tissue metabolism. There was a 
diurnal rhythm of the ratio of cortisol with cortisone in both plasma and tissue, but the ratio 
in tissue was significantly lower in tissue than in circulating plasma, and during the rest period 
cortisol levels were lower than cortisone. As a further step, examining tissue ratio dynamics in 
high BMI participants would potentially be extremely interesting, since adipose tissue 
contains 11β-HSD1 and is able to release cortisol regenerated from cortisone240.  
Significantly, there were hormones with ultradian rhythms in tissue. Pulsatility of aldosterone 
was a feature present in all participants and its measurement in tissue microdialysate is 
entirely novel. The ability to detect patterns of tissue free aldosterone not only has the 
potential to revolutionise the diagnosis of primary aldosteronism, but to further the 
understanding of the local tissue effects of mineralocorticoid excess. It is already established 
that the mineralocorticoid receptor is expressed in human skin241, and pathological skin 
changes associated with primary aldosteronism include upregulation of 11β-HSD2, 
mineralocorticoid and glucocorticoid receptors244.  
But probably the most interesting, novel, and important finding was the identification of an 
ultradian rhythm of the adrenal steroid 18-hydroxycortisol in tissue, which was very strongly 




hydroxycortisol was equally well correlated with ACTH as cortisol in plasma, and in tissue 
was a far superior predictor of plasma ACTH/cortisol dynamics than tissue cortisol. As a 
compound, 18-hydroxycortisol has received relatively little attention to date, associated with 
the rare glucocorticoid remediable hypertension, but otherwise generally dismissed as a low 
concentration, inactive metabolite, other than potentially as an aide for discrimination of 
primary aldosteronism from other forms of high blood pressure248. As demonstrated in the 
current studies, there is a tantalising suggestion that 18-hydroxycortisol could serve as a 
proxy measure of ACTH activity in healthy microdialysate samples, and potentially as a 
marker of adrenal dysfunction in endocrine diseases, including primary aldosteronism and 
Cushing’s syndrome. 
7.4 Metabolite dynamics 
In Chapter 5, I presented pilot data demonstrating the ability to profile numerous metabolites 
in subcutaneous tissue simultaneously with plasma in a small cohort of healthy males. Amino 
acids, some biogenic amines and short chain acetylcarnitines were detected and most were 
highly correlated and synchronised with plasma. Other lipid metabolites including long chain 
fatty acids were not detected, presumably because of the combination of low tissue 
concentrations and the effect of adsorption to the U-RHYTHM device and sample spool. 
Almost all detected metabolites showed a daily rhythm, and rhythms were significantly 
impacted by prandial changes in metabolite concentrations. Timing of meals17 and the 
composition of food215 have been identified as potential zeitgebers of the circadian system in 
humans. The pilot metabolite profile data from the U-RHYTHM microdialysis technique 
provides initial evidence of the ability to study, in high resolution, metabolic effects of meal 
type and timing in relation to other environmental and circadian cues. Mistiming of food in 
relation to the circadian clock is implicated in the pathogenesis of metabolic disease, for 




technology, it could be easily and readily deployed in a shift-working population to obtain 
real-life evidence of the effects of chrono disruption on meal-related metabolism. 
7.5 Measurement of melatonin, and towards an integrated view of daily 
rhythmicity 
In Chapter 6, I described an observatory pilot study of healthy volunteers that examined the 
rhythmic milieu of circadian hormones and other physiological processes, using a combination 
of U-RHYTHM sampling technology and passive sensing wearable devices. In free living 
conditions, cortisol anticipated the waking time for each participant, was consistent in timing 
across 4 sampling days, and demonstrated a strong phase relationship with melatonin. The 
lack of a dim light control condition made assessment of the effect of deliberate pre-bedtime 
bright light exposure difficult; there was no evidence for a difference in melatonin onset time 
on days with the bright light exposure compared with those without. It is likely that day-to-
day variation in melatonin onset was already strongly influenced by environmental light 
exposure in the hours prior.  
Using data from wearable devices, daily rhythms were identified in rest/activity, glucose, 
peripheral skin temperature, and light exposure, alongside the rhythms of the endogenous 
circadian hormones. These were visually expressed as phase plots, and as circular heatmaps, 
which provided alternate views of the relative alignment of the different physiological 
rhythms between participants. These methods, successfully tested as a proof of principle in 
healthy volunteers, could be deployed to test specific hypotheses – for example to determine 
the effect of sleep deprivation or shift work on phase alignment of rhythms in metabolism, 
circadian hormones, and sleep, and to gain a greater understanding of the mechanisms by 




7.6 Individual variation 
It was striking that for all rhythmic parameters interindividual variation was evident, despite 
cohorts being similar in age, body weight, and general daily activity pattern. In the laboratory-
based adrenal hormone studies, the diurnal rhythms of glucocorticoids were broadly similar, 
but the ultradian secretion patterns were not - there was almost no commonality in the 
profiles of aldosterone across the 4 participants. In the metabolomics studies, there were 
clear differences between the participants, even in conditions of identical meals and minimal 
activity. In the ambulatory studies, variations in biorhythms were observed between a 
selected group of healthy volunteers making their own decisions about the timing of food, 
sleep, and activity. While traditional approaches seek to control conditions and minimise 
variability, out of curiosity and because it was possible, this final study took the opposite 
approach by controlling very little and measuring multiple systems to observe biorhythmic 
patterns in real life. Considering interindividual variability in this way contrasts with ordinary 
laboratory-based studies that force alignment, obtain meaned data and define general trends. 
While this is a valid and often useful in many circumstances, important signals that could 
characterise individual risk traits may be lost. The flexibility of the ambulatory monitoring 
system means that both approaches could be taken simultaneously – the U-RHYTHM device 
and wearable sensors could just as easily be deployed in highly controlled lab conditions as it 
is in free living conditions. 
7.7 Limitations 
7.7.1 Small cohort size 
The purpose of the clinical studies described in this thesis was to demonstrate proof-of-
principle, and the numbers available for analysis were small. Further information from 
additional participants is clearly necessary, and to that end, data from 280 healthy volunteers 
and similar numbers of patients with endocrine disease who completed studies using U-




data has provided hints at the normal daily response to meals in a select group of metabolites 
and would clearly benefit from additional sampling studies. Validation of the ambulatory 
microdialysis measurement of melatonin under dim light conditions is a high priority for 
completion as soon as possible. 
7.7.2 Uncertainty about precision of measurement 
Variability in recovery is a significant issue for microdialysis-based clinical studies. In a very 
recent publication, Busse et al. (2020) found that interindividual variation was the biggest 
contributor to differences in the relative recovery of drugs (antibiotics and paracetamol) from 
arm subcutaneous tissue, and also identified recovery differences in obese compared with 
lean participants193. The authors recommended that to overcome this, relative recovery for 
each analyte should be determined at every individual sampling session193. It is difficult to 
conceive how this would be possible for multiple metabolites in large scale ambulatory 
microdialysis studies; nevertheless, uncertainty about differences in hormone and metabolite 
recovery between and within participants is a concern, particularly given the large 
interindividual differences observed in the recovery of amino acids in the metabolomics pilot 
study. One possible solution to trial would be to include a standard calibration substance in 
the perfusate (e.g. a biologically inactive and safe isotope with generally similar properties to 
the metabolite(s) of interest) and compare the infused concentration with that measured in 
recovered microdialysate samples.  
7.8 Future directions 
7.8.1 Further development of U-RHYTHM 
Feedback from participants identified a need to make the U-RHYTHM device smaller – the 
current prototype is relatively bulky and can make some daily activities difficult. Practical 
adjustments to the sampler connections have been identified and discussed and will make the 




retrieval from the spool, which could be at least partially automated. As asserted, it is my 
opinion that reducing contact of recovered sample with plastic surfaces through minimisation 
of the internal sampler volume and devising an alternative method for sample storage should 
be the priorities for future versions of U-RHYTHM. 
7.9 Conclusions 
Traditional approaches tend to apply generalisations based on groups such as ‘lark’ and ‘owl’ 
chronotype, and general statements tend to ignore details of the significant interindividual 
variation that can be observed in almost all the rhythmic processes. U-RHYTHM microdialysis 
provides a solution for these problems by implementing high resolution dynamic sampling 
that can capture general daily trends, ultradian detail, and process interactions. The 
unintrusive ambulatory nature of the technique provides flexibility to sample both in free 
living and controlled laboratory conditions. 
Once daily testing, as is the traditional approach in almost all domains of diagnostic medicine, 
is extremely reliant on precise measures of absolute concentration, since no dynamical 
information can be conveyed in a single sample. On the other hand, microdialysis comes as a 
trade-off between certainty about tissue levels, and the ability to unobtrusively measure 
dynamics at high resolution. The argument here is that dynamic changes convey information 
that may be as equally important as the absolute concentration of a metabolite or hormone, 
and perhaps in many circumstances, may be more informative. Obtaining and visualising daily 
high-resolution dynamic data reminds us that many important, and indeed crucial, biological 
processes occur during the night, typically during sleep, at times that are inaccessible to 
measurement except in controlled laboratory conditions. The ability of U-RHYTHM to easily 
sample in this space could potentially revolutionise the diagnosis of endocrine conditions, for 




Finally, there is a need to investigate human populations with disrupted circadian rhythms, 
given the increasing associative evidence linking disordered circadian timing with disease. 
Further carefully designed studies that include U-RHYTHM microdialysis with passive 
wearable sensing have the potential to generate important data that could lead to 
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9.1 Appendix A 
9.1.1 Effect of albumin and human interstitial fluid tube surface modification 































































Figure 9-1 Relative recovery (% of reference) of cortisol, cortisone, androstenedione, 17-OH-P and testosterone from 
PTFE sample collection tubing pre-treated with plain perfusion fluid [here labelled H2O], 0.002% bovine serum albumin, 
or human interstitial fluid (IF). These unpublished data are provided courtesy of Dr Paal Methlie, Haukeland University 














































9.2 Appendix B 
9.2.1 Material composition of U-RHYTHM sampling system 
Section Component Material Volume 
Microdialysis probe Membrane Polyarylethersulphone N/A 
 Probe outlet tubing Polyurethane 1.8µL 
Extension  FEP tubing Fluorinated ethylene 
propylene 
2.4-3.0µL  
U-RHYTHM Inlet Stainless steel  





ether ketone (PEEK), silicon, 
TYGON® thermoplastic 
Mean 81.6µL (SD = 
15.1) – see Table 
below 
 




Table 9-1 Material composition and volume of the microdialysis sampling probe, extension tubing, and U-RHYTHM 
device components 
9.2.2 Estimation of manifold volume 
The manifold volume describes the internal dead space within U-RHYTHM devices and 
consists of the volume of the transit tubing and peristaltic fluid pump. To assess this volume, 
samplers were perfused with deionised water until fluid appeared at the outlet tubing, 
indicating the manifold was full. The contents of the manifold were then expelled into a pre-




The difference in weight of the sample vial before and after filling was used to estimate the 
internal volume in microlitres of U-RHYTHM sampling devices.  



















Figure 9-2 Estimated manifold volume [µL] of 6 U-RHYTHM sampling devices (n=3 replicates for each device, mean data 
and individual values shown)  
 063 062 027 052 034 036 
Mean volume 
(µL) ± SD 
102.9±2.5 80.6±1.4 68.3±0.4 74.5±1.0 60.6±1.8 80.0±1.9 






9.3 Appendix C  
9.3.1 ULTRADIAN Sampling Outcome 
 
Figure 9-3 Identification of ULTRADIAN sampling success or failure. Procedures after April 1 2017 (n=688) were 
reviewed to ensure that samplings were completed using the U-RHYTHM device, not the ‘blue box’ prototype. Only 
records containing a valid PID-SID combination (n=671) were included – those without or labelled as ‘test’ were excluded 
(n=17). Review of sampling comments excluded a further 6 samplings (breach of inclusion/exclusion criteria n=5, 
duplicate record n-=1). Successful sampling was defined as technical sampling success (n=508) AND sample quality 
adequate for inclusion (n=483). Sampling failure was defined as the sum of sampling failure (n=141) and those sampling 




9.4 Appendix D 
9.4.1 Sampling issues – ULTRADIAN studies 
9.4.1.1 Issues directly attributed to U-RHYTHM device 
1 Sample merging in otherwise good quality collection 
2 Sampler fell out of pouch during sampling session 
3 Poor quality sampling, sampler motor running when no fluid flow 
Table 9-3 Critical sampling issues affecting sample quality and directly related to use of the U-RHYTHM device  
9.4.1.2 Non-critical sampling incidents 
1 U-RHYTHM fluid inlet pin dislodged requiring repair; sampling unaffected 
2 U-RHYTHM fluid inlet pin dislodged requiring repair 
3 Spool-sampler fitting defective, poor sampling in bench test (non-clinical trial) 
4 Microdialysis catheter broke during removal of sampling system. Did not affect 
sampling quality 
Table 9-4 Non-critical sampling issues that did not affect clinical sample quality but directly related to use of the U-





9.5 Appendix E 
9.5.1 Device Satisfaction Questionnaire 
Thinking back over the time using the sampling device, please read the following statements 
















































1. Having the sampling probe fitted was not too 
uncomfortable 1. 2. 3. 4. 5. 
2. Carrying the sampling device was easy 
1. 2. 3. 4. 5. 
3. I was able to continue with my normal daily activities  
1. 2. 3. 4. 5. 
4. I did not experience any pain from the sampling probe 
1. 2. 3. 4. 5. 
5. During the day I was not bothered by noise from the 
sampler  1. 2. 3. 4. 5. 
6. It was easy to sleep wearing the sampling device 
1. 2. 3. 4. 5. 
7. During sleep, noise from the sampler did not disturb me 
1. 2. 3. 4. 5. 
8. I would be happy to wear the sampler again if I was 
asked 1. 2. 3. 4. 5. 





9.5.2 Summary of responses 
 n Mean SD 
1. Having the sampling probe 
fitted was not too 
uncomfortable 
506 5 0.8 
2. Carrying the sampling device 
was easy 
505 4 1 
3. I was able to continue with my 
normal daily activities  
505 4 1 
4. I did not experience any pain 
from the sampling probe 
504 5 0.8 
5. During the day I was not 
bothered by noise from the 
sampler  
506 5 0.8 
6. It was easy to sleep wearing the 
sampling device 
500 4 1 
7. During sleep, noise from the 
sampler did not disturb me 
501 4 0.8 
8. I would be happy to wear the 
sampler again if I was asked 
502 4 0.9 






9.5.3 Participant comments 
Comments (reported verbatim) 
a bit big and bulky, difficulties to bend over and sit down  
i agreed on 3, it was difficult to bend over when i was placing dishes in the dishmachine. I could 
not manage to put on shoes on the side where the sampler was placed on.  
Comfortable to wear, but can be noisy overnight 
Although I have answered 2 & 3 having the belt was not more restricting than expected. I could 
not do all my normal activities which would be difficult with a box attached i.e.  jumping on to the 
work surface, getting in and out of the car. However it was not more restricting than I expected. 
The probe hurts when I thought the box slipped to rest on it. Slight modification to the belt would 
fix this. 
A little tender when the area was moved & I was sat down but went when the device was taken 
out. Would be nice if it was quiet - disturbed our lab meeting. But the device did wake me up a 
couple of times in the morning. 
Would be good if all the tubing was contained. 
i slept very bad, position of sampler,  i needed to sleep on my back or on the left side, i usually 
sleep on stomach 
difficult to sleep, unusual to sleep on my back 
no available yet the form 
the device is heavy, worse through the day 
she preferred the blue box (lighter and less noisy) 
All the new set u is a good improvement 
First day wearing I was very aware of it, but by the next morning I was used to it and didn't notice 
it. 
Re 3. difficulty cycling due to size of device  Re 5. Noisy during cinema 
difficult to do the daily tasks and change clothes. therefore an very quiet day than usual 
the pouch is quite heavy for the belt, sitting no problem but when moving i constantly felt the 
need to take care of it because it was moving up and down. I could not move around as normal 
only much slower, maybe a broader belt would give more support 
it would need longer interconnections and tubings  and it may make better feeling when moving 
and also less worry about damaging something 
It was well fitted and securely "plastered" together 
Had to be cautious bending over. Prevented exercise. Not a problem for a 24 hr period 
Only issues were with bending over. Possibly worth wearing higher so movement at the waist not 
restricted.    *2 - Pain only insertion - not during 
N.A.  Because I was also undergoing various blood sampling 
The band should be adjustable due to fluctuations in size over the course of the day 
N/A - last time commented about an adjustable band but band fit fine this time. No discomfort at 
all. 
a little difficult  to find clothes to fit outside of the sampler.   The light was green on sampler i 
hope it was ok.  
did not reply all questions 
a bit loud noise particularly when sitting in a lecture or meeting the people may notice  a bit 
warm, i was sweating 
i sleep normally restless and also i snore a lot.  However with the sampler attached it was even 
worse i could not find position for sleeping.  
it was 3rd time with the sampler on . the sampler is smaller and that helped to live with it. Needed 




Comments (reported verbatim) 
The device should be rectified, especially with regard to ambulatory use.  
it felt like the sampler was in the way when driving, but something went out when i was fully 
focused on driving 
short tubings, managed to tag it, very bad sleeping, participant was very worried about the 
sampler. 
slept with earphones 
"I felt I had to be extra careful with every step I made. The sound gave me nightmares.  
i was worried that i may had destroyed something 
a bit big 
no problem with sampler when i was still, it was difficult when i was doing something and do my 
usual routines 
the need for a more comfortable belt 
the sampler is uncomfortable 
i could have thought about the position of the sampler if i had gotten the info earlier. too short 
tubings, i think it was very difficult to do daily routines and normal things, difficult to bend over 
and play with my kid, i had to be very careful with the black belt.     note of recording person:   
missing answer to last question 
it is big. Could not it be placed more up on the body? i think it was very difficult to go to toilet, 
sitting on a sofa, to get off and on a car.       note of recording person : missing two answers 
it was big and bulky to have it on. Difficult to bend over, do some home activity, i was worried that 
i may destroy it. Could it be better to put it more up on the body? I struggled to go to toilet  and 
put clothes on and off.  
i was worried all the time that i may damage something 
Having trialled the device when used in a bum-bag, in comparison the waist band and compact 
machine is much more comfortable and I barely noticed it was there unless the machine pump 
come on. 
i think it was too big the sampler, had a problem to bend over and i was worried that i may have 
damaged the tubes 
not practical the box with the sampler, size of the sampler and the belt were very unpleasant 
the sampler is bothersome big og bulky. A bit hanging on the tubes, it was difficult to move and sit 
down without bend/ kink tubes/ lines 
a big sampler 
 it was too big and i was worried that i may kink the tubings since the sampler was a bit moving by 
itself 
needed to watch the sampler all the time, i could not bend over, difficulties at work.   i could not 
have the sampler on me at work since i work in nursery but i think it was sitting on me better than 
last time 
simple life with the sampler, only issue to go to toilet. Could not have had it on when i was at work 
when i had a  lot of  coming in or out.  
i needed a bit longer period to fall asleep than usual  
1. a bit painful when attaching.  2. difficult with small kid.  3. struggled to find a good position for 
sleeping 
it would be better to heave the box on the stomach, it was very difficult to have it on a hip side, 
heavy and big. 
it would have been an advantage when the sampler would sitting on me more tight. it made me 
nervous the entire period to doublecheck the position.  But it was sampling for entire day it was 
absolutely worth of it.    




Comments (reported verbatim) 
Conscious of kinking the probe, made it a bit difficult to bend to pick up things off the floor and sit 
at my desk. I was worried about bending it, otherwise fairly comfortable. 
Plastic film covered my belly button & after a few hours became quite itchy - had to peel back the 
film in order to air it and scratch it! Otherwise, all fine and comfy.  
the sampler is a little big and make some noise, a little hard to sleep with this, by not sure about it, 
whether i slept bad because of the sampler or another thing 
should have been placed in the middle on the stomach area not on side  diffucult to roll over in 
the night since you had to stay on one side  it would be ok to take a shower with a little help of 
someone to cover the sampler, it may be still placed on an dry area    
Easier than expected & more comfortable 
it should have been little bit smaller, it was difficult to bend over to put socks on etc. 
Q2 The device is quite bulky  Q7 It was reassuring to hear the buzz! 
I would like the sampling device to be smaller 
I found the experience pain free, comfortable and not restrictive to my daily activities - would be 
happy to participate again. 
i needed some help , but the investigation went on  
i felt limited in my moving and  worried  that i may  bend/kink the membrane 
it's very bulky!! 
short tubings gave me problem with moving      note of recording person:  one question was not  
replied 
it was big, diffucult when moving and  do something, worried that i may tear off the tubes or pull 
them. It should have had longer tubes.  
it was difficult to do usual things, i planned be at working as usually and it did not work. very 
stinging between 18-2100.  
interesting and educational 
interesting  
it was a bit painfull and uncomfy 
Before the research I was very nervous but it all went smoothly and I am happy to have 
participated  
Normal movement is difficult without pulling on the probe and causing a small sting. Therefore I 
would no attempt much movement if I were to wear again. 
Would have been good to have been able to loosen the belt for dressing/undressing. Able to cycle 
comfortably wearing belt & device. 
As a prototype it's rather bulky - Hopefully a slimmer model will be forthcoming 
having done this twice now - the position & height of insertion makes a difference 
I did not sleep much with the sampler on however, I get nights where I do not sleep well 
Thank you so much so supportive 
Just a little awkward in the sitting position otherwise no problems 
A bit difficult to cycle with it - Otherwise fine 
A way of reducing sampler noise would be an improvement 
The weight of the sampler was slightly uncomfortably against hip bone when lying on back at 
night 
The size is problematic 
The only negative was you couldn´t shower with the prob and belt. Otherwise simple and flexible 
to carry.   




Comments (reported verbatim) 
Difficult to sit, if not leaned back. All positions which included that stomach and thigh squeezed 
the sampler or the catheters. then the belt goes up and covers the tube and squeeze the 
membrane inside my stomach. The sampler needs to be smaller and the connections safer and 
more hidden so I could perform my Daily activities. With low cut trousers underneath the belt and 
a big t-shirt it could easily be used anytime. 
Easy to happen to squeeze the catheter when siting 
Difficult to sit upright and to take on and off sock, trousers etc, Everything below waist-line. 
Only issue is being unable to carry out normal exercise wearing it. 
Just a bit awkward with clothing worrying about the leads 
The catheter between stomach and sampler is not covered and very easy to remove. Should be 
able to improve with some kind of larger tube. 
A bit bulky (that made bending over to pick things up harder) at night I could feel the weight of 
the device - but not too uncomfortable. 
OK, but almost dropped my trousers  
Water proof? Need to shower after a day wearing the devise 
i would prefer a smaller device 
Some difficulties sitting up and also going to the toilet. The belt was a Little loose over time. The 
catheters felt short and I worried about them, Would be good if you could move the device 
yourself a bit to be able to sleep better. 
Comfortable, somewhat difficult to relax as I have Young children at home who might touch the 
sampler 
The sampler is rather big and bulky. Gets rather hot against the skin behind the sampler 
It doesn't work to sit in cough without discomfort. Chair works fine. Difficult to do rotary 
movements. 
The catheter could easily break 
Better than the cannula 
3: i felt that i had to be more careful   7: i thought i may tear off it when i was falling asleep when 
night started  
this is a very good basicaly for a lot of talks and a lot of people may be recruited for this study 
The sampler fell out of the belt a couple of times 
Fairly comfortable - Most uncomfortable when walking. Got very used to it as time went on. 
it was big and and heavier when on the body. The attaching procedure took very long time and 
too low on my body, on a side and i may say when i was in bed. I had a problem to sleep. 
Otherwise ok.  
to find a procedure to manufacture better sampler and decrease price of the pump  
in the future would be good to develop much user-friendly device 
Overall no difficulties. The device could of course be a little smaller, and be assembled more 
stable. Somewhat bulky, men not very much. 
a bit big and bulky. i was worried that the tubings, lines and membrane may loose.  
The only pain was the second puncture of the needle on insertion. 
If the sampler was placed a bit higher up it would be easier to sit. 
Too big device. and bulky to carry during the day, worried that i may destroy it 
I had to lower my chair so I could get under my desk 
I had to lower my desk chair to enable me to sit at my desk properly. Just for a straight desk, it 
was fine against a curved desk. 





Comments (reported verbatim) 
- Should've shaved more hair off my belly - Gets in the way of sitting and bending over 
Hard to bend over, otherwise fine 
It is slightly difficult when dressing/using the toilet or bending down, but for a day or two, doesn't 
significantly interfere. 
I wear ear plugs anyway, so no problem sound wise, but sleep was an issue. I drive for work or am 
sat down so it was quite hard to do things. I didn't have a negative experience - it is what it is :) 
Thanks 
Was surprised by some of the noises recommend making people aware of them at fitting stage. 
Awkward with car seat belt. 
Purely the issue around driving with the device in place. May want to use diary to establish when 
and for how long they were using a seat belt in a car for whilst wearing the device, 
Spent a total of one hour driving which I recorded in case it lead to undue pressure on the sensor. 
I am not sure if I should go back to sleep when I've already been awake for a period. Overall it's 
good 
Only difficulty was when driving, sitting position and wearing of the belt 
Last time I experienced small discomfort driving, none this time 
Found it to be more comfortable wearing it with regular trousers; with a belt. Also, some feedback 
questions were a bit confusing with double negative meanings (for a non-native species) 
tiring to watch the sampler, a lot of things might destroy the sampler, i was worried about the 
tubings- ref to nr3.  
to many things that may destroy the sampling 
A bit sweaty otherwise fine. It would be ideal to shower with the device in future 
It could be less hot and sticky.  Ideal if it was waterproof 
Waterproof it please. 
It is difficult to get dressed because the wires are very delicate 
Slight pain only when going up/downstairs after having machine on for approx. 5 hrs 
Sampling device was hassle free, only thing that was slightly annoying is that the device would ride 
up every time  I sat  down so perhaps a pouch that was non slip would be better than the running 
pouch. 
it was limiting me in my activities, bending over, sleeping, i also would need to have it in higher 
position on my stomach next time.  
problem with sampler  when sitting in his car .   
The catheter was located in the waist that when sitting down folds, clamping? A bit worried about 
the thin catheters and especially in night-time. Risk to stuck. But OK to participate :) 
i would have had in on the left side, troubles when car driving 
Comment on Question number 8: because of the time required - hard to sqeeze into work 
calendar. 
Very easy to wear. No problem with the noise 
nr3. not possible to exercise and could not sleep in my usual position on stomach,  nr 2, i felt the 
membrane under my skin 
too big 
The Microdialysis pump slide out of the girdle in the morning. Quickly Catch it and put it back in 
the girdle. 
No problems easy to sleep wearing it. 
Sitting becomes more complicated with the device 
Having blood taken was the best I've ever had - no pain at all. Putting the probe in was very quick 




Comments (reported verbatim) 
I was nice to help other people. Jade was very friendly and put me at my ease. 
Woke up in the night because of the squeeze from the sampler. The squeeze caused I was needed 
go to toilet (Pee). The Daily activities I could't implement was physical exercise. 
It felt big, a bit unsecure to have the tubes hanging free. Afraid them get stuck in something 
Pretty straightforward & easy. 
More information about the procedure 





9.6 Appendix F  







Purpose of sampling 
Clinical trial 
Bench test 
Problem or issue(s) to report [multiple] 
Missing or incorrect number of samples 
High number of samples containing micro bubbles 
Merged samples 
Short samples 
Sampler ticking sound absent when connected to pump 
Sampler makes ticking noise when not connected 
Debris seen in or exiting manifold 
Poor air bubble separation 
Cloudy interconnection tube 
Loose manifold inlet tube 
Sampler makes loud whirring noise 
Slide or push buttons not working 
Rattling noise coming from inside sampler 
Other 
Sampling ID 
Microdialysis Pump ID 
PUMP [confirm all] 
Correct rate set on pump 1.0ul/min 
Battery in date and <10 uses 
Pump lid intact with no broken parts 
Syringe contained appropriate volumes at start and end of sampling 
Pump serviced within past 2 years 
Other 
CONNECTIONS [confirm all] 
FEP was prefitted to sampler with silicon coating 
Pink/green connector intact at end of sampling 
Pink MAB connector fitted correctly to inlet 
Click'n'Seal microfitting attached correctly 
Waistband type 
Device used 
Sampler checks [confirm] 
New AA lithium batteries used 
Device had been cleaned as per SOP 
Sampler was quiet/silent at power on 
Sampler RESET was confirmed 
Sample was seen within manifold tubing within first 2 hours of sampling 





Probe insertion and removal checks 
Local anaesthetic was used 
Complications (describe in 'other') 
Bruising or bleeding at probe site seen 
Probe appeared intact when removed 
Spool checks 
Spool was clamped and allowed to equilibrate as per SOP 
Samples identified and measured 
Spool sheet photographed as per recommended procedure 
Spool length 
Have you identified the cause for the sampling failure? 
Provide any further details 
Table 9-6 Form data used to capture issues related to sampling problems in the ULTRADIAN clinical trial. Respondents 
were required to confirm if standard operating procedure had been followed, and any further information that might help 





9.7 Appendix G 
9.7.1 Protocols for ‘tube blocking’ with methylprednisolone 
9.7.1.1 Items required 
1. 5.0 metres lengths of PTFE spool tubing 
2. FEP tubing 
3. Methylprednisolone as sodium succinate. Each vial of powder contains methylprednisolone 
sodium succinate 1326.0 mg equivalent to 1000 mg of methylprednisolone. After 
reconstitution in water for injections, each ml of solution contains the equivalent of 59.6 mg 
of methylprednisolone. Each vial of solvent contains 15.6 ml of water for injection. 
4. Phosphate buffered saline for dilution 
5. 5mL Terumo luer lock syringes with blunt metal luer lock needle 
6. Nitrogen gas cylinder + regulator + tubing adaptor 
9.7.1.2 Procedure 
1. Reconstitute methylprednisone with water for injection as directed (15.6mL). Each mL of 
solution will contain 59.6mg methylpred 
a. To achieve target concentration of 1000 micromol/litre methylprednisolone 
i. MW 374.471 gram/mol 
ii. 1 molar = 374.471g/litre 
iii. 1000 micromol = 374.471mg/litre 
b. For 100ml of 1000 micromolar solution – need 37.447mg methylpred 
i. Since 59.6mg/mL need 0.628mL of methylpred solution 
ii. Add 0.628mL to 99.371 mL of PBS 
iii. i.e. take 630microL out of 100mL PBS and replace with 630microl methylpred 
solution 
2. Fill spool tubing  
a. Draw 5.0mL of methylprednisolone solution into syringe 
b. Attach blunt needle to PTFE tubing ensuring snug fit 
c. Use Harvard Apparatus syringe driver to push solution into tubing 
i. Volume of 5.0m of spool tubing  
1. = π x 0.5mm2 x 5000mm 
2. = 3926.9microlitres or 3.93mL 
ii. Infusing at 20 microl/min = 1200microl/hour = approximately 3.3 hours to fill 
tubing 
iii. Continue to infuse for 4.2 hours to complete 5.0mL volume 
d. Leave spool with methylpred solution to incubate at bench/room temperature for 48 
hours 
3. Dry spool tubing 
a. Expel methylprednisolone solution using air filled syringe and syringe driver 
b. Connect nitrogen gas outlet to end of spool tube and perfuse tubing with nitrogen gas 
until all liquid is expelled and tubing appears dry  
c. Used 6 PSI pressure for 30 minutes/spool  
4. Incubate FEP tubing 
a. Draw up methylprednisolone into a 1ml syringe with blunt needle attachment 
b. Use a pink FEP connector to attach blunt needle to FEP 




9.7.2 Protocol for ‘tube blocking’ with Pluronic® F127 (poloxamer 407) 
Poloxamer 407 is a hydrophilic non-ionic surfactant of the more general class of copolymers 
known as poloxamers.  
9.7.2.1 Items required 
1. 5.0 metres lengths of PTFE spool tubing 
2. FEP tubing 
3. Pluronic® F127 powder 
4. Phosphate buffered saline for dilution 
5. 5mL Terumo luer lock syringes with blunt metal luer lock  
6. Nitrogen gas cylinder + regulator + tubing adaptor 
9.7.2.2 Procedure 
1. Prepare a 5% w/v Pluronic® solution 
a. For each 100g PBS, add 5g of Pluronic powder and stir to dissolve. Note that 
Pluronic® dissolves more easily if the solution is warmed in a water bath at 60°C 
2. Fill spool tubing  
a. Draw 5.0mL of Pluronic® solution into syringe 
b. Attach blunt needle to PTFE tubing ensuring snug fit 
c. Use Harvard Apparatus syringe driver to push solution into tubing 
i. Volume of 5.0m of spool tubing  
1. = π x 0.5mm2 x 5000mm 
2. = 3926.9microlitres or 3.93mL 
ii. Infusing at 20 microl/min = 1200microl/hour = approximately 3.3 hours to fill 
tubing 
iii. Continue to infuse for 4.2 hours to complete 5.0mL volume 
d. Leave spool with Pluronic® solution to incubate at bench/room temperature for 48 
hours 
e. Rinse with Millipore water as per step 2c, then with air again as per 2c 
3. Dry spool tubing 
a. Connect nitrogen gas outlet to end of spool tube and perfuse tubing with nitrogen gas 
until all liquid is expelled and tubing appears dry  
b. Used 6 PSI pressure for 30 minutes/spool  
4. Fill FEP tubing 
a. Draw up Pluronic® into a 1ml syringe with blunt needle attachment 
b. Use a pink FEP connector to attach blunt needle to FEP 
c. Gently fill lengths of FEP with Pluronic® and allow to incubate for 24-48 hours 
d. Rinse with Millipore water 
e. Dry with air 
9.7.3 Protocol for testing adsorption properties  
9.7.3.1 Equipment 
1. 2 x U-RHYTHM 1.x samplers 
2. 6 x 5.0m PTFE spools prepared as below 




4. Normal saline for dilution 
5. 300 µL polypropylene PCR vials 
6. Waters 96-well plate + silicone mat cover 
7. 2.5mL syringes, FEP tubing, luer lock blunt needles 
8. Tubing adaptors 
9.7.3.2 Spools 
1. Incubate and label spools x2 (methylprednisolone 1000microlmol/L or 5% poloxamer 407 
as described in I. and II. above). Label these spools 2 and 3 
2. Label 2 standard untreated 5.0m spools 1 and 4 
3. Sampler 1 – Spool 1 and 3 
4. Sampler 2 – Spool 2 and 4 
9.7.3.3 Prepare samplers 
1. Clean 2 samplers with  
a. isopropyl alcohol 0.5mL @ 5microl minute, 
b. then Millipore water 0.5mL  
c. then air 0.5mL @ 5microl minute 
2. Fill manifold of Sampler 1 with either methylprednisolone or poloxamer solution 
@5uL/min, leave to incubate overnight 
3. Expel contents with air @ 5microl/min 
4. Load Sampler 1 with Spool 1 and Sampler 2 with Spool 2 
5. Fix 25cm of FEP tubing to each sampler 
9.7.3.4 Prepare hydrocortisone solution for infusion 
1. 100 µlitres of hydrocortisone ampoule 
(100mg/mL) + 9.90mL saline 
2.76mmol/L 
2. 100 microlitres of (1) + 9.90mL saline 27.6µmol/L 
3. 100 microlitres of (1) + 9.90mL saline 276nmol/L 
4. 360µL of (3) + 9.64ml saline 9.94nmol/L 
9.7.3.5 Method 
1. Fill 2 x 5mL Terumo luer lock syringe with 4.5mL hydrocortisone solution [sufficient for 
54 hours sampling], connect to luer lock adapted probe tubing and flush through 
2. Connect syringe/tube sampler to FEP with MAB adaptor 
3. Perfuse samplers at 1µL/min for 27hours using standard Harvard Apparatus infusion 
protocol (0.5µL delivered every 30 seconds) 
4. At 27 hours, pause method,  
5. Clamp and swap spool 3 into Sampler 1 and spool 4 into Sampler 2.  
6. Continue for further 27 hours sampling 
7. Clamp and equalise spool 3 and 4. 
9.7.3.6 Retrieval of samples from spool 
1. For each spool, mark and identify: 
a. First 16 sequential samples (5 hours 20 minutes) 
b. Final 6 sequential samples (2 hours) 
2. Decant all samples into standard (untreated) PCR vials and then transfer 10 µL into 





9.8 Appendix H  
9.8.1 Standardised meals provided to participants during 24-hour sampling sessions 
9.8.1.1 Breakfast 
Cornflakes Simply M&S 30g 
Semi skimmed Milk 200mL 
Supersoft Wholemeal Thick Sliced bread, M&S - toasted 
Lurpak Slightly Salted spreadable butter 10g x 2 
Tiptree strawberry jam 28g 
9.8.1.2 Lunch 
M&S Farmhouse Cheddar cheese ploughman’s sandwich 
Medium apple 130g approx.. 
M&S Count On Us low fat sour cream and chive baked potato 
crisps 25g 
9.8.1.3 Dinner 
M&S Spaghetti Bolognese 400g 
M&S Low fat strawberry yoghurt pot 150g 
M&S Fruit Salad 185g  
9.8.1.4 Snack 
M&S digestive biscuits (2 given) 





9.9 Appendix I 
9.9.1 Performance of the ULTRADIAN serum and plasma assay 
Compound LoQ   Accuracy (%)   RSD Total (%)   RSD wtn(%) 
18oxoF 46 pM 
 
97 - 100 
 
5.5 - 7.7 
 
4.7 - 5.5 
18OHF 46 pM 
 
96 - 99 
 
4.4 - 7.2 
 
3.6 - 4.7 
Cortisol 0.9 nM 
 
98 - 100 
 
2.8 - 5.8 
 
1.6 - 4.5 
Cortisone 0.9 nM 
 
94 - 104 
 
3.3 - 5.0 
 
2.2 - 3.7 
Aldo 6.9 pM 
 
95 - 98 
 
5.6 - 6.2 
 
2.4 - 4.6 
21DOC 69 pM 
 
95 - 97 
 
5.4 - 9.0 
 
2.2 - 7.9 
CCS 114 pM 
 
95 - 101 
 
4.7 - 7.4 
 
2.7 - 5.1 
11DOC 114 pM 
 
97 - 101 
 
4.4 - 6.2 
 
2.6 - 4.0 
aTHF 0.34 nM 
 
93 - 97 
 
5.3 - 7.4 
 
1.8 - 3.0 
THF 0.34 nM 
 
94 - 96 
 
4.5 - 6.1 
 
2.9 - 3.3 
aTHE 1.03 nM 
 
104 - 108 
 
5.7 - 10.2 
 
2.6 - 3.6 
THE 1.03 nM 
 
105 - 107 
 
5.4 - 10.9 
 
2.8 - 5.4 
DXM 23 pM 
 
96 - 109 
 
5.6 - 19.7 
 
1.9 - 18.1 
Andro 206 pM 
 
95 - 100 
 
5.5 - 6.2 
 
2.9 - 5.5 
Testo 23 pM 
 
95 - 109 
 
2.7 - 6.2 
 
0.5 - 2.2 
DHEAS 69 pM 
 
90 - 101 
 
5.5 - 6.6 
 
3.5 - 4.1 
DHEA 617 pM 
 
96 - 96 
 
6.0 - 6.3 
 
1.2 - 2.9 
17OHP 114 pM 
 
97 - 101 
 
4.1 - 6.3 
 
2.5 - 4.4 
epiTesto 23 pM 
 
96 - 109 
 
3.9 - 6.5 
 
0.0 - 3.3 
DHT 206 pM 
 
94 - 97 
 
5.0 - 6.4 
 
2.5 - 3.6 
Prog 114 pM 
 
98 - 101 
 
2.4 - 4.6 
 
1.3 - 2.5 
11deoxyCCS 23 pM 
 
95 - 109 
 
3.9 - 8.5 
 
1.8 - 4.0 
THAldo 185 pM 
 
102 - 108 
 
9.8 - 10.6 
 
4.3 - 7.0 
THCCS 3.08 nM 
 
96 - 99 
 
5.2 - 6.8 
 
3.6 - 4.0 
Table 9-7 Method validation of the ULTRADIAN multiplex steroid panel in serum and plasma. Data were generated by 
repeated analysis of 6 replicate samples over a period of 8 days. Samples contained hormone concentrations from low to 
very high. LoQ = limit of quantification. Accuracy is determined vs. internationally certified reference materials (where 
available) or at least two independently prepared dilutions of certified material in serum. Precision is reported as the 
relative standard deviation (RSD) total (within batch + between batch precision) and within (RSD wtn) (Data supplied by 





9.10 Appendix J 
9.10.1 ULTRADIAN Microdialysis adrenal steroid hormone assay 
Steroid Hormone Measuring range Total 
Precision 
Accuracy 
Cortisol 0.067 – 50 nM <5.6 100 – 108 
Cortisone 0.067 – 50 nM <4.4 100 – 108 
11DOC 21 – 5000 pM <3.5 99 – 105 
21DOC 21 – 5000 pM <12.7 102 – 105  
THF 0.21 – 50 nM  <6.0 99 – 108  
aTHF 0.21 – 50 nM <5.8 100 – 106 
THE 0.21 – 50 nM <10.5 102 – 104 
aTHE 0.21 – 50 nM <11.4 103 – 108 
Aldosterone 6.7 – 5000 pM < 4.2 101 – 108 
Corticosterone 21 – 5000 pM < 4.9 98 – 105 
11-deoxycorticosterone 21 – 5000 pM < 4.8 98 – 104 
Tetrahydro-aldosterone 21 – 5000 pM < 9.3 101 – 105 
Testosterone 6.7 – 5000 pM < 4.6 99 – 105 
Androstenedione 21 – 5000 pM < 6.5 98- 100 
17OH-Progesterone 21 – 5000 pM < 9.8 98 – 108 
Dihydrotestosterone 6.7 – 5000 pM < 12.3 98-101 
DHEA 185 – 5000 pM < 11.4 97 - 102 
DHEAS 500 -5000 pM < 8.1 101 – 103 
Epi-testosterone 61 – 5000 pM < 6.2 97 – 107 
Progesterone 21 – 5000 pM < 6.3 96 – 105 
Dexamethasone 6.7 – 5000 pM < 8.1 99 – 108 
Tetrahydrocorticosterone 61 – 5000 pM < 16.8 100 - 103 
18oxo-cortisol 21 – 5000 pM < 5.9 95 – 106 
18OH-cortisol 21 – 5000 pM < 7.0 99 – 108 
Table 9-8 ULTRADIAN adrenal steroid hormone assay. Total precision is the sum of intrabatch precision + between 
batch precession, and expressed as a percentage relative standard deviation (SD/mean of repeated measures). Accuracy 
is bias of the assay compared with international reference standard and expressed as measured concentration/nominal 
concentration). Data supplied by Dr Paal Methlie, ULTRADIAN analysing Unit, Haukeland University Hospital, Bergen, 
Norway. 
9.10.1.1 A note about aTHE: 
5-alpha-THE (aTHE, alloTHE) is uncommonly reported; however a method for its detection in 
urine has been published 342 and also implemented in analysis of serum 167. Nevertheless, 
levels in tissue microdialysate were below the lower level of quantification and not included 






Figure 9-4 Example of assay precision for cortisol and 11-deoxy-cortisol (11DOC). The same quality control sample was 






9.11 Appendix K 
9.11.1 Comparison of hormones recovered in simultaneous plasma and microdialysis sampling 
 18oxoF 18OHF Aldo Cortisol Cortisone 18OHCCS DHEAS 21DOC 11DOC CCS aTHF THF aTHE THE 
1 0.0% 98.6% 100.0% 98.6% 98.6% 0.0% 98.6% 37.5% 80.6% 98.6% 98.6% 98.6% 73.6% 98.6% 
2 8.3% 100.0% 100.0% 100.0% 100.0% 0.0% 100.0% 43.1% 100.0% 100.0% 100.0% 100.0% 94.4% 98.6% 
3 0.0% 100.0% 100.0% 100.0% 100.0% 0.0% 100.0% 30.4% 100.0% 100.0% 100.0% 100.0% 89.3% 100.0% 
4 5.8% 100.0% 100.0% 100.0% 100.0% 2.9% 100.0% 21.7% 73.9% 100.0% 100.0% 100.0% 100.0% 100.0% 
 THAldo Andro 11deoxyCCS Testo DHEA 17OHP EpiTesto DHT Prog      
1 0.0% 98.6% 51.4% 93.1% 98.6% 98.6% 97.2% 0.0% 80.6%      
2 0.0% 100.0% 34.7% 94.4% 98.6% 100.0% 100.0% 0.0% 38.9%      
3 0.0% 100.0% 94.6% 94.6% 100.0% 100.0% 100.0% 0.0% 98.2%      
4 2.9% 100.0% 14.5% 95.7% 100.0% 100.0% 100.0% 2.9% 4.3%      
Table 9-9 Percentage of plasma samples containing valid measurements for each analyte in the ULTRADIAN multiplex steroid panel, n=4 participants, n=72 samples. Cells are colour 
coded: Green >75% of samples, yellow 50-75%, red <50% of samples. 
 18oxoF 18OHF Aldo Cortisol Cortisone 18OHCCS DHEAS 21DOC 11DOC CCS aTHF THF aTHE THE 
1 0.0% 83.3% 55.6% 98.6% 98.6% 91.7% 98.6% 0.0% 0.0% 94.4% 94.4% 93.1% 2.8% 91.7% 
2 0.0% 100.0% 93.1% 100.0% 100.0% 98.6% 100.0% 0.0% 0.0% 98.6% 100.0% 100.0% 0.0% 45.8% 
3 0.0% 100.0% 95.8% 98.6% 98.6% 45.8% 98.6% 98.6% 80.6% 93.1% 47.2% 55.6% 0.0% 22.2% 
4 0.0% 100.0% 20.0% 100.0% 100.0% 85.0% 100.0% 0.0% 21.7% 91.7% 100.0% 100.0% 65.0% 15.0% 
 THAldo Andro 11deoxyCCS Testo DHEA 17OHP EpiTesto DHT Prog      
1 0% 0% 0% 1% 0% 0% 0% 0% 0%      
2 0% 0% 0% 0% 0% 0% 0% 0% 0%      
3 0% 0% 11% 0% 0% 3% 0% 0% 1%      
4 0% 0% 0% 0% 0% 0% 0% 0% 0%      
Table 9-10 Percentage of microdialysis samples containing valid measurements for each analyte in the ULTRADIAN multiplex steroid panel n=4 participants, n=72 samples. Cells are 




9.12 Appendix L 
9.12.1 Lists of metabolites 
9.12.1.1 Biocrates AbsoluteIDQ® p180 targeted metabolomics kit
Metabolite:  




























































































 lysoPC a C14:0 
lysoPC a C16:0 
lysoPC a C16:1 
lysoPC a C17:0 
lysoPC a C18:0 
lysoPC a C18:1 
lysoPC a C18:2 
lysoPC a C20:3 
lysoPC a C20:4 





lysoPC a C26:0 
lysoPC a C26:1 
lysoPC a C28:0 
lysoPC a C28:1 
PC aa C24:0 
PC aa C26:0 
PC aa C28:1 
PC aa C30:0 
PC aa C32:0 
PC aa C32:1 
PC aa C32:3 
PC aa C34:1 
PC aa C34:2 
PC aa C34:3 
PC aa C34:4 
PC aa C36:0 
PC aa C36:1 
PC aa C36:2 
PC aa C36:3 
PC aa C36:4 
PC aa C36:5 
PC aa C36:6 
PC aa C38:0 
PC aa C38:3 
PC aa C38:4 
PC aa C38:5 
PC aa C38:6 
PC aa C40:1 
PC aa C40:2 
PC aa C40:3 
PC aa C40:4 
PC aa C40:5 
PC aa C40:6 
PC aa C42:0 
PC aa C42:1 
PC aa C42:2 
PC aa C42:4 
PC aa C42:5 
PC aa C42:6 
PC ae C30:0 
PC ae C30:1 
PC ae C30:2 
PC ae C32:1 
PC ae C32:2 
PC ae C34:0 
PC ae C34:1 
PC ae C34:2 
PC ae C34:3 
PC ae C36:0 
PC ae C36:1 
PC ae C36:2 
PC ae C36:3 
PC ae C36:4 
PC ae C36:5 
PC ae C38:0 
PC ae C38:1 
Metabolite:  
PC ae C38:2 
PC ae C38:3 
PC ae C38:4 
PC ae C38:5 
PC ae C38:6 
PC ae C40:1 
PC ae C40:2 
PC ae C40:3 
PC ae C40:4 
PC ae C40:5 
PC ae C40:6 
PC ae C42:0 
PC ae C42:1 
PC ae C42:2 
PC ae C42:3 
PC ae C42:4 
PC ae C42:5 
PC ae C44:3 
PC ae C44:4 
PC ae C44:5 
PC ae C44:6 
Sphingomyelins (15) 
 
 SM (OH) C14:1 
SM (OH) C16:1 
SM (OH) C22:1 
SM (OH) C22:2 














9.12.1.2 Metabolites with substantial change at ambient temperature













lysoPC a C20:4 +26.8 
lysoPC a C20:3 +25.5 
PC ae C38:1 +23.7 
PC ae C36:0 -21.4 
lysoPC a C18:0 -23.7 
lysoPC a C28:0 -29.1 
lysoPC a C24:0 -29.7 
lysoPC a C26:1 -30.8 
PC aa C36:0 -31.1 
PC aa C24:0 -34.2 
lysoPC a C26:0 -35.8 
Table 9-11 Metabolites with substantial changes after 
48 hours at ambient temperature. Substantial change 





Metabolites recovered during in vivo plasma and microdialysis sampling sessions 
Compound PLASMA1 PLASMA 2 PLASMA 3 IF1 IF2 IF3 
AC C0 C0 C0 C0 C0 
 
AC C2 C2 C2 C2 C2 C2 
AC C3 C3 C3 C3 
  
AC C3:1 
     
AC C4 C4 C4 C4 
  




     
AC C9 C9 C9 
   
AC C14:1 C14:1 C14:1 
   
AC C16 C16 C16 
   
AC C18 C18 C18 
   
AC C18:1 C18:1 C18:1 
   
AA Alanine Ala Ala Ala Ala 
 
AA Arginine Arg Arg Arg Arg 
 
AA Asparagine Asn Asn Asn Asn 
 
AA Citrulline Cit Cit Cit Cit 
 
AA Glutamine Gln Gln Gln Gln 
 
AA Glutamate Glu Glu Glu 
  
AA Glycine Gly Gly Gly Gly 
 
AA Histidine His His His His 
 
AA Isoleucine Ile Ile Ile Ile 
 
AA Leucine Leu Leu Leu Leu 
 
AA Lysine Lys Lys Lys Lys 
 
AA Methionine Met Met Met Met 
 
AA Ornithine Orn Orn Orn Orn Orn 





Compound PLASMA1 PLASMA 2 PLASMA 3 IF1 IF2 IF3 
AA Proline Pro Pro Pro Pro 
 
AA Serine Ser Ser Ser Ser 
 
AA Threonine Thr Thr Thr Thr 
 
AA Trytophan Trp Trp Trp 
  
AA Tyrosine Tyr Tyr Tyr Tyr 
 












BA Creatinine Creatinine Creatinine Creatinine Creatinine Creatinine 




Methionine-sulfoxide Met-SO Met-SO 
  




SDMA SDMA SDMA SDMA SDMA 
BA Serotonin 
     
BA Trans-4-
hydroxyproline 




BA Taurine Taurine Taurine Taurine Taurine Taurine 
BA 
 
Dihydroxyphenylalanine DOPA   
  
GC lysoPC a C16:0 lysoPC a C16:0 lysoPC a 
C16:0 
   
GC lysoPC a C16:1 lysoPC a C16:1 lysoPC a 
C16:1 
   
GC lysoPC a C17:0 lysoPC a C17:0 lysoPC a 
C17:0 
   
GC lysoPC a C18:0 lysoPC a C18:0 lysoPC a 
C18:0 




Compound PLASMA1 PLASMA 2 PLASMA 3 IF1 IF2 IF3 
GC lysoPC a C18:1 lysoPC a C18:1 lysoPC a 
C18:1 
   
GC lysoPC a C18:2 lysoPC a C18:2 lysoPC a 
C18:2 
   
GC lysoPC a C20:3 lysoPC a C20:3 lysoPC a 
C20:3 
   
GC lysoPC a C20:4 lysoPC a C20:4 lysoPC a 
C20:4 
   
GC lysoPC a C24:0 lysoPC a C24:0 lysoPC a 
C24:0 
   
GC lysoPC a C26:0 lysoPC a C26:0 lysoPC a 
C26:0 
   
GC lysoPC a C26:1 lysoPC a C26:1 lysoPC a 
C26:1 
   
GC lysoPC a C28:0 lysoPC a C28:0 lysoPC a 
C28:0 
   
GC lysoPC a C28:1 lysoPC a C28:1 lysoPC a 
C28:1 
   
GC PC aa C24:0 PC aa C24:0 PC aa C24:0 
   
GC PC aa C28:1 PC aa C28:1 PC aa C28:1 
   
GC PC aa C30:0 PC aa C30:0 PC aa C30:0 
   
GC PC aa C32:0 PC aa C32:0 PC aa C32:0 
   
GC PC aa C32:1 PC aa C32:1 PC aa C32:1 
   
GC PC aa C32:2 PC aa C32:2 PC aa C32:2 
   
GC PC aa C32:3 PC aa C32:3 PC aa C32:3 
   
GC PC aa C34:1 PC aa C34:1 PC aa C34:1 
   
GC PC aa C34:2 PC aa C34:2 PC aa C34:2 
   
GC PC aa C34:3 PC aa C34:3 PC aa C34:3 
   
GC PC aa C34:4 PC aa C34:4 PC aa C34:4 




Compound PLASMA1 PLASMA 2 PLASMA 3 IF1 IF2 IF3 
  PC aa C36:0 PC aa C36:0    
GC PC aa C36:1 PC aa C36:1 PC aa C36:1 
   
GC PC aa C36:2 PC aa C36:2 PC aa C36:2 
   
GC PC aa C36:3 PC aa C36:3 PC aa C36:3 
   
GC PC aa C36:4 PC aa C36:4 PC aa C36:4 
   
GC PC aa C36:5 PC aa C36:5 PC aa C36:5 
   
GC PC aa C36:6 PC aa C36:6 PC aa C36:6 
   
GC PC aa C38:0 PC aa C38:0 PC aa C38:0 
   
GC PC aa C38:3 PC aa C38:3 PC aa C38:3 
   
GC PC aa C38:4 PC aa C38:4 PC aa C38:4 
   
GC PC aa C38:5 PC aa C38:5 PC aa C38:5 
   






GC PC aa C40:2 PC aa C40:2 PC aa C40:2 
   
GC PC aa C40:3 PC aa C40:3 PC aa C40:3 
   
GC PC aa C40:4 PC aa C40:4 PC aa C40:4 
   
GC PC aa C40:5 PC aa C40:5 PC aa C40:5 
   
GC PC aa C40:6 PC aa C40:6 PC aa C40:6 
   
GC PC aa C42:0 PC aa C42:0 PC aa C42:0 
   
GC PC aa C42:1 PC aa C42:1 PC aa C42:1 PC aa C42:1 
  
GC PC aa C42:2 PC aa C42:2 PC aa C42:2 
   
GC PC aa C42:4 PC aa C42:4 PC aa C42:4 
   
GC PC aa C42:5 PC aa C42:5 PC aa C42:5 
   
GC PC aa C42:6 PC aa C42:6 PC aa C42:6 
   
GC PC ae C30:0 PC ae C30:0 PC ae C30:0 
   
GC PC ae C30:1 PC ae C30:1 PC ae C30:1 
   
GC PC ae C30:2 PC ae C30:2 PC ae C30:2 
   
GC PC ae C32:1 PC ae C32:1 PC ae C32:1 
   
GC PC ae C32:2 PC ae C32:2 PC ae C32:2 




Compound PLASMA1 PLASMA 2 PLASMA 3 IF1 IF2 IF3 
GC PC ae C34:0 PC ae C34:0 PC ae C34:0 
   
GC PC ae C34:1 PC ae C34:1 PC ae C34:1 
   
GC PC ae C34:2 PC ae C34:2 PC ae C34:2 
   
GC PC ae C34:3 PC ae C34:3 PC ae C34:3 
   
GC PC ae C36:0 PC ae C36:0 PC ae C36:0 
   
GC PC ae C36:1 PC ae C36:1 PC ae C36:1 
   
GC PC ae C36:2 PC ae C36:2 PC ae C36:2 
   
GC PC ae C36:3 PC ae C36:3 PC ae C36:3 
   
GC PC ae C36:4 PC ae C36:4 PC ae C36:4 
   
GC PC ae C36:5 PC ae C36:5 PC ae C36:5 
   
GC PC ae C38:0 PC ae C38:0 PC ae C38:0 
   
GC PC ae C38:1 PC ae C38:1 PC ae C38:1 
   
GC PC ae C38:2 PC ae C38:2 PC ae C38:2 
   
GC PC ae C38:3 PC ae C38:3 PC ae C38:3 
   
GC PC ae C38:4 PC ae C38:4 PC ae C38:4 
   
GC PC ae C38:5 PC ae C38:5 PC ae C38:5 
   
GC PC ae C38:6 PC ae C38:6 PC ae C38:6 
   
GC PC ae C40:1 PC ae C40:1 PC ae C40:1 
   
GC PC ae C40:2 PC ae C40:2 PC ae C40:2 
   
GC PC ae C40:3 PC ae C40:3 PC ae C40:3 
   
GC PC ae C40:4 PC ae C40:4 PC ae C40:4 
   
GC PC ae C40:5 PC ae C40:5 PC ae C40:5 
   
GC PC ae C40:6 PC ae C40:6 PC ae C40:6 
   
GC PC ae C42:1 PC ae C42:1 PC ae C42:1 
   
GC PC ae C42:2 PC ae C42:2 PC ae C42:2 
   
GC PC ae C42:3 PC ae C42:3 PC ae C42:3 
   
GC PC ae C42:4 PC ae C42:4 PC ae C42:4 
   
GC PC ae C42:5 PC ae C42:5 PC ae C42:5 
   
GC PC ae C44:3 PC ae C44:3 PC ae C44:3 




Compound PLASMA1 PLASMA 2 PLASMA 3 IF1 IF2 IF3 
GC PC ae C44:4 PC ae C44:4 PC ae C44:4 
   
GC PC ae C44:5 PC ae C44:5 PC ae C44:5 
   
GC PC ae C44:6 PC ae C44:6 PC ae C44:6 
   
SL SM (OH) C14:1 SM (OH) C14:1 SM (OH) 
C14:1 
   
SL SM (OH) C16:1 SM (OH) C16:1 SM (OH) 
C16:1 
   
SL SM (OH) C22:1 SM (OH) C22:1 SM (OH) 
C22:1 
   
SL SM (OH) C22:2 SM (OH) C22:2 SM (OH) 
C22:2 
   
SL SM (OH) C24:1 SM (OH) C24:1 SM (OH) 
C24:1 
   
SL SM C16:0 SM C16:0 SM C16:0 
   
SL SM C16:1 SM C16:1 SM C16:1 
   
SL SM C18:0 SM C18:0 SM C18:0 
   
SL SM C18:1 SM C18:1 SM C18:1 
   
SL SM C20:2 SM C20:2 SM C20:2 
   
SL SM C24:0 SM C24:0 SM C24:0 
   
SL SM C24:1 SM C24:1 SM C24:1 
   
SL SM C26:0 SM C26:0 SM C26:0 
   
SL SM C26:1 SM C26:1 SM C26:1 
   
SL 
      
 138 137 137 35 26 8 
TOTAL       
Table 9-12 Metabolites recovered during simultaneous plasma and microdialysis sampling in 3 healthy volunteers. The full names of the amino acids and biogenic amines are shown in the 





9.12.2 Effect of contact with U-RHYTHM system  
 U-RHYTHM U-RHYTHM Spool Spool QCend 
 
0-40 160-200 min Most time Least time 
 
Ala -15.1 -1.8 9.9 22.9 16.9 
Arg -31.6 -19.8 3.4 16.0 8.4 
Asn -22.7 -18.5 -18.5 0.0 16.3 
Asp -8.3 -1.7 12.6 26.1 17.0 
Cit -19.7 2.0 14.8 37.7 15.2 
Gln -31.9 -11.7 -1.2 18.5 0.6 
Glu 5.8 24.7 47.4 48.1 36.8 
Gly -8.6 -2.7 19.6 33.1 16.2 
His -25.2 -16.5 4.1 14.7 13.8 
Ile -19.0 -12.7 10.7 19.0 13.7 
Leu -12.4 -9.6 19.2 11.3 19.2 
Lys -28.3 -20.7 -1.0 18.0 6.6 
Met -10.3 -10.8 11.3 23.1 12.8 
Orn -23.7 -11.1 11.1 25.8 6.3 
Phe -14.3 -12.1 14.3 20.1 12.9 
Pro -31.8 -8.6 26.3 23.2 18.9 
Ser -13.0 -14.9 7.9 23.7 14.0 
Thr -14.6 -8.5 2.7 16.2 14.2 
Trp -15.9 -15.0 4.1 17.9 2.4 
Tyr -17.2 -14.9 8.1 21.7 14.5 
Val -14.5 -2.7 22.1 30.9 17.7 
Ac-Orn -15.3 -2.0 8.7 17.3 2.6 
ADMA -13.4 -4.5 0.0 30.4 23.2 
alpha-AAA -13.5 3.6 9.4 19.1 -1.5 
c4-OH-Pro -11.5 -9.6 23.8 22.2 14.5 
Carnosine -17.7 -7.5 16.7 32.3 11.3 
Creatinine -14.6 71.4 115.5 120.4 103.1 
DOPA -82.9 -78.7 -99.4 -98.8 -99.4 
Dopamine -95.5 -77.5 
  
-100.0 
Histamine -9.4 1.9 8.4 26.1 -2.9 
Kynurenine -14.5 -11.1 4.5 25.2 -0.9 
Met-SO -8.7 -6.3 20.2 39.2 26.5 
Nitro-Tyr -4.0 -5.4 10.4 30.1 7.7 
PEA -94.3 -75.5 -66.0 -58.5 -18.9 
Putrescine -31.0 -16.7 -9.5 -21.4 14.3 
Sarcosine -27.6 -3.6 6.6 13.9 19.0 
SDMA -14.0 -14.0 14.0 18.0 28.0 
Serotonin -40.0 -26.7 -44.4 -40.0 -44.4 




 U-RHYTHM U-RHYTHM Spool Spool QCend 
 
0-40 160-200 min Most time Least time 
 
Spermine -91.2 -42.5 -54.0 -49.6 6.2 
t4-OH-Pro -14.0 -11.1 23.2 21.5 15.2 
Taurine -8.3 -9.2 12.5 19.2 21.7 
C0 8.9 -13.6 13.1 0 36.1 
C2 13.9 -10.0 -18.9 -9.4 -21.7 
C3 -28.4 -15.2 -46.2 -18.0 -9.9 
C4 -30.4 -13.3 -41.4 -2.0 -1.9 
C5 -23.8 -6.9 -24.0 6.0 -2.4 
C6 (C4:1-DC) -60.4 17.1 -68.5 -50.5 23.6 
C8 -57.8 -11.4 -51.3 -24.6 5.4 
C10 -42.4 -14.4 -46.8 -17.3 -9.4 
C12 -27.9 -15.9 -20.8 -3.9 -4.1 
C14 -27.7 -10.7 -16.5 3.7 -1.6 
C14:1 28.6 -19.0 31.0 47.6 -2.4 
C16 -24.7 -12.1 -19.2 4.0 -7.0 
C18 -31.9 -16.4 -25.7 -1.6 -13.2 
lysoPC a C16:0 0.0 -27.6 48.0 63.4 0.0 
lysoPC a C16:1 3.6 -26.4 47.2 72.0 9.6 
lysoPC a C17:0 2.2 -28.4 40.6 60.1 -3.0 
lysoPC a C18:0 6.6 -29.6 21.7 37.5 -23.7 
lysoPC a C18:1 0.0 -28.3 47.4 67.2 -1.6 
lysoPC a C18:2 1.7 -30.5 39.8 69.5 4.1 
lysoPC a C20:3 16.5 -24.3 86.4 115.2 25.5 
lysoPC a C20:4 14.7 -25.4 77.3 109.4 26.8 
lysoPC a C24:0 15.9 -14.1 -3.4 10.3 -29.7 
lysoPC a C26:0 -7.4 -27.8 -17.9 4.9 -35.8 
lysoPC a C26:1 -17.6 -38.5 -5.5 5.5 -30.8 
lysoPC a C28:0 27.0 -26.4 13.5 25.0 -29.1 
lysoPC a C28:1 34.5 -21.8 17.6 0.7 -12.7 
PC aa C24:0 -22.2 -13.8 
 
-28.8 -34.2 
PC aa C28:1 -13.6 -14.1 -6.2 11.9 -2.8 
PC aa C30:0 -8.1 -13.3 -4.1 15.9 0.0 
PC aa C32:0 -11.0 -13.4 -9.1 7.6 -4.7 
PC aa C32:1 -13.0 -12.0 -12.5 4.5 -8.7 
PC aa C32:2 -18.3 -22.1 -13.6 -4.7 -13.6 
PC aa C32:3 -12.1 -14.7 -3.5 17.3 8.0 
PC aa C34:1 11.7 -16.5 22.3 37.9 -8.3 
PC aa C34:2 17.9 -17.1 52.0 42.3 -9.8 
PC aa C34:3 -8.8 -13.8 -8.5 7.6 -8.6 
PC aa C34:4 -14.4 -17.5 -10.9 4.7 -5.3 
PC aa C36:0 25.4 -29.1 54.9 41.0 -31.1 
PC aa C36:1 -15.5 -12.9 -14.1 8.3 0.0 




 U-RHYTHM U-RHYTHM Spool Spool QCend 
 
0-40 160-200 min Most time Least time 
 
PC aa C36:3 -8.2 -11.1 -0.1 14.2 -2.1 
PC aa C36:4 7.6 -17.4 20.0 32.4 -8.1 
PC aa C36:5 -9.5 -14.0 -1.9 11.1 -5.2 
PC aa C36:6 -10.1 -13.4 -6.0 8.8 -13.8 
PC aa C38:0 -6.9 -15.1 -1.9 17.0 -1.9 
PC aa C38:3 -4.4 -14.6 3.0 18.7 -3.6 
PC aa C38:4 -8.0 -14.6 5.0 18.8 -1.2 
PC aa C38:5 -8.4 -15.0 1.0 15.7 -0.3 
PC aa C38:6 -7.1 -13.4 1.1 15.7 -3.4 
PC aa C40:2 -1.0 7.4 8.1 32.3 4.5 
PC aa C40:3 -6.1 -14.9 11.9 12.1 -8.5 
PC aa C40:4 -4.3 -13.0 5.4 20.4 -1.8 
PC aa C40:5 -4.8 -10.5 6.7 23.7 0.4 
PC aa C40:6 -5.1 -14.4 5.9 22.0 -1.7 
PC aa C42:0 -10.1 -10.6 -1.7 13.8 -1.4 
PC aa C42:1 -15.4 -16.8 -2.3 17.8 -9.3 
PC aa C42:2 -7.5 -11.8 -5.7 17.9 -3.3 
PC aa C42:4 -5.4 -7.9 -8.7 17.8 -7.4 
PC aa C42:5 -5.5 -13.8 5.8 17.5 5.8 
PC aa C42:6 -11.8 -19.5 -6.9 9.9 -1.9 
PC ae C30:0 -18.0 -3.9 3.9 3.9 1.1 
PC ae C30:1 -21.1 -22.1 -31.6 8.4 -9.5 
PC ae C30:2 -14.3 -9.5 -7.9 -4.8 1.6 
PC ae C32:1 -14.2 -10.7 -5.1 11.7 -1.5 
PC ae C32:2 -12.8 -14.1 -8.1 0.6 -1.1 
PC ae C34:0 -10.1 -13.5 -14.9 8.6 -7.2 
PC ae C34:1 -14.5 -15.9 -7.2 12.0 1.4 
PC ae C34:2 -10.5 -13.0 -3.7 12.5 -1.0 
PC ae C34:3 -10.2 -9.7 -2.0 17.4 1.2 
PC ae C36:0 -6.0 -18.0 -24.6 -3.9 -21.4 
PC ae C36:1 -12.3 -13.8 -8.7 4.3 -7.2 
PC ae C36:2 -10.9 -12.4 -4.2 12.9 -4.1 
PC ae C36:3 -10.4 -14.8 -0.6 13.4 -1.8 
PC ae C36:4 -11.8 -14.2 -2.4 11.8 -2.4 
PC ae C36:5 -12.7 -14.0 0.7 13.7 -1.0 
PC ae C38:0 -11.7 -16.7 -9.4 6.1 -11.2 
PC ae C38:1 1.8 -9.6 23.3 38.4 23.7 
PC ae C38:2 2.4 -4.9 9.7 24.3 11.3 
PC ae C38:3 -9.2 -14.4 -5.3 10.3 -5.8 
PC ae C38:4 -11.0 -13.4 -2.5 13.0 -1.1 
PC ae C38:5 -9.0 -13.3 2.7 18.0 3.6 
PC ae C38:6 -11.1 -14.8 -0.6 17.6 0.0 




 U-RHYTHM U-RHYTHM Spool Spool QCend 
 
0-40 160-200 min Most time Least time 
 
PC ae C40:2 -6.8 -18.5 -0.6 17.9 -6.2 
PC ae C40:3 -6.2 -8.4 5.8 22.7 3.6 
PC ae C40:4 -9.0 -11.7 0.4 16.6 -1.8 
PC ae C40:5 -13.2 -17.8 -2.2 12.6 -3.0 
PC ae C40:6 -8.4 -15.4 2.6 16.7 1.3 
PC ae C42:1 -6.1 -11.3 -10.3 1.8 -13.9 
PC ae C42:2 -12.9 -19.8 -7.8 6.2 -7.4 
PC ae C42:3 -13.6 -14.2 -13.1 3.4 -6.6 
PC ae C42:4 -9.0 -14.6 6.4 14.2 -6.6 
PC ae C42:5 -6.1 -11.7 5.0 16.7 5.0 
PC ae C44:3 -2.8 -12.1 -15.0 -7.5 -14.0 
PC ae C44:4 -11.0 -10.7 13.7 14.0 -6.4 
PC ae C44:5 -5.5 -14.5 4.4 18.7 -0.6 
PC ae C44:6 2.1 -12.3 10.1 23.8 5.7 
SM (OH) C14:1 -1.0 -21.1 14.5 31.0 -6.6 
SM (OH) C16:1 10.4 -20.5 19.7 38.8 -3.4 
SM (OH) C22:1 7.1 -23.3 34.1 46.8 -9.5 
SM (OH) C22:2 5.0 -24.0 35.6 41.6 -8.2 
SM (OH) C24:1 5.2 -24.0 39.0 48.1 -7.1 
SM C16:0 2.5 -20.3 16.1 36.4 -5.9 
SM C16:1 0.0 -20.1 17.8 36.1 -5.3 
SM C18:0 6.9 -17.5 22.0 39.8 -4.5 
SM C18:1 6.0 -16.0 24.0 39.3 -2.7 
SM C20:2 0.9 -20.5 23.6 34.5 -15.8 
SM C24:0 10.7 -22.7 39.3 49.6 -7.9 
SM C24:1 6.6 -22.6 38.8 49.2 -6.4 
SM C26:0 31.7 -14.0 45.2 60.8 2.2 
SM C26:1 2.8 -36.3 -5.4 10.7 -18.2 
Table 9-13 Effect of contact with the U-RHYTHM sampler after 40 minutes; after 200 minutes; samples with the most 
contact with the spool tubing; samples with the least contact; the ambient reference control sample. All values are 




9.12.3 Spool temperature plot 
 
Figure 9-5 Temperature of U-RHYTHM sampling system during an experiment in which reference metabolite solution 
(Biocrates AbsoluteIDQ® p180) was infused over 27 hours. The total exposure time of the metabolite solution to 
ambient storage conditions was 48 hours. The pump containing the metabolite solution and the U-RHYTHM device were 
carried in a waist band for 20 hours to simulate conditions of an in vivo microdialysis session. The temperature adjacent 
to the sample spool reached 34°C overnight; ambient temperature of the laboratory during equilibration was 21.4°C. 
9.12.4 Metabolite ratios plasma:microdialysate  
 Ratio of plasma to microdialysate 
 1 2 3 
ALA 1.45 4.16  
ARG 1.6 5.45  
ASN 1.35 5.22  
CIT 1.52 6.96  
GLN 1.57 5.05  
GLU 2.12   
GLY 1.22 3.97  
HIS 1.46 5.36  
ILE 1.46 8.41  
LEU 1.38 7.85  
LYS 2.03 6.48  
MET 1.71 9.58  
ORN 1.48 6.79 6.97 
PHE 1.56 6.52  
PRO 1.34 4.23  
SER 1.39 3.99  




 Ratio of plasma to microdialysate 
 1 2 3 
TRP 5.39   
TYR 1.61 6.4  
VAL 1.51 5.1  
T4-OH-P 1.49 4.59 2.27 
TAU 0.94 3.91 33.41 
C0 1.41 4.06  
C2 1.79 5.13  
MEAN 1.68 4.99  
Table 9-14 Ratio of plasma:microdialysate concentrations of individual metabolite expressed as the mean concentration 




9.12.5 F-statistics and p-values for linear and cosinor models 
Cosinor vs. zero slope (M3) 
   
linear vs. zero slope (M2) 
   









1 2 3 1 2 3 1 2 3 1 2 3 
pALA 2.9908 0.5319 2.3341 0.0577 0.5899 0.1043 8.8518 0.6788 8.9507 0.0042 0.4128 0.0038 
pARG 10.1930 9.2381 9.9328 0.0002 0.0003 0.0002 14.1113 0.9434 4.8895 0.0004 0.3347 0.0302 
pASN 7.8206 3.4909 3.1049 0.0009 0.0360 0.0509 1.8753 1.0730 5.8249 0.1758 0.3038 0.0183 
pCIT 9.5178 26.8087 1.0017 0.0003 0.0000 0.3723 0.1918 18.1403 0.0013 0.6629 0.0001 0.9716 
pGLN 2.8300 0.8874 0.8888 0.0668 0.4162 0.4156 13.7171 1.6448 4.2151 0.0005 0.2038 0.0437 
pGLU 8.9568 1.6640 0.7089 0.0004 0.1967 0.4956 17.0338 0.0095 0.1055 0.0001 0.9226 0.7463 
pGLY 9.7001 1.4239 0.9118 0.0002 0.2476 0.4064 34.9122 0.4164 6.7002 0.0000 0.5208 0.0116 
pHIS 4.6138 2.0656 1.6651 0.0136 0.1343 0.1964 8.2438 2.6529 3.2988 0.0056 0.1077 0.0734 
pILE 10.8179 5.5815 49.8215 0.0001 0.0056 0.0000 0.2422 0.0004 17.8768 0.6243 0.9847 0.0001 
pLEU 4.3876 1.9335 23.6822 0.0166 0.1522 0.0000 1.5072 0.5541 20.6582 0.2242 0.4591 0.0000 
pLYS 6.2455 4.7161 17.7276 0.0034 0.0119 0.0000 5.8413 0.3513 18.6861 0.0186 0.5552 0.0000 
pMET 5.6238 2.5275 11.3697 0.0057 0.0870 0.0001 3.2034 0.0060 7.4483 0.0784 0.9386 0.0080 
pORN 2.0050 4.2037 0.6361 0.1434 0.0188 0.5323 1.7613 5.4460 1.6154 0.1893 0.0224 0.2078 
pPHE 2.4731 2.2360 3.3418 0.0927 0.1144 0.0409 0.5326 0.4777 6.0562 0.4683 0.4917 0.0162 
pPRO 3.9264 12.0167 2.2765 0.0249 0.0000 0.1100 0.6339 12.2300 0.4674 0.4290 0.0008 0.4963 
pSER 4.1400 1.6548 2.0671 0.0206 0.1984 0.1340 6.4947 0.0018 0.7410 0.0133 0.9664 0.3922 





0.0000 6.2147 NaN 10.3373 0.0154 NaN 0.0019 
pTYR 6.9023 9.7376 15.4042 0.0020 0.0002 0.0000 11.4885 7.4996 10.3333 0.0012 0.0078 0.0019 
pVAL 2.9261 5.7809 20.2352 0.0612 0.0047 0.0000 0.1382 2.4897 22.2750 0.7114 0.1190 0.0000 
pC0 0.5069 2.6519 6.4043 0.6049 0.0774 0.0028 9.4636 0.5699 23.3795 0.0031 0.4527 0.0000 
pC2 5.9792 4.2926 34.6514 0.0043 0.0173 0.0000 13.5927 0.1814 49.6298 0.0005 0.6715 0.0000 
pT4-OH-PRO 43.8340 18.1190 76.2908 0.0000 0.0000 0.0000 10.3724 7.6604 46.2357 0.0020 0.0071 0.0000 




Cosinor vs. zero slope (M3) 
   
linear vs. zero slope (M2) 
   









1 2 3 1 2 3 1 2 3 1 2 3 




0.8796   0.3520   
pPC AA C38:6 0.5827 2.8695 4.1913 0.5615 0.0632 0.0190 8.0173 3.0996 0.5411 0.0062 0.0825 0.4643 




61.5990 3.9108  3.5E-11 5.2E-02  




213.1950 12.3178  0.0E+00 7.7E-04  




139.1706 0.7328  0.0E+00 3.9E-01  




114.2980 0.4756  2.2E-16 4.9E-01  









34.3307   1.3E-07   




206.3846 21.9927  0.0E+00 1.2E-05  




210.0841 9.6591  0.0E+00 2.7E-03  




68.9296 2.1247  4.6E-12 1.5E-01  




105.6827 0.5306  1.1E-15 4.7E-01  




94.9939 2.2999  1.2E-14 1.3E-01  




93.8495 0.0106  1.3E-14 9.2E-01  
mORN 19.7094 6.8286 3.5525 0.0000 0.0019 0.0336 65.0787 0.0001  1.3E-11 9.9E-01  




130.2003 3.5964  0.0E+00 6.2E-02  




44.5023 0.5072  4.7E-09 4.8E-01  




160.9810 0.3313  0.0E+00 5.7E-01  









117.9409   1.1E-16   




146.1977 0.0153  0.0E+00 9.0E-01  




91.5555 3.6173  2.1E-14 6.1E-02  




174.8964 8.8015  0.0E+00 4.1E-03  
mC2 64.2599 23.5048 13.7056 0.0000 0.0000 0.0000 311.4923 29.2724  0.0E+00 8.1E-07  
mT4-OH-PRO 111.8518 40.0500 107.5771 0.0000 0.0000 0.0000 23.8503 0.0239  6.3E-06 8.8E-01  




9.13  Appendix M 
9.13.1 Proof-of-principle detection of melatonin in microdialysis samples 
A high-sensitivity method for detection of cortisol, cortisone and melatonin using liquid 
chromatography-mass spectrometry (LC-MS) had been developed by collaborators at 
University Medical Center Groningen169. The method was tested for measurements in 
microdialysate for the first time in 2017 (Figure 9-6). 
 
Figure 9-6 First ever ambulatory microdialysis profile measured in a 36-year-old healthy male volunteer, August 2017. 
Microdialysis melatonin (red circles) samples were obtained every 20 minutes from 13:50 on day 1 until 09:00 on day 2. 
Dim light (lux <20) was maintained from 19:30 and throughout the sleep period. Free melatonin was also measured in 
saliva samples (red ‘x’ markers). Concentrations of melatonin were higher and detected earlier in saliva than in the 
microdialysis samples. 
9.13.2 Comparisons with plasma and saliva 
Following optimisation of the method for detection of melatonin (performed by collaborators 
at University Medical Center Groningen), simultaneous profiles of cortisol, cortisone and 
melatonin were again obtained in the same volunteer during two consecutive sampling 
periods, separated by 8 days. Other than maintaining a regular sleep/wake schedule, and dim 






Figure 9-7 Profiles of melatonin measured in microdialysate and compared with plasma (left) and saliva (right). Samples 
were obtained from the same volunteer as in Figure 9-6. Microdialysis samples were obtained every 20 minutes. Dim 
light was maintained from 20:00.  





















Figure 9-8 Linear regression of melatonin [pmol/L] in microdialysate samples collected between 20:20-23:00 compared 
with n = 9 simultaneous measurements in plasma (r2 = 0.902, p=<0.001, black squares, solid regression line) and n=8 




9.13.3 Week-to-week variation 
 
Figure 9-9 Profiles of melatonin obtained in microdialysate 8 days apart in the same individual (Spearman correlation rs = 
0.77, p<0.0001). The profile on day 9 (blue squares) is phase advanced by 20 minutes compared with day 1 (red circles).  
 
Figure 9-10 Profiles of cortisol (solid lines) and cortisone (dashed lines) obtained in microdialysate 8 days apart in the 





9.14 Appendix N 
9.14.1 Comparison of OURA temperature measurement method 






















































































































































Figure 9-11 Peripheral temperature measurements simultaneously recorded by a wrist iButton (blue), finger iButton 
(green) and Oura ring (black) in 4 participants. Samples were obtained at 1-minute intervals and all participants wore the 





9.14.2 OURA vs. iButton correlation tables 
9.14.2.1 Panel A 
  iButton [radial] iButton [finger] Oura 




































9.14.2.2 Panel B 
  iButton [radial] iButton [finger] Oura 









































9.14.2.3 Panel C 
  iButton [radial] iButton [finger] Oura 




































9.14.2.4 Panel D 
  iButton [radial] iButton [finger] Oura 








































9.16 Appendix O 
9.16.1 Testing the brightness of the Luminette visor 
The Luminette device (Luminette®, Lucimed SA, Villers-le-Bouillet, Belgium) is a head-
mounted visor that reflects blue-enriched light into the eye from a set of light emitting diodes 
(LEDs). Previous studies have found the device to be well tolerated343 and effective at 
suppressing melatonin when used for 2 hours prior to bed time and in otherwise dim light 
conditions323. The manufacturer claimed peak-light output is 1500 lux. In experiments 
performed using a two light sensors (HOBO Pendant® UA-002-08, Onset Computer 
Corporation, MA, USA) mounted on a dummy human head (Figure 2-9), the mean maximum 
brightness recorded was 779 lux (SD ± 157). 
Figure 9-12 Testing the brightness of the Luminette visor 




9.17 Appendix P 
9.17.1 Measured parameters with significant daily rhythm as determined by significance of fit to cosine curve 
            
Participant 1 2 3 4 5 6 7 8 9 10 11 
 
Cortisol 
          
F 34.0702 45.1941 82.0620 31.6377 28.2503 21.7842 42.4629 76.4279 23.5678 
  
p 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
  
Acrophase 8.6005 8.2241 9.3511 12.0465 8.7934 10.5002 8.7592 10.5919 9.0379 
  
 
08:36:02 08:13:27 09:21:04 12:02:47 08:47:36 10:30:01 08:45:33 10:35:31 09:02:16 
  
            
 
Cortisone 
          
F 17.6203 52.1016 47.0142 10.5696 15.6777 13.4133 46.9288 35.1562 19.1779 
  
p 0.0000 0.0000 0.0000 0.0001 0.0000 0.0000 0.0000 0.0000 0.0000 
  
Acrophase 8.6484 8.3160 9.1115 13.5610 10.0560 11.0582 8.4043 11.2423 9.2187 
  
 
08:38:54 08:18:58 09:06:41 13:33:40 10:03:22 11:03:30 08:24:16 11:14:32 09:13:07 
  
            
 
Melatonin 
          
F 76.5424 111.3388 69.9816 169.9439 64.4019 81.9054 127.0100 147.5239 117.3315 
  
p 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
  
Acrophase 3.9143 2.3049 3.2932 5.3221 4.7631 3.8124 3.9765 4.8965 3.9767 
  
 
03:54:52 02:18:17 03:17:36 05:19:20 04:45:47 03:48:45 03:58:35 04:53:48 03:58:36 
  
            
 
Temperature 
         
F 403.5650 844.8690 472.4314 237.5215 234.7972 106.2983 142.5708 193.3574 83.5921 210.6594 124.8950 
p 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
Acrophase 2.9808 2.2399 4.0958 4.2415 1.7322 4.4277 1.5943 2.7236 0.5727 2.5802 2.8386 
 
02:58:51 02:14:24 04:05:45 04:14:29 01:43:56 04:25:40 01:35:40 02:43:25 00:34:22 02:34:49 02:50:19 
            
 
Motion 




            
Participant 1 2 3 4 5 6 7 8 9 10 11 
F 140.1016 88.4269 194.0349 238.4351 238.6614 231.3765 231.0049 201.1174 218.8863 343.9063 294.5698 
p 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
Acrophase 15.9402 16.0747 14.1253 15.8377 14.5583 14.8873 13.3422 15.5598 14.2554 15.4332 14.6072 
 
15:56:25 16:04:29 14:07:31 15:50:16 14:33:30 14:53:14 13:20:32 15:33:35 14:15:19 15:26:00 14:36:26 
            
 
Light 
          
F 30.6834 48.5898 133.5211 67.0307 82.2411 32.6026 175.0977 82.7479 167.3219 64.2114 60.7906 
p 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
Acrophase 13.9496 13.5213 12.9370 14.5530 14.1640 13.3983 13.5892 12.2875 12.4209 13.2608 12.6441 
 
13:56:59 13:31:17 12:56:13 14:33:11 14:09:50 13:23:54 13:35:21 12:17:15 12:25:15 13:15:39 12:38:39 
            
 
Glucose 
          
F 146.5203 10.1164 40.5567 16.2856 47.0380 209.1367 41.6049 71.1851 143.3817 17.4425 47.9996 
p 0.0000 0.0001 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
Acrophase 17.1515 19.2806 18.2702 22.1771 16.2910 17.5054 17.4404 17.9322 17.3615 20.2770 19.9234 
 
17:09:05 19:16:50 18:16:13 22:10:37 16:17:28 17:30:20 17:26:25 17:55:56 17:21:41 20:16:37 19:55:24 
Table 9-15 Table of results following cosinor analysis for daily rhythmicity in measurements of cortisol, cortisone, melatonin, peripheral skin temperature, motion, light, and glucose for 11 participants in the 
bioRHYTHM study (Chapter 6). The F-statistics, p-values (significant if p<0.05), and acrophase given in both decimal- and 24-hour times are shown for each participant. 
 
 
 
 
